Official Protocol Title:
NCT number:                [STUDY_ID_REMOVED]
Document Date:            21-Oct-2022
A Phase 2b open-label, single-arm study to evaluate 
pharmacokinetics, efficacy, safety and tolerability of 
letermovir in pediatric participants from birth to less 
than 18 years of age at risk of developi[INVESTIGATOR_660126]/or disease following allogeneic 
haematopoietic stem cell
transplantation (HSCT)

PRODUCT: MK-8228 1
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889955] -2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD) .
Protocol Title: A Phase 2b open- label, single -arm study to evaluate pharmacokinetics, 
efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 
18 years of age at risk of developi[INVESTIGATOR_660127]/or disease following allogeneic 
haematopoietic stem cell transplantation (HSCT)
Protocol Number: 030-08
Compound Number: MK-8228
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_889956], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
EudraCT 2018- 001326- 25
IND104,706 (tablet) 
118,361 ( intravenous )
Approval Date: [ADDRESS_889957]: MK-8228 2
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889958] -2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08C0PW
PRODUCT: MK-8228 3
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889959] -2022
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 08
(global, including 
for Spain)21-OCT -2022 The primary reason for Amendment 08 was Sponsor underwent entity name [CONTACT_660250].
Amendment 07
(global including
for Spain)31-AUG- 2021 The primary rationale for the changes in Amendment 07 are as follows:
To provide the initial dose of oral and intravenous (IV)letermovir ( LET)for Age Group 3, 
which has been determined by [CONTACT_660178] s (PK)analyses using data from 
participants in Age Group 1 and Age Group 2 of this study .To add a requirement for PK 
sampling of hydroxypropyl- beta-cyclodextrin ( HPCD ), an excipi[INVESTIGATOR_660128] ,forAge Group [ADDRESS_889960] 4 
consecutive days.
In addition, the 10 -mg oral capsule of LET is now available for use in Spain.
This amendment is intended to merge Amendment 06, a country -specific amendment for 
Spain, with global Amendment 03 , which has been used for all other participating countries , 
to dat e. Thus, Amendment 07 will be used globally, including for Spain.
Amendment 06 
(country- specific 
for Spain)22-NOV- [ADDRESS_889961]: MK-8228 4
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889962] -2022
Document Date of Issue Overall Rationale
Amendment 05 
(country- specific 
for Spain)16-O CT-2019 To include all changes from Amendment 02 made in both Amendment 03 (addition of in -line
filter and related requirements for administration of the IV formulation of LET and 
Amendment 04 (removal of the 10 -mg and 30 -mg oral capsules from the protocol until they 
become available) in the Summary of Changes table . This country -specific amendment is 
being released to Spain in lieu of Amendment 03, which was released to the rest of the world . 
Amendment 04 was not released because the Amendment 04 Summary of Changes 
inadvertently omitted the changes made in Amendment 03.
Amendment 04 
(country- specifi c 
for Spain)17-SEP-[ADDRESS_889963] be administered through a sterile 0.2 -micron or 0.22 -micron 
polyethersulfone (PES) in -line filter andusing diethylhexyl phthalate (DEHP) -free IV bags 
and infusion set materials . This requirement is being added to prevent the possible 
administration of produc t-related particulate matter . The presence of visible product -related 
particulate matter is an expected characteristic of new clinical supplies of the IV formulation 
of LET . This requirement is being implemented to allow for the release of new clinical 
supplies of IV LET, and, as a precaution, it must be applied regardless of whether the clinical 
site considers its current clinical supply to be impacted .
08C0PW
PRODUCT: MK-8228 5
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889964] description of the coating of the oral granule formulation being used (Opadry coating 
without Surelease) and provides the rationale for selecti on of this oral granule formulation . 
Additional minor changes have been made to incorporate changes communicated in prior 
protocol clarification letters.
Amendment 01 24-JAN- 2019 Testicular toxicity testing was removed, and creatinine clearance monitoring every 2 weeks 
was added to the protocol .
Original Protocol 
(Version 00)08-O CT-[ADDRESS_889965]: MK-8228 6
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889966] -2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 08
Overall Rationale for the Amendments:
The primary reason for Amendment 08 was Sponsor underwent entity name [CONTACT_26406] .
Summary of Changes Table:
Section # and Name [CONTACT_660251] 10.1.[ADDRESS_889967], NJ, [LOCATION_003]. This conversion result edonly 
in an entity name [CONTACT_26406].
Other Changes in the Amendment
1.1 Synopsis
4.3.1 Starting Dose for This 
Study
6.1 Study Intervention(s) 
Administered Adjusted oral and IV doses of LET to be 
administered in Age Group [ADDRESS_889968]: MK-8228 7
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889969] -2022
Section # and Name [CONTACT_11029]  
1.3.1 Schedule of Activities 
Screening/Treatment Period
[IP_ADDRESS] Dosing in Age Group 
[ADDRESS_889970] 
intensive PK , regardless offormulation use d; those on 
oral formulation will have intensive PK on the 7th
consecutive day of oral L ET while those on IV 
formulation will have intensive PK on the 5th
consecutive day o f LET administration .
2.2.5 Ongoing Clinical 
StudiesDeleted text of ongoing studies and added 
statement to refer to the Investigator’s 
Brochure (IB).To align with the m ost current version of the IB.
4.[ADDRESS_889971]: MK-8228 8
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889972] -2022
Section # and Name [CONTACT_11029]  
4.4.1 Clinical Criteria for 
Early Study TerminationRevised language about early termination 
based on changing benefit/risk ratio.To correct grammar and ensure clarity and intent of the 
section.
5 Study Population Added statement about the collection of 
demographic data and participant 
confidentiality.To clarify the collection, use, and confidentiality of 
demographic data provided by [CONTACT_660179].
6.1 Study Intervention(s) 
AdministeredAdded a cross- reference to Appendix 7. To align with recent PMDA regulation changes.
6.1 Study Intervention Table Revised column heading and footnotes to 
include AxMP.
Changed ‘Experimental’ in the ‘Use’ 
column to ‘Test Product.To align with EU CTR.
7.[ADDRESS_889973] language related 
to "lost to follow- up" that is appropriate for the study.
8.1.[ADDRESS_889974] (ECIs)Revised language defining potential DILI. To clarify for the investigator/site to define what a 
potential DILI is and to align with this acronym being 
used in the reporting table.
08C0PW
PRODUCT: MK-8228 9
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889975] -2022
Section # and Name [CONTACT_11029]  
[IP_ADDRESS] Additional Creatinine 
Clearance Measurements for 
Participants in Age Group 3 
Receiving Intravenous 
Letermovir FormulationConsolidated rows in Table 15. To clarify when samples for creatinine clearance in 
participants receiving IV LET should be collected.
8.4 Adverse Events (AEs), 
Serious Adverse Events 
(SAEs), and Other 
Reportable Safety Events
10.3 Adverse Events: 
Definitions and Procedures 
for Recording, Evaluating, 
Follow -up, and ReportingAdded details on the definition and 
recording of medication error, misuse, and 
abuse.To align with EU CTR.
Throughout Minor administrative formatting, 
grammatical, and typographical changes 
were made throughout the document.The ensure clarity and accurate interpretation of the 
intent of the protocol.
08C0PW
PRODUCT: MK-8228 10
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889976] -2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 6
1 PROTOCOL SUMMARY ............................................................................................ 20
1.1 Synopsis ................................................................................................................. 20
1.2 Schema .................................................................................................................. 24
1.3 Schedule of Activities (SoA) ................................................................................ 25
1.3.1 Schedule of Activities Screening/Treatment Period ....................................[ADDRESS_889977] Recipi[INVESTIGATOR_840] ......................................................... 35
2.2.3 Pharmacokinetic Background of LET ......................................................... 38
[IP_ADDRESS] LET, Absorption, Metabolism, and Disposition ................................ 38
[IP_ADDRESS] Drug Interactio ns Between LET and Immunosuppressant Agents ....38
[IP_ADDRESS] Pharmacokinetic Modeling and Simulation in Adults ....................... 39
2.2.4 Preclinical and Clinical Studies ...................................................................40
2.2.5 Ongoing Clinical Studies ............................................................................. 42
2.3 Benefit/Risk Assessment ...................................................................................... 42
3 HYPOTHESIS, OBJECTIVES, AND ENDPOINTS ................................................. 43
4 STUDY DESIGN ............................................................................................................ 43
4.1 Overall Design ......................................................................................................43
4.2 Scientific Rationale for Study Design ................................................................ .51
4.2.1 Rationale for Endpoints ............................................................................... 51
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 51
[IP_ADDRESS] Safety Endpoints ................................................................................ 51
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 52
[IP_ADDRESS] Palatability and Acceptance Assessment Endpoint ........................... 53
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................53
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 53
[IP_ADDRESS] Future Biomedical Research .............................................................. 54
4.3 Justification for Dose ........................................................................................... 54
4.3.1 Starting Dose for This Study ........................................................................54
[IP_ADDRESS] Dose Justifications ............................................................................. [ADDRESS_889978]: MK-8228 11
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889979] -2022
[IP_ADDRESS] Dose in Age Group 1 (12 to <18 years), Panel A .............................. 60
[IP_ADDRESS] Dose in Age Group 2 (2 to <12 years), Panel A................................ 60
[IP_ADDRESS] Dose in Age Groups 1 and 2, Panel B............................................... 61
[IP_ADDRESS] Age Groups 1 and 2 Pharmacokinetic Experience Through 
Interim Analysis 2.............................................................................. 61
[IP_ADDRESS] Dose in Age Group 3 ......................................................................... 63
4.3.2 Maximum Dose/Exposure for This Study ................................................... 63
4.4 Beginning and End of Study Definition ............................................................. 63
4.4.1 Clinical Criteria for Early Study Termination ............................................. 63
5 STUDY POPULATION ................................................................................................ 63
5.1 Inclusion Criteria ................................................................................................ .64
5.2 Exclusion Criteria ................................................................................................ 65
5.3 Lifestyle Considerations ...................................................................................... 68
5.3.1 Meals and Dietary Restrictions ....................................................................68
5.4 Screen Failures .....................................................................................................68
5.5 Participant Replacement Str ategy ......................................................................69
6 STUDY INTERVENTION ............................................................................................ 69
6.1 Study Intervention(s) Administered ...................................................................69
6.2 Preparation/Handling/Storage/Accountability ................................................. 73
6.2.1 Dose Preparation .......................................................................................... 73
6.2.2 Handling, Storage, and Accountability ........................................................ 73
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 73
6.3.1 Intervention Assignment.............................................................................. 73
6.3.2 Stratification ................................................................................................ .74
6.3.3 Blinding ........................................................................................................74
6.4 Study Intervention Compliance .......................................................................... 74
6.5 Concomitant Therapy .......................................................................................... 74
6.5.1 Allowed Medications/Therapi[INVESTIGATOR_014] ..................................................................74
[IP_ADDRESS] Allowed Medications/Therapi[INVESTIGATOR_660129] ........................................................................... 74
[IP_ADDRESS] Allowed Medications/Therapi[INVESTIGATOR_126473]/or Drug -level Monitoring ............................................................ 75
6.5.2 Prohibited Medications ................................................................................ 76
[IP_ADDRESS] Medications Prohibited with LET ...................................................... 77
[IP_ADDRESS] Additional Medications Prohibited when LET is Coadministered 
with CsA ............................................................................................ 78
6.5.3 Rescue Medications and Supportive Care ................................................... 79
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_889980]: MK-8228 12
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889981] to Follow -up................................................................................................ .82
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 83
8.1 Administrative and General Procedures ........................................................... 83
8.1.1 Informed Consent/Assent ............................................................................. 83
[IP_ADDRESS] General Informed Consent/Assent ..................................................... 84
[IP_ADDRESS] Consent/Assent and Collection of Specimens for Future 
Biomedical Research ......................................................................... 84
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_889982] .....................................................................84
8.1.4 Medical History ........................................................................................... 85
8.1.5 Prior and Concomitant Medications Review ............................................... 85
[IP_ADDRESS] Prior Medications ............................................................................... 85
[IP_ADDRESS] Concomitant Medications ..................................................................[ADDRESS_889983] Details Review .................................................................................. 85
8.1.7 Assignment of Screening Number ............................................................... 86
8.1.8 Assignment of Treatment/Randomization Number .....................................86
8.1.9 Study Intervention Administration .............................................................. 86
[IP_ADDRESS] Timing of Dose Administration ......................................................... 86
[IP_ADDRESS] Study Medication Diary .....................................................................87
8.1.10 Discontinuation and Withdrawal ................................................................ .88
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 88
8.1.11 Participant Blinding/Unblinding ..................................................................[ADDRESS_889984]: MK-8228 13
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889985] -2022
8.3.6 Confirmation of Contraception (WOCBP Only) ......................................... 93
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 93
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Inf ormation .......................................................... 93
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......95
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...95
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 95
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 96
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_889986] (ECIs) ................................................................ 96
8.5 Treatment of Overdose ........................................................................................ 96
8.6 Pharmacokinetics ................................................................................................ .97
8.6.1 Blood Collection for Letermovir Pharmacokinetic Sampling ..................... 97
8.6.2 Blood Collection for HPCD Pharmacokinetic Sampling ............................. 99
[IP_ADDRESS] Additional Creatinine Clearan ce Measurements for Participants in 
Age Group 3 Receiving Intravenous Letermovir Formulation .......... 99
8.7 Pharmacodynamics ............................................................................................ 100
8.8 Future Biomedical Research Sample Collection ............................................. 100
8.9 Planned Genetic Analysis Sample Collection .................................................. 100
8.10 Palatability and Acceptance Assessment ......................................................... 100
8.11 Visit Requirements ............................................................................................. 101
8.11.1 Screening ....................................................................................................101
8.11.2 Treatment Period Visits ............................................................................. 101
[IP_ADDRESS] Day 1 Visit ....................................................................................... 102
[IP_ADDRESS] Study Intervention Administration Visit .......................................... 102
[IP_ADDRESS] Additional Tre atment Period Visits ................................................. 103
8.11.3 Follow -up Period/Visits ............................................................................. 103
8.11.4 Participants Discontinuing Study Intervention but Continuing to be 
Monitored in the Study .............................................................................. 104
[IP_ADDRESS] Discontinuation of Study Intervention Due to CS -CMVi ............... 104
[IP_ADDRESS] Discontinuation of Study Intervention for Reasons Other Than 
CS-CMVi ......................................................................................... 104
8.11.5 Discontinuation from Study .......................................................................105
[IP_ADDRESS] Study Discontinuation Prior to Week [ADDRESS_889987] -transplant: ............... 105
[IP_ADDRESS] Study Discontinuation After Week [ADDRESS_889988]: MK-8228 14
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889989] -2022
9.2 Responsibility for Analyses/In -house Blinding ............................................... 106
9.3 Hypotheses/Estimation ...................................................................................... 107
9.4 Analysis Endpoints ............................................................................................. 107
9.4.1 Pharmacokinetics Endpoints ......................................................................107
9.4.2 Safety Endpoints ........................................................................................ 107
9.4.3 Efficacy Endpoints ..................................................................................... 107
9.5 Analysis Populations .......................................................................................... 108
9.5.1 PK Analysis Population ............................................................................. 108
9.5.2 Safety Analysis Population ........................................................................108
9.5.3 Efficacy Analysis Population .....................................................................109
9.6 Statistical Methods ............................................................................................. 109
9.6.1 Statistical Methods for Pharmacokinetic Analyses ....................................109
9.6.2 Pharmacokinetic Modeling and Simu lation for Dose Selection ................ 109
9.6.3 Statistical Methods for Safety Analyses .................................................... 110
9.6.4 Statistical Methods for Efficacy Analyses................................................. 111
9.6.5 Summaries of Baseline Characteristics, Demographics, and Other 
Analyses .....................................................................................................112
[IP_ADDRESS] Demogra phic and Baseline Characteristics .....................................112
[IP_ADDRESS] Palatability and Acceptance Assessment .........................................113
9.7 Interim Analyses ................................................................................................ 113
9.8 Multiplicity ......................................................................................................... 114
9.9 Sample Size and Power Calculations ............................................................... 114
9.9.1 Sample Size and Power for PK Analysis ................................................... 114
9.9.2 Sample Size and Power for Safety Analysis .............................................. 114
9.9.3 Sample Size and Power for Efficacy Analysis .......................................... 115
9.10 Subgroup Analyses ............................................................................................. 116
9.11 Compliance (Medication Adherence) ............................................................... 117
9.12 Extent of Exposure ............................................................................................. 117
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ...................................................................................................118
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ......[ADDRESS_889990] for Clinical Trials ........................................................... 118
10.1.2 Financial Disclosure ................................................................................... 120
10.1.3 Data Protection ........................................................................................... 120
[IP_ADDRESS] Confidentiality of Data ....................................................................121
[IP_ADDRESS] Confidentiality of Participant Records ............................................. 121
[IP_ADDRESS] Confidentiality of IRB/IEC Information .......................................... [ADDRESS_889991]: MK-8228 15
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889992] -2022
[IP_ADDRESS] Executive Oversight Committee ...................................................... 121
[IP_ADDRESS] External Data Monitoring Committee ............................................. 121
[IP_ADDRESS] Clinical Adjudication Committee (CAC) ........................................122
10.1.5 Publication Policy ...................................................................................... 122
10.1.6 Compliance with Study Registration and Results Posting Requirements .122
10.1.7 Compliance with Law, Audit, and Debarment .......................................... 123
10.1.8 Data Q uality Assurance ............................................................................. 123
10.1.9 Source Documents ..................................................................................... 124
10.1.10 Study and S ite Closure ............................................................................... 124
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 125
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 130
10.3.1 Definitions of Medication Error, Misuse, and Abuse ................................ 130
10.3.2 Definition of AE ........................................................................................ 130
10.3.3 Definition of SAE ...................................................................................... 131
10.3.4 Additional Events Reported .......................................................................132
10.3.5 Recording AE and SAE ............................................................................. 133
10.3.6 Reporting of AE, SAE, and Other Reportable Safety Events t o the 
Sponsor ......................................................................................................136
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow- up, and Reporting .........................................138
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ...................... 139
10.5.1 Definitions ..................................................................................................139
10.5.2 Contraception Requirements ......................................................................139
10.5.3 Pregnancy Testing ...................................................................................... 141
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 142
10.7 Appendix 7: Country -specific Requirements .................................................. 147
10.8 Appendix 8 Definition of CMV Disease in Hematopoietic Stem Cell 
Transplant (HSCT) Recipi[INVESTIGATOR_840] ......................................................................... 148
10.9 Appendix 9 Child -Pugh Classification for Severity of Liver Disease ............ 151
10.10 Appendix 10: Medications Allowed for HSV/VZV Prophylaxis ................... 152
10.10.1 Acyclovir ....................................................................................................152
[IP_ADDRESS] HSV Prophylaxis ............................................................................. 152
[IP_ADDRESS] Varicella (Chickenpox) or Herpes Zoster (Shingles), Proph ylaxis .152
10.10.2 Valacyclovir ............................................................................................... 153
[IP_ADDRESS] Herpes Simplex Virus (HSV), Prophylaxis .....................................153
[IP_ADDRESS] Varicella (Chickenpox), Prophylaxis ............................................... 153
10.11 Appendix 11: Palatability and Acceptance Assessment Form ....................... [ADDRESS_889993]: MK-8228 16
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889994] -2022
10.12 Appendix 12: Calculation of Creatinine Clearance by [CONTACT_660180] .......................................................................................................... 156
10.13 Appen dix 13: Abbreviations ............................................................................. [ADDRESS_889995]: MK-8228 17
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889996] OF TABLES
Table 1 Number of Haematopoietic Stem Cell Transplantation by [CONTACT_70566] ........... 35
Table 2 Distribution of Allogeneic Haematopoietic Stem Cell 
Transplanta tions in 2014 in the [LOCATION_002] ................................................. 35
Table 3 Cytomegalovirus Seroprevalence in General Population, United 
States ................................................................................................................ 36
Table 4 Predicted Letermovir AUC (ng.hr/mL) Values in Adult HSCT 
Recipi[INVESTIGATOR_840] ......................................................................................................... 40
Table 5 Summary of the Geometric Mean Ratios and 90% Confidence 
Intervals for MK -8228 Plasma PK of AUC0 -inf and Cmax Following 
Administration of a Single Oral Dose of 240 mg (2x120 mg) MK -
8228 Coated Granule Formulations Administered Alone, in 
Applesauce, or in Vanilla Pudding C ompared With 240 mg Tablet in 
Healthy Adult Participants ............................................................................... 42
Table 6 Enrollment Requirements and Pharmacokinetic Sampling by [CONTACT_243677] ............................................................................................................... 48
Table 7 Oral Letermovir Dosing Table ......................................................................... 55
Table 8 Intravenous Letermovir Dosing Table ............................................................. 55
Table 9 Study Intervention ............................................................................................ 70
Table 10 Dosing for Oral Formulations of LET ............................................................. 71
Table 11 Dosing for Intravenous Formulation LET ....................................................... 72
Table 12 Lower B ound of Creatinine Clearance by [CONTACT_31365] ................................................ 82
Table 13 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events .......................................................................94
Table 14 Pharmacokinetic Sampling for Protocol 030 ................................................... 98
Table 15 Creatinine Clearance Timepoints for Age Group 3 Participants 
Receiving Intravenous Letermovir ................................................................ 100
Table 16 Analysis Strategy for Safety Parameters ........................................................ 111
Table 17 Analysis Strategy for key Efficacy Variables ................................................ 112
Table 18 Estimate of Incidence of AEs and 95% Upper Confidence Bound 
Based on Hypothetical Numbers of Participants With AEs .......................... 115
Table 19 Two-sided 95% Confidence Interva ls for the Proportion of 
Participants With Clinically Significant CMV Infection Through 
Week 24 (~6 Months) Post -transplant (FAS Population) .............................. 116
Table 20 Protocol -required Laboratory Assessments (Local Laboratory) .................... 125
Table 21 Protocol -required Laboratory Assessments (Central Laboratory) ................. 126
Table 22 Approximate Blood Volumes Drawn/Collected by [CONTACT_660181] – Research Testing (Age Group 1) .........................................[ADDRESS_889997]: MK-8228 18
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_889998] -2022
Table 23 Approximate Blood Volumes Drawn/Collected by [CONTACT_660181] – Research Testing (Age Group 2) ......................................... 128
Table 24 Approximate Blood Volumes Drawn/Collected by [CONTACT_660181] – Research Testing (Age Group 3) .........................................[ADDRESS_889999]: MK-8228 19
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890000] OF FIGURES
Figure 1 Study Design .................................................................................................... 24
Figure 2 Sequential Evaluation of Age Groups .............................................................. 46
Figure 3 LET Median AUC (With 5th and 95thPercen tile Prediction Intervals) 
by [CONTACT_660182], Based on the Phase 3 Population PK 
Model With Allometric Scaling. Age Group 1 (12 to <18 yrs) and 
Age Group 2 (2 to <7 yrs and 7 to <12 yrs), Without 
Coadministration of CsA, are Given LET IV at the Same Dose as 
Oral .................................................................................................................. 57
Figure 4 LET Exposure Predictions Corresponding to the Dosing Paradigm 
for This Study, Showing LET Median AUC (With 5thand 95th
Percentile Predict ion Intervals) by [CONTACT_660183], Based on 
the Phase 3 Population PK Model With Allometric Scaling. Age 
Group 2 (2 to <7 yrs and 7 to <12 yrs), Without Coadministration of 
CsA, has a 50% Reduction in LET IV Dose Relative to Oral ......................... 58
Figure 5 Age Group 3 LET Exposure Predictions Corresponding to the Initial 
Dosing Paradigm, Showing LET Median AUC (With 5thand 95th
Percentile Prediction Intervals) by [CONTACT_5122], Based on the Phase 3 
Population PK Model With Allometric Scaling. ............................................. 59
Figure 6 Letermovir Exposure (AUC24) in All Participants From Age Groups 
1 and 2 who had Intensiv e PK (N=20) ............................................................. [ADDRESS_890001]: MK-8228 20
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890002] -2022
1 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase 2b open- label, single -arm study to evaluate pharmacokinetics, 
efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 
18 years of age at risk of developi[INVESTIGATOR_660127]/or disease following allogeneic 
haematopoietic stem cell transplantation (HSCT)
Short Title: LET for the prevention of CMV infection/disease in pediatric HSCT recipi[INVESTIGATOR_660130]: Not applicable
Hypotheses, Objectives ,and Endpoints :
There are no hypotheses to be tested in this study. 
Inpediatric (birth to <18 years of age) participants who received an allogeneic HSCT and are 
at risk for CMV infection and/or disease:
Objectives Endpoints
Primary
Objective : To evaluate letermovir PK in 
pediatric participants grouped by [CONTACT_654].AUC0 -24, Cmax (for participants 
receiving oral formulation), Ceoi (for 
participants receiving IV formulation), and 
Ctrough
Secondary
To evaluate the safety and tolerability of 
treatment with letermovir throu gh Week [ADDRESS_890003]-trans plant based on the proportion of 
participants with adverse events.Adverse Events (AEs)
AEs R esulting in Study Medication 
Discontinuation
To evaluate the efficacy of letermovir in 
prevention of clinically significant CMV 
infection thr ough Week 14 (~100 days) 
post-trans plant and through Week 24 
(~6months) post-trans plant . Clinically significant CMV infection (CS-
CMVi, defined as initiation of pre emptive 
therapy [PET] for documented CMV 
viremia and/or CMV disease ).
To evaluate the pal atability and acceptability 
oftreatment with letermovir oral granules.Score on a palatability scale.
08C0PW
PRODUCT: MK-8228 21
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890004] -2022
Overall Desig n:
Study Phase Phase [ADDRESS_890005] at risk for CMV 
infection and/or disease
Study Type Interventional
Intervention Model Single Group
This is a multi- sitestudy.
Type of Control No treatment control
Study Blinding Unblinded Open -label
Masking No Masking
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately [ADDRESS_890006] 
participant (or their legally acceptable representative) 
provides documented informed consent/assent until the 
last participant’s last study -related contact.
Number of Participant s:
Approximately 60 participants will be allocated /enrolled .
08C0PW
PRODUCT: MK-8228 22
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890007] -2022
Intervention Groups and Du ration :
Intervention 
Group sThe study will enroll participants in 3 Age Groups :
Age Group 1: From 12 to <18 years of age (adolescents)
Age Group 2: From 2 to <12 years of age (children)
Age Group 3: From birth to <2 years of age(neonates, infants and 
toddlers)
All participants will receive open- label LET for 14 weeks (~100 days) 
post-trans plant . The following tables show estimated starting oral and 
intravenous (IV) dosesof LET for participants in Age Groups 1 ( 12 to <18 
years )and 2 (2 to <12 years ). The starting doses are based on available PK 
data from adult HSCT recipi[INVESTIGATOR_660131] a review of interim PK, safety and tolerability results in the dose -
finding panels of Age Groups 1 and 2 (Panel A) . Doses for Age Group 3
(birth to <2 years) are based on the accumulated PK , safety ,and tolerability 
data from Age Group 1 (Panels A and B) and Age Group 2 Panel A.
Oral Letermovir Dosing Table
Age 
Group Age Range BW limits (kg)Oral dose LET
(mg)Oral dose LET
(mg) with CsA
112 to
<18 yearsAny weight 480 240
2 2to 
<12 years≥30 480 240
18 to <30 240 120
10to <18 120 60
3birth to 
<2 years10 to ≤15 120 60
7.5 to <10 120 60
5.0 to <7.5 60 40
2.5 to <5.0 40 20
BW=body weight; CsA=Cyclosporin A; LET=letermovir; PK=pharmacokinetic s.
Intravenous L etermovir Dosing Table
Age 
Group Age Range BW limits (kg) IV dose LET (mg)IV dose LET (mg) 
with CsA
112 to 
<18 yearsAny weight 480 240
2 2 to 
<12 years≥30 240a240b
18 to <30 120a120b
10 to <18 60a60b
3birth to 
<2 years10 to ≤15 60a60b
7.5 to <10 60c60b,c
5.0 to <7.5 40c40b,c
2.5 to <5.0 20c20b,c
BW=body weight; CsA=Cyclosporin A; IV=intravenous; LET=letermovir; 
PK=pharmacokinetics.
aBased on modeling, for Age Group 2 and Age Group 3, the IV dose of LET without CsA is 
reduced by 50% compared with oral LET in order to maintain target exposures.
bNo further reduction of IV LET is necessary when coadministered with CsA.
cBased on interim analyses results, doses are increased for participants weighing <[ADDRESS_890008]: MK-8228 23
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890009] -2022
Total 
Number1 (single -arm study)
Duration of 
ParticipationEach participant will participate in the study for approximately 50weeks 
from the time the participant or the participant’s legal representative
provide sdocumented i nformed c onsent /assent through the final contact . 
Participants can be screen edfrom up to 15days prior to receipt of HSCT to 
[ADDRESS_890010] . Enrollment/allocation can be initiated as early as the 
day of transplant , but must be completed by [CONTACT_2006] [ADDRESS_890011]-trans plant .
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee Yes
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 13.
08C0PW
PRODUCT: MK-8228 24
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890012] -2022
1.2 Schema
The study design is depi[INVESTIGATOR_6517] 1.
Figure 1Study Design
PK=pharmacokinetics .
Refer to Figure 2(Section 4.1)for further details of study design ( sequential enrollment ).
08C0PW
PRODUCT: MK-8228 25
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890013] -2022
1.3 Schedule of Activities (SoA)
1.3.1 Schedule of Activities Screening/Treatment Period
Study Period Treatment PeriodaEnd of 
Treat -
ment 
VisitCMV 
Infection
VisitbEarly 
Study 
Discon 
VisitcNotes (Protocol Section 
Reference for further details )
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26
Visit Name [CONTACT_660252]1dD7 W2 W3 W4 W5 W6 W7 W8 W9W
10eW
11eW
12eW
13eW14eDays and Weeks correspond to 
the time since enrollment
(Day 1)e
Visit Window+2
days +/-3days
Administrative Procedures
Informed 
Consent /AssentX
Informed Consent 
for FBR (optional)X
Participant 
Identification CardX
Inclusion/Exclusion 
CriteriaX X
Medical History X
Prior/Concomitant 
Medication ReviewX X X X X X X X X X X X X X X X X XVaries by [CONTACT_6960] (Section 
8.1.5 )
Treatment 
AllocationX
Study intervention
dispensingX X X X X X XContact [CONTACT_660184] 
(Section [IP_ADDRESS] ).
08C0PW
PRODUCT: MK-8228 26
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890014] -2022
Study Period Treatment PeriodaEnd of 
Treat -
ment 
VisitCMV 
Infection
VisitbEarly 
Study 
Discon 
VisitcNotes (Protocol Section 
Reference for further details )
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26
Visit Name [CONTACT_660252]1dD7 W2 W3 W4 W5 W6 W7 W8 W9W
10eW
11eW
12eW
13eW14eDays and Weeks correspond to 
the time since enrollment
(Day 1)e
Visit Window+2
days +/-3days
Study intervention
administrationX X X X X X X X X X X X X X XParticipants discharged on oral 
granules to be taken in the 
outpatient setting must be trained 
on correct procedure for preparing 
and administering the formulation 
(Section [IP_ADDRESS]).
HSCT Details 
ReviewX
Study Medication 
Diary ReviewX X X X X X X X X X X X X X XParticipant/caregiver will be 
trained in the use of the paper 
study medication diary prior to 
discharge from hospi[INVESTIGATOR_307]
(Section [IP_ADDRESS]).
Safety Procedures
Full Physical 
ExaminationX X
Height X X X X X X X X X X X
Weight X X X X X X X X X X XWeight recorded at enrollment 
(Day 1) will be used to determine
initia l dosing . Thereafter, thedose 
must be adjusted according to the 
most recent body weight (Section 
8.3.1) .
Targeted Physical 
ExaminationX X X X X X X X X X X X X X X XPerformed only when clinically 
indicated (Section 8.11.2) .
Vital Signs X X X X X X X X X X X X X X X X X X
08C0PW
PRODUCT: MK-8228 27
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890015] -2022
Study Period Treatment PeriodaEnd of 
Treat -
ment 
VisitCMV 
Infection
VisitbEarly 
Study 
Discon 
VisitcNotes (Protocol Section 
Reference for further details )
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26
Visit Name [CONTACT_660252]1dD7 W2 W3 W4 W5 W6 W7 W8 W9W
10eW
11eW
12eW
13eW14eDays and Weeks correspond to 
the time since enrollment
(Day 1)e
Visit Window+2
days +/-3days
12-Lead 
Electrocardiogram
(ECG)X X X XPerformed locally ; ECG only 
required at CMV infection visit or 
the Early Study Discontinuation 
visit if the participant was on study 
therapy at the time of the visit
(Section 8.3.3) .
Child -Pugh Score X X X X X X X X X X X
Adverse Events 
MonitoringX X X X X X X X X X X X X X X X X XVaries by [CONTACT_6960] 
(Section 8.4)
Hematology X X X X X X X X X X X Performed locally.
Section 8.3.4 &Appendix 2.
Creatinine clearance and liver 
function tests must also be 
evaluated in all participants within 
5 days prior to enrollment.Chemistry X X X X X X X X X X X
Creatinine 
ClearanceX X X X X X X X X X XCalculated per equations provided 
in Appendix 12 . See Section 7.1
for criteria for discontinuation 
from study intervention . See 
Section 8.6.2 .1for additional 
monitoring requirements for Age 
Group 3 participants on IV LET.
Coagulation 
PT/INRX X X X X X X X X X X Performed locally (Appendix 2)
Urinalysis X X X X X Performed locally
08C0PW
PRODUCT: MK-8228 28
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890016] -2022
Study Period Treatment PeriodaEnd of 
Treat -
ment 
VisitCMV 
Infection
VisitbEarly 
Study 
Discon 
VisitcNotes (Protocol Section 
Reference for further details )
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26
Visit Name [CONTACT_660252]1dD7 W2 W3 W4 W5 W6 W7 W8 W9W
10eW
11eW
12eW
13eW14eDays and Weeks correspond to 
the time since enrollment
(Day 1)e
Visit Window+2
days +/-3days
Date of menarche 
(females only)X X X X X X X X X X X X X X XReview at each visit as appropriate 
in prepubescent female 
participants. Once a date of 
menarche has been confirmed, 
participant is considered to be a 
WOCBP .
Pregnancy Test 
(urine or serum 
tests for WOCBP 
only)X X X X X X XPerformed locally (Appendices 2 
and 5)
Participant 
Confirmation of 
Birth Control 
(WOCBP only)X X X X X X X X X X X X X X X X
HIV and Hepatitis 
B and C ScreenX Performed locally (Appendix 2)
Patient Reported Outcome
Palatability and 
Acceptability 
Assessment 
(pediatric oral 
granules only)------------------------- X-------------------------- Palatability assessment should 
occur on the first day of oral 
granule administration by [CONTACT_660185] 1 week later. Not 
required for participants 
receiving oral granules via 
Gtube /NG tube (Section 8.10).
08C0PW
PRODUCT: MK-8228 29
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890017] -2022
Study Period Treatment PeriodaEnd of 
Treat -
ment 
VisitCMV 
Infection
VisitbEarly 
Study 
Discon 
VisitcNotes (Protocol Section 
Reference for further details )
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26
Visit Name [CONTACT_660252]1dD7 W2 W3 W4 W5 W6 W7 W8 W9W
10eW
11eW
12eW
13eW14eDays and Weeks correspond to 
the time since enrollment
(Day 1)e
Visit Window+2
days +/-3days
CMV Procedures/Assessments
CMV DNA PCR X X X X X X X X X X X X X X X X X XPerformed locally (Section 8.2.1)
CMV DNA PCR must also be 
performed within 5 days prior to 
enrollment in all participants.
CMV Disease 
AssessmentX X X X X X X X X X X X X X X X X X
CMV DNA 
Sequence AnalysisXPlasma sample required 
(Section 8.2.2)
PET Initiation/ 
Treatment of CMV 
Disease XCMV DNA PCR must be collected 
on the same day as PET 
initiation/treatment of CMV 
disease .
PK/Biomarkers
Buccal Swab for 
Planned Genetic 
Analysis XBuccal swab should be obtained 
prior to tran splant when possible 
(Section s8.8 and 8.9 ).
Sparse PK X X X X X X X X XCollected within 2 hours predose
for all study participants on study 
intervention (Section 8.6.1)
Intensive PKon 
oral formulation at 
Day 7 visit 
(Panel A)XAll participants in Panel A of Age 
Groups [ADDRESS_890018]: MK-8228 30
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890019] -2022
Study Period Treatment PeriodaEnd of 
Treat -
ment 
VisitCMV 
Infection
VisitbEarly 
Study 
Discon 
VisitcNotes (Protocol Section 
Reference for further details )
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26
Visit Name [CONTACT_660252]1dD7 W2 W3 W4 W5 W6 W7 W8 W9W
10eW
11eW
12eW
13eW14eDays and Weeks correspond to 
the time since enrollment
(Day 1)e
Visit Window+2
days +/-3days
Intensive PK on 
oral formulation
(Age Group 3)------------------------- X------------------------- Allparticipants in Age Group [ADDRESS_890020] intensive PK sampling 
done (starting on the 7th
consecutive day of oral LET, only 
in participants who did not 
previously have intensive PK on 
IV formulation ) (Se ction 8.6.1 ).
Intensive PKon IV 
formulation------------------------- X------------------------- Start on the 5thconsecutive day of 
IV dosing and only in 
participants who did not 
previously have intensive PK on 
oral formulation (Section 8.6.1).
HPCD PK sampling 
(for Age Group 3 
participants on IV 
formulation only)------------------------- X------------------------- Start on the 4thconsecutive day of 
IV dosing. See Sections 8.6.2 & 
[IP_ADDRESS] for timepoints and 
additional requirements for 
creatinine clearance monitoring.
08C0PW
PRODUCT: MK-8228 31
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890021] -2022
ALT = alanine aminotransferase; AST = aspar tate aminotransferase; β-hCG = β -Human Chorionic Gonadotropin; CMV = cytomegalovirus; CS-CMVi = 
clinically significant CMV infection; Discon = discontinuation; DNA = deoxyribonucleic acid; D = day; EOT = end of treatment; FBR = Future Biomedical 
Research; FSH = follicle -stimulating hormone; FU =follow -up; HPCD =hydroxypropyl -beta-cyclodextrin; HIV = human immunodeficiency virus ; h= hour; 
HSCT = hematopoietic stem cell transplant; IRT = interactive response technology; IV = intravenous; LET =letermovir ;LH = luteinizing hormone; 
PCR =polymerase chain reaction; PET =preemptive therapy ; PK = pharmacokinetics ; PT/INR = prothrombin time/international normalized ratio; SCR = 
screening ; W = week; WOCBP =woman of childbearing potential.
aThe“treatment period” is defined as the period from Day [ADDRESS_890022] -transplant . 
Study intervention will continue through Week 14 ( ~100 days) post -transplant . Day 1 procedures/assessments must be performed prior to first dose of study 
intervention. 
bThe visit will be a CMV Infecti on Visit f orall participants who meet the endpoint of CS-CMVi defined as the occurrence of CMV disease or the initiation of 
PET. During the treatment period , LET must be discontinued (if the participant is still on LET ). All procedures indicated in the SoA should be completed
prior to initiating PET for CMV infection or treatment for CMV disease at this visit . 
cThevisit will be an Early Study Discontinuation Visit for those participants who are prematurely discontinued from the study (no t study intervention alone) 
through Week [ADDRESS_890023] 
CMV viremia assessed using a CMV DNA P CR assay . After establishing absence of CMV viremia, participants should be tested once a week until 
enrollment (Day 1) . The following are to be assessed within 5 days prior to enrollment: CMV DNA, Child -Pugh Score; serum AST, ALT, and total bilirubin; 
andcreatinine clearance. Note: Screening and enrollment (Day 1) Visits will occur on separate days. 
eAll participants will receive treatment until Week [ADDRESS_890024]-trans plant . The EOT Visit will coincide with Week 10, Week 11, Week 12, Week 13 or Week 14
depending on the day the participant was enrolled relative to the day of transplant as follows:
For participants enrolled from the day of transplant to [ADDRESS_890025]-trans plant, participants attend Day 1 to Week 13 (Visits 1 -15)and Week 14 (Visit 16 ) will 
be the EOT Visit.
For participants enrolled from Day 7to Day 13post-trans plant, participants attend Day 1 to Week 12 ( Visits 1 -14)and Week 13 ( Visit 15 ) will be the EOT 
Visit.
For participants enrolled from Day 14to Day 20post-trans plant, participants attend Day 1 to Week 11 (Visits 1 -13) and Week 12 (Visit 14 ) will be the EOT 
Visit.
For participants enrolled from Day 21to Day 27post-trans plant, participants attend Day 1 to Week 10 (Visit 1 -12)and Week 11 ( Visit 13 ) will be the EOT 
Visit.
For participants enrolled on Day 28post-trans plant, participants attend Day 1 to Week 9 ( Visits 1 -11)and Week 10 ( Visit 12 )will be the EOT Visit.
All procedures listed under Visit No. 16 , EOT Visit, should be performed at th etrue end of treatment .
After the EOT Visit, all study participants should enter follow- up(Visit No. 17) . Refer to SoA Follow -up Period Section 1.3.2.
08C0PW
PRODUCT: MK-8228 32
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890026] -2022
1.3.2 Schedule of Activities Follow -up Period
Study PeriodFollow -upPeriod
(through Week [ADDRESS_890027]-trans plant)Follow -upPeriod
(through Week [ADDRESS_890028]-trans plant)CMV 
Infection 
VisitaEarly 
Study 
Discon 
Visit
(follow -
up)bNotes (Protocol Reference Section for further details)
Visit Number [ADDRESS_890029]-trans plant.
Visit Window +/-[ADDRESS_890030] X X X Virtual Visit, not a site visit
Concomitant Medication 
ReviewX X X X X X X X X Varies by [CONTACT_6960] (Section 8.1.5)
Safety Procedures
Height X X X
Weight X X X
Targeted Physical 
ExaminationX X X X X X X Performed only when clinically indicated (Section 8.3.1)
Vital Signs X X X X X X XHeart rate, blood pressure, respi[INVESTIGATOR_697], and body 
temperature (Section 8.3.2)
Adverse Events 
MonitoringX X X X X X X X X X Varies by [CONTACT_6960] (Section 8.4)
Hematology X X X Performed locally (Section 8.3.4 )
Chemistry X X X Performed locally (Section 8.3.4)
Creatinine ClearanceXX XCalculated per equations provided in Appendix 12 . See Section 
7.1for discontinuation criteria for study intervention.
Urinalysis X X X Performed locally (Section 8.3.4)
08C0PW
PRODUCT: MK-8228 33
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890031] -2022
Study PeriodFollow -upPeriod
(through Week [ADDRESS_890032]-trans plant)Follow -upPeriod
(through Week [ADDRESS_890033]-trans plant)CMV 
Infection 
VisitaEarly 
Study 
Discon 
Visit
(follow -
up)bNotes (Protocol Reference Section for further details)
Visit Number [ADDRESS_890034]-trans plant.
Visit Window +/-4 Days
Date of menarche 
(females only)X XReview at specified visits as appropriate in prepubescent 
female participants . Once a date of menarche has been 
confirmed, participant is considered to be a WOCBP.
Pregnancy Test ( urine or 
serum for WOCBP only)X X Performed locally (Appendices 2 and 5)
Participant Confirmation 
of Birth Control 
(WOCBP only)X XAcceptable methods of contraception to be used f rom the time 
of consent /assent through 28days after the last dose of study 
intervention (Appendix 5 ).
CMV Procedures/Assessments
CMV DNA PCR X X X X X X X Performed locally (Section 8.2.1)
CMV Disease 
AssessmentX X X X X X X
CMV DNA Sequence 
AnalysisXPlasma sample required . Performed only in participant s with 
CS-CMVi
PET Initiation /Treatment 
of CMV DiseaseX
AE = adverse event; CMV = cytomegalovirus; CS-CMVi = clinically significant CMV infection; Discon = discontinuation; DNA = deoxyribonucleic acid; FU 
= follow -up; LET = letermovir; PCR=polymerase chain reaction ; PET = preemptive therapy; W = week; WOCBP = women of childbearing potential .
aThe visit will be a CMV Infection Visit for all participants who meet the endpoint of CS-CMVi (defined as the occurrence of CMV disease or the 
initiation of PET )through Week [ADDRESS_890035] be discontinued (if the participant is still on LET) . All 
procedures indicated in the So A should be completed prior to initiating PET for CMV infection or treatment for CMV disease at this visit .
bThevisit will be an Early Study Discontinuation Visit for those participants who are prematurely discontinued from the study thr ough Week [ADDRESS_890036]: MK-8228 34
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890037] -2022
2 INTRODUCTION
Letermovir ( LET, also known as MK -8228, AI C246, AIC001) is an inhibitor of the CMV 
viral terminase inhibitor and has been approved for prophylaxis of CM Vinfection or disease 
in adult CMV -seropositive recipi[INVESTIGATOR_840] (R+) of an allogeneic HSCT.
2.1 Study Rationale
In a pi[INVESTIGATOR_22735], global, Phase 3 study (P001) ,LET was demonstrated to be effective in the 
prevention of CMV infection and disease in adult R+ allogeneic HSCT recipi[INVESTIGATOR_840] . LET has 
been developed and approved for adult CMV -seropositive allogeneic HSCT recipi[INVESTIGATOR_840] (R+) . 
The purpose of this study is to assess PK, safety, tolerability ,and efficacy of LET in pediatric 
allogeneic HSCT recipi[INVESTIGATOR_660132] <18 years . 
The pathogenesis and manifestations of CMV disease are similar in adults and in pediatric 
patients [Castagnola, E., et al 2004] . Therefore, LET isanticipated to have a similar safety 
and efficacy profile in pediatric patients when given at doses that achieve a similar exposure 
to that observed in adult patients . The PK data obtained in this study will be used to update 
currently available population PK and physiologically based pharmacokinetic s (PBPK )
model sbased on adult PK data to support dosing recommendations in the pediatric 
population . 
2.2 Background
Refer to the IB for detailed background information on LET.
2.2.1 Pharmaceutical and Therapeutic Background
LET is a novel inhibitor of the CMV viral enzyme DNA terminase , which cleaves newly 
synthesized CMV DNA into individual viral genomes and guides them into empty viral 
capsids . The mechanism of action of LET is highly specific ,suggesting a limited potential 
for mechanism -based toxicity . 
LET is currently available as an oral formulation (tablet s) andan intravenous (IV) 
formulation for use in adult allogeneic HSCT recipi[INVESTIGATOR_840]. Participants in this study will either 
receive the currently marketed oral adult tablets ( 240-mgstrength or multiples thereof ) or the 
newly developed age -appropriate pediatric oralformulation (consist ingof encapsulated
coated granules of LET; henceforth referred to as “oral granules ”) for oral administration
(see Sec tion2.2.4 for the bioavailabil ity evaluation of the oral granules ). During the course 
of the study, participants may use the IV formulation when a transient condition ( such as
vomiting) prec ludes oral intake . The IV formulation that will be used in P030 will be the 
same IV formulation previously used in adult participants in P001 and currently ma rketed for 
adult administration .
08C0PW
PRODUCT: MK-8228 35
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890038] countries . Similar to other herpes viruses, acute 
infection is generally followed by [CONTACT_660186] (dormant) infection . Among individuals with intact 
immune systems, reactivation of CMV infection is uncommon and general ly asymptomatic . 
However, CMV reactivation in immunocompromised patients, such as transplant recipi[INVESTIGATOR_840], 
can cause significant morbidity and mortality. 
Data on the number of HSCTs by [CONTACT_660187] . Preliminary data 
on allogen eic HSCTs (unpublished) from 358 centers in Europe across 46 countries for the 
years 2008 to 2012 provided by [CONTACT_218088] 
(EBMT) are summarized in Table 1. During this period 62,[ADDRESS_890039] ,
of which 13,513 (21.4%) were performed in children up to 18 years of age . 
Table 1 Number of Ha ematopoietic Stem Cell Transplantation by [CONTACT_660188] (%)
0-23 months 2 ,280 (3.6% of 62 940)
2-11 years 7 ,277 (11.5% of [ZIP_CODE])
12-<18 years 3,956 (6.2% of 62 940)
All children (0 -<18 years) 13,513 (21.4% of [ZIP_CODE])
≥18 years 49,427 (78.6% of [ZIP_CODE])
aEBMT Data from 358 centers in 46 countries in the EU, 2008 -2012
Table 2shows the distribution of allogeneic HSCTs in the US by [CONTACT_660189] 2014 [Center 
for International Blood and Marrow Transplant Research 2017] . Asseen in the European 
database, approximately 20% of HSCT sperformed in United Stated were performed in the 
pediatric subpopulation.
Table 2 Distribution of Allogeneic Ha ematopoietic Stem Cell Transplantation sin 2014 in 
the U nited States
Age at Transplant (Years) Number (%)
0-10 908 (10.7%)
11-20 703 (8.3%)
21+ 6,859 (81.0%)
Total 8,470 (100%)
[Center for International Blood and Marrow Transplant Research 2017]
08C0PW
PRODUCT: MK-8228 36
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890040]-trans plant [Emery V, Zuckerman M, Jackson G, Aitken C, Osman H 2013] 
[Tomonari, A., et al 2007] . InHSCT recipi[INVESTIGATOR_840], the risk of CMV reactivation and progression 
to disease is greatest in CMV -seropositive recipi[INVESTIGATOR_840], where up to 80% of recipi[INVESTIGATOR_660133], regardless of the serostatus of the donor (D- /R+ or D+/R+)
[Ljungman, P., et al 2011] [Ljungman, P. 2014] [Razonable, R. R. 2005] [Zhou, W., et al 
2009] . The highest risk period for developi[INVESTIGATOR_660134] (as defined by [CONTACT_660190]) is during the first 100days post-trans plant [Özdemir, E., et al 2007] . 
Worldwide, CMV seroprevalence increases with increasing age (Table 3). In the US, 
seroprevalence is between 5%to 20% in children between 0 to 5 years of age [Cannon, M. J., 
et al 2010] and increase stoaround 42.7% for children 12 to 19 years of age [Bate, S. L., et al 
2010] . A similar trend in increasing CMV seroprevalence with increasing age was also 
reported in studies from the European Union (EU) [Just -Nubling, G., et al 2003] [Ludwig, A. 
2009] [Lopo, S., et al 2011] .
Table 3 Cytomegalovirus Seroprevalence in General Population , [LOCATION_002]
Age Group Seroprevalence (%)
0-5 yearsa5-20
6-11 yearsb34-41
12-19 yearsb40-46
20-29 yearsb46-53
30-39 yearsb53-60
40-49 yearsb55-61
>50 yearsa65-90
aCannon, 2010
bBate, 2010
[Cannon, M. J., et al 2010] [Bate, S. L., et al 2010]
Given the relatively small number of HSCTs performed in pediatric patients and the lower 
CMV seroprevalence in younger individuals, enrollment in the current study may be 
challenging, particularly in the youngest age group . These considerations have been taken 
into account when designing the study to enable broad enrollment across the subpopulation 
of HSCT reci pi[INVESTIGATOR_840]. 
The clinical effects of CMV infection can be divided into direct and indirect effects 
[Ljungman, P., et al 2002] [Boeckh, M. 2011] . The direct effects include the spectrum of 
CMV disease manifest ations , including pneumonia, hepatitis, retinitis ,and encephalitis ;these
are associated with considerable morbidity and mortality [Boeckh, M. and Geballe, A. P. 
2011] [Ljungman, P., et al 2002] [Boe ckh, M. 2011] . 
The indirect effects of CMV infection include increased risk of opportunistic bacterial and 
invasive fungal infections, graft -versus- host disease (GVHD), and nonrelapse mortality 
08C0PW
PRODUCT: MK-8228 37
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890041] -2022
[Craddock, C., et al 2001] [Miller, W., et al 1986] [Özdemir, E., et al 2007] [Martino, R., et 
al 2001] [Söderberg , C., et al 1993] [Larsson, K., et al 2004] [Marty, F. M. and Boeckh, M. 
2011] [Ariza -Heredia, E. J., et al 2014] . Since the introduction of PET forthe management of 
CMV reactivation in allogeneic HSCT recipi[INVESTIGATOR_840], the incidence of CMV disease has been 
dramatically reduced. However, allogeneic HSCT patients have a high likelihood of 
developi[INVESTIGATOR_660135] [Ariza -Heredia, E. J., et al 2014] ,which is associated with an 
increased risk of overall mortality [Green, M. L., et al 2016] .
CMV Prevention in HSCT recipi[INVESTIGATOR_660136] [ADDRESS_890042] recipi[INVESTIGATOR_840]: 1) prophylaxis with 
antivirals, and 2) PET ,defined as the practice of active surveillance for viral replication and 
initiating treatment with anti- CMV agents when CMV viremia is detected [Ljungman, P., et 
al 2002] .
With the exception of LET , all other available anti-CMV agents arenucleo side analogues 
with associated toxicities including myelosuppression and nephrotoxicity that limit their 
clinical utility in the HSCT setting . 
Due to the concerns fortoxicities associated with the nucleoside analogue anti-CMV agents, 
PET isgenerally pre ferred to prophylaxis, and has been the preferred approach for preventing 
CMV disease in the majority of HSCT transplant centers worldwide, especially during the 
first [ADDRESS_890043]-trans plant. However, PET is suboptimal for several reasons: 
PET is initiated after patients develop CMV viremia . A recent study concluded that CMV 
viremia is associated with an increased risk of overall mortality regardless of the 
initiation of PET [Green, M. L., et al 2016] .
Given the toxicities associated with anti -CMV agents, it is important not to initiate PET 
unless it is clear that the benefit outweighs the risks . However, there is no universally 
accepted viral load threshold for the initiation of PET to guide clinicians when to initiate 
PET [Romkens, T. E., et al 2016] .
Based on these considerations, a safe and efficacious prophylaxis strategy offers advantages 
over PET. LET, an anti-CMV agent with a novel mechanism of action, has recently been 
shown to be generally well tolerated and efficacious in a pi[INVESTIGATOR_9205] 3 study (P001) when 
used for CMV prophylaxis in adult CMV -seropositive HSCT recipi[INVESTIGATOR_840] (refer to 
accompanying the IBfor further details ). Ithas recently been approved and is available in 
several regions of the world for CMV prophylaxis in adult HSCT recipi[INVESTIGATOR_840] . CMV 
prophylaxis with LET will likely represent a paradigm shift from the practic e of PET with 
nucleoside analogues for CMV prevention currently employed by [CONTACT_660191] . The current study will evaluate the PK , safety ,and efficacy of LET in this 
subpopulation of HSCT recipi[INVESTIGATOR_840] . 
08C0PW
PRODUCT: MK-8228 38
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890044] recipi[INVESTIGATOR_841] s. 
[IP_ADDRESS] LET, Absorption, Metabolism ,and Disposition
Based on population PK analyses , LET bioavailability in HSCT patient sisapproximately 
35%, while coadministration with CsA increases bioavailability to approximately 85%
(Table4). The population mean total volume of distribution is estimated to be 45.[ADDRESS_890045] recipi[INVESTIGATOR_840] . LET is extensively bound (98.7%) to human plasma protein in vitro and 
there was no dependence on concentration over the range from 0.2 to 50 mg/L . Biliary 
excretion is the major route of elimination and LET is primarily eliminated as parent drug 
(~70% of dose ) and an acyl -glucuronide (~6% of dose) in human feces . In vitro studies 
indicated that LET is a substrate of UGT1A1 and UGT1A3 and the hepatic uptake 
transporters OATP1B1 and OATP1B3 . Drug interaction studies with the OATP1B inhibitor 
CsA increased LET exposure suggesting that OATP1B plays a central role in the elimination 
of LET. Although LET is a substrate of CYP3A, CYP2D6, and CYP2J2 in vitro, oxidative 
metabolism of LET is a minor pathway in vivo.
[IP_ADDRESS] Drug Interaction sBetween LET and Immunosuppress ant Age nts
The Effect of Immunosuppres sant Agents on LET :
CsA is an inhibitor of CYP3A, P -gp, OATP1B1/ 3, and several other transporters . In Phase 1 
drug-drug interaction (DDI) studies , coadministration of LET with 50- or 200-mg CsA
resulted in approximately 1.[ADDRESS_890046] recipi[INVESTIGATOR_841] s (Table 1). Therefore, the adult LET dose of 
480mgis reduced to [ADDRESS_890047] of LET on Immunosuppressant Agents:
Coadministration of 240-mg QD oral LET with a single dose of 50-mg CsA resulted in 66% 
and 8% increase in CsA AUC an d Cmax, respectively. Co administration of 480-mg QD oral 
LET with a single dose of 5-mg tacrolimus resulted in 2.[ADDRESS_890048] of LET on mycophenolate mofetil . Coadministration of LET
increases the exposures of the immunosuppre ssants (CsA, sirolimus ,and tacrolimus) . 
Frequent monitoring of CsA, sirolimus ,or tacrolimus whole blood concentrations should be 
performed during and at discontinuation of LET and the dose of immunosuppressant should 
08C0PW
PRODUCT: MK-8228 39
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890049] -2022
be adjusted accordingly. The dose of LET is not adjusted when LET is given with tacrolimus, 
sirolimus, or mycophenolate mofetil.
For the full description of other DDI studies with LET, refer to the IB or the local prescribing 
information (if available ) for LET.
[IP_ADDRESS] Pharmacokinetic Model ingand Simulation in Adults
There are currently no PK data for LET in pediatric patients. In order to guide dose selection 
for the proposed clinical study in pediatric participant s, the Phase 3 population PK model, as 
well as a PBPK m odel based on adult data , will be used.
A Phase 1 population PK model was developed to characterize the nonlinear and time -
varying LET PK in healthy adult participants , and to evaluate the effects of selected intrinsic 
factors [Prohn M, Dykstra K, Cho C, et al. 2017] . The final PK model is a 4-compartment 
open model with first -order elimination and nonlinearity on clearance (CL) and 
intercompartmental clearance (Q1) . The Phase 1 population PK model identified a 
statistically significant increase in both the maximum CL and volume of distribution ( Vd)
with an increase in body weight , and a raceeffect (Asian )on Vd.
A Phase 3 population PK model was developed using data pooled from the Phase 3 study
(P001), one Phase 2b study , and [ADDRESS_890050] recipi[INVESTIGATOR_660137], and to evaluate the effects of selected intrinsic and 
extrinsic factors on the PK of LET [Viberg A, Prohn M, Dykstra K, et al. 2017] . The final 
PK model is two- compartment with linear absorption and clearance (dose proportional) . The 
only significant covariate sidentified w erea raceeffect (Asian) that decreased peripheral 
volume , and CsA coadministration that increased bioavailability and decreased clearance . 
Overall, oralbioavailability ofLET was approximately 35% , increasing to approximately 
85% with CsA co administration . LET clearance was 4.84 L/h, decreasing to 3.38 L/h with 
CsA coadministration . 
The Phase [ADDRESS_890051] recipi[INVESTIGATOR_660138] 480 mg QD oral or IV , or240 mg when coadministered with CsA (Table4). LET
exposures in HSCT recipi[INVESTIGATOR_660139] 480mg IV LET were similar to healthy participants
given the same regimen . However, exposures in HSCT recipi[INVESTIGATOR_660140], which may be attributed to 
gastrointestinal mucosal injury, reported as a common side -effect of chemotherapy in HSCT 
recipi[INVESTIGATOR_840], and a similar effect is also anticipated in pediatric HSCT recipi[INVESTIGATOR_840].
08C0PW
PRODUCT: MK-8228 40
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890052] -2022
Table4 Predicted Letermovir AUC (ng.hr/mL) Values in Adult HSCT Recipi[INVESTIGATOR_660141]/SubgroupMedian
AUCa(ng.hr/mL) 90% Prediction Interval
480mg Oral, no CsA 34,400 (16,900- 73,700)
480mg IV, no CsA 100,000 (65,300- 148,000)
240mg Oral, with CsA 60,800 (28,700- 122,000)
240mg IV, with CsA 70,300 (46,200- 106,000)
AUC=area under the concentration -time curve; CI=confidence interval: CsA=cyclosporin A; 
HSCT=haematopoietic stem cell transplantation; IV=intravenous.
Overall Median AUC (90% CI) = 49,200 (26,900 –87,400) ng.hr/mL.
aValues are rounded to 3 significant digits.
Exposure -response analyses for efficacy indicated that the entire range of exposures achieved 
with LET 480mg QD, adjusted to 240 mg QD LET with CsA co administration, in the Phase 
3 study (P001) is efficacious. There was no significant dependence of the efficacy endpoint 
(proportion of participant s with CS-CMVi ) on LET exposures over the range of exposu res 
assessed using exposure quartiles . The exposure -safety analyses showed that there was no 
exposure dependency for the selected AEs over the exposure range sachieved in the Phase 3 
study. 
A PBPK model was developed for exploring the basis of differences in LET PK between 
populations, including adult and pediatric . The PBPK model incorporated key absorption, 
distribution, metabolism, and excretion ( ADME )and PKproperties of LET such as biliary 
excretion as the major route of elimination , saturable UGT -mediated metabolism, and 
CYP3A -mediated metabolism as a minor pathway.
A full PBPK model with first -order absorption and a permeability- limited liver model were 
applied to describe the distribution of LET. The final model successfully described the key 
plasma disposition properties of LET including the nonlinear PK and the magnitude of 
greater -than-dose-proportional increase in exposure in white healthy volunteers . The 
mechanism of nonlinear PK was best described by [CONTACT_660192]1B -mediated 
hepatic uptake transporter and was most sensitive towards changes in Michaelis- Menten 
parameters of OATP1B transporter.
Both the adult Phase [ADDRESS_890053] exposures to support initial dose selection in the pediatric population, as 
described in Section 4.3.
2.2.4 Prec linical and Clinical Studies
In animal studies, LET was not shown to be genotoxic . Complete details of additional 
preclinical studies (including repeat dose -toxicity studies in rats [Barrow, P. C., et al 2011]
and monkeys [Barrow, P. C., et al 2011] and fertility and embryo- fetal development study in 
08C0PW
PRODUCT: MK-8228 41
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890054] -2022
rats[Barrow, P. C., et al 2011] ) can be found in the accompanying IB. These studies support 
the evaluation of LET in the pediatric population .
LET has been shown to be generall y well tolerated in 29 Phase 1 studies , 1 biopharmaceutic 
study evaluating the oral granule formulation (P031, described below), 2Phase 2 clinical 
studies (P019 and P020) and a single, pi[INVESTIGATOR_9205] 3 study (P001) conducted in adult HSCT 
recipi[INVESTIGATOR_840]. Proof -of-concept (antiviral activity) was established in the Phase 2a study (P019), 
while the safety and efficacy of LET for CMV prophylaxis in HSCT recipi[INVESTIGATOR_660142] a dose -dependent manner in the Phase 2b study (P020) . The results of the 
pi[INVESTIGATOR_9205] 3 study (P001) established the safety and efficacy of LET for CMV 
prophylaxis in adult CMV -seropositive recipi[INVESTIGATOR_840] (R+) of an allogeneic HSCT . These studies
are described in greater detail in the accompanying IB.
Comparative Bioavailability S tudy of LET Oral Pediatric Formulations (P031 )
P031 evaluated the comparative bioavailability of 2different LET pediatric oral granule 
formulations ( 2 x 120 mg; an Opadry®coating, and an Opadry + Surelease®coating), 
compared with the currently marketed adult tablet (240mg) (in n=24 h ealthy adult s). For 
each pediatric formulation, a subset of 6 participants was randomized to co administration 
with either applesauce or vanilla pudding . The PK profiles of both pediatric formulations 
were bioequivalent to the adult tablet. The geometric mean ratios (GMR ) and 90% 
confidence intervals (CI) for AUC0- inf and Cmax of the formulation comparisons are 
summarized in Table [ADDRESS_890055] of food on the PK profile of the Opadry- coated granules was 
assessed as not clinically significant as the 90% CI of the LET AUC GMR (fed / fasted) fell 
within the clinical comparability range (0.5 to 3.0). Applesauce resulted in a 20% increase in 
LET AUC and 33% increase in Cmax, while vanilla pudding resulted in a 13% increase in 
AUC and 25% increase in Cmax. The Opadry coating was also considered to provide 
advantages in stability and manufacturing . Furthermore, in a palatability assessment, the 
majority of participants indicated that the oral granules (Opadry coating) mixed in vanilla 
pudding or applesauce were neutral to very easy to swallow, had a neutral or pleasant taste 
and texture, and had a neutral or pleasant aftertaste (10 minutes after administrat ion). No 
safety concerns were observed with LET administration.
08C0PW
PRODUCT: MK-8228 42
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890056] -2022
Table 5 Summary of the Geometric Mean Ratios and 90% Confidence Intervals for 
MK-8228 Plasma PK of AUC 0-infand Cmax Following Administration of a Single Oral 
Dose of 240 mg (2x120 mg) MK -8228 Coated Granule Formulations Administered Alone, in 
Applesauce, or in Vanilla Pudding Compared With 240mg Tablet in Healthy Adult 
Participants
GMR and 90% CI
Oral Granule Comparisons AUC0 -infaCmaxa
Granules (2 x 120 mg) vs Tablet (240 mg) fasting
MK-8228 Granules (Opadry)/MK -8228 Tablet 1.00
(0.95, 1.06)1.05
(0.97, 1.14)
MK-8228 Granules (Opadry+Surelease)/ MK -8228 Tablet 0.97
(0.90, 1.03)0.94
(0.86, 1.04)
Granules (2 x 120 mg) mixed with soft food vs Granules alone (2 x 120 mg)
MK-8228 Granules (Opadry) in vanilla pudding/ 
MK-8228 Granules (Opadry)1.13
(1.04, 1.22)1.25
(1.13, 1.39)
MK-8228 Granules (Opadry) in applesauce/ 
MK-8228 Granules (Opadry)1.20
(1.00, 1.43)1.33
(1.09, 1.63)
MK-8228 Granules (Opadry+Surelease) in vanilla pudding/ MK -8228 
Granules (Opadry+Surelease)1.15
(1.04, 1.28)1.42
(1.26, 1.61)
MK-8228 Granules (Opadry+Surelease) in applesauce/
MK-8228 Granules (Opadry+Surelease)1.10
(0.99, 1.23)1.15
(1.01, 1.31)
CI=Confidence interval; G MR=Least- squares Geometric Mean Ratio between treatments; 
MK-8228=letermovir (LET) .
aBack-transformed least -squares mean and confidence interval from linear mixed -effects model performed 
on natural log -transformed values .
2.2.5 Ongoin g Clinical Studies
Refer to the IB for further details on the ongoing studies.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safety and effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and ICF do cuments.
08C0PW
PRODUCT: MK-8228 43
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890057] -2022
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
There are no hypotheses to be tested in this study. 
In pediatric (birth to <18 years of age) participants who received an allogeneic HSCT and are 
at risk for CMV infection and/or disease:
Objectives Endpoints
Primary
•Objective : To evaluate letermovir PK in 
pediatric participants grouped by [CONTACT_654] .•AUC0 -24, Cmax (for participants 
receiving oral formulation) , Ceoi (for 
participants receiving IV formulation) ,
and Ctrough
Secondary
•To evaluate the safety and to lerability of 
treatment with letermovir through Week 
[ADDRESS_890058] -trans plant based on the proportion 
of participants with adverse events.•Adverse Events (AEs)
•AEs R esulting in Study Medication 
Discontinuation
•To evaluate the efficacy of letermovir in 
prevention of clinically significant CMV 
infection through Week 14 (~ 100days) 
post-trans plant and through Week 24 (~6 
months) post-trans plant . •Clinically significant CMV infection 
(CS-CMVi, defined as initiation of 
preemptive therapy [PET] for 
documented CMV viremia and/or 
CMV disease)
•To evaluate the palatability and 
acceptability of treatment with letermovir
oral granules .•Score on a palatability scale
[ADDRESS_890059]. 
Clinically significant CMV infection is defined as the occurrence of either one of the 
following outcomes:
onset of CMV end -organ disease,
08C0PW
PRODUCT: MK-8228 44
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890060] -2022
and/or
initiation of anti -CMV PET based on documented CMV viremia and the clinical 
condition of the participant .
Appr oximately [ADDRESS_890061] recipi[INVESTIGATOR_660143]. Only R+ participants will 
be enrolled in the oldest age group (Age Group 1, see below) . CMV seroprevalence 
decreases with decreasing age . Therefore ,enrollment criteria for Age Groups [ADDRESS_890062]
been broadened to include participants with any risk for CMV reactivation (ie,R+and/or D+;
Section 5.1).
Screening of participants may begin [ADDRESS_890063]-trans plant (Figure 1 ). Participants will be tested for CMV 
viremia using aCMV DNA PCR as say. After establishing absence of CMV viremia, 
participants will be tested once a week in order to minimize enrollment of those with active 
CMV replication in the study . Any participant who tests positive for CMV viremia prior to 
enrollment will be excluded from the study. 
On the day of enrollment , eligibility criteria should be confirmed . Participants should have 
no documented CMV viremia as confirmed from a sample collected within 5days prior to 
enrollment . Creatinine clearance and liver function test results within 5days prior to 
enrollment should be within the range allowable as outlined in Section 5.2. Once enrolled , 
CMV viremia will be monitored at the time intervals detailed i n the S chedule of Activities
(SoA; Section 1.3) . LET prophylaxis (study intervention) may begin as early as the day of 
transplant and will continue through Week 14 (~100days) post-trans plant . 
The study will e nroll (allocate to receive LET) participants in 3 Age Groups:
Age Group 1: From 12 to <18 years of age (adolescents)
Age Group 2: From 2 to <12years of age (children)
Age Group 3: From birth to <2 years of age ( neonates, infants ,and toddlers)
See Figure 2 andTable 6for distribution of study participants by [CONTACT_660193] .
Enrollment wil l begin with Age Group 1 and move sequentially to younger age groups based 
on evaluation of PK in Panel A of the preceding age group ( Figure 2). For Age Group 1 and 
Age Group 2 , an initial smal l cohort of participant s (Panel A, n=6 participants ) will be 
evaluated prior to enrolling more participant s in the same age group ( Panel B, n=20) . 
For Age Group 2, approximately half of the enrolled participants will be 7 to <12 years of 
age; the remainder will be from 2 to <[ADDRESS_890064]: MK-8228 45
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890065] -2022
Age group assignment is based on the age atthe time of document edinformed 
consent/assent .
Panel A willexamine the PKto identify the correct dosing for an age group.
Non-compartmental analysis of PK paramet erswill be performed, population PK and PBPK 
models will be updated as necessary, andoptimal doses confirmed for further study. The 
final dose selected in Panel A will trigger initiation of Panel B in the same age group, and 
Panel A in the younger age group, simultaneously. In the event that the PK exposure results 
from Panel A suggest the dose should be modified, anyparticipant remaining on LET in 
Panel A will have their dose adjusted for the remainder of the treatment period . All 
participants that en rollin Panel B will receive the modified dose . Recommendations for d ose 
modifications will be communicated to sites via a Protocol Clarification Letter (PCL) as soon 
as they are available .
Due to anticipated enrollment challenges (few HSCTs performed and low CMV 
seroprevalence), there will be only 1 panel (n=8) for the youngest age group (Age Group 3) . 
Enrollment in this panel will be temporarily held after 3 participants are enrolled for further 
PK analysis to confirm dosing prior to continuing enrollmen t in this age group. The dose for 
the remaining participants (n=5) will be confirmed or modified by [CONTACT_660194] . The recommended dosing for each age group will be 
confirmed or modified by [CONTACT_660195] .
08C0PW
PRODUCT: MK-8228 46
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890066] -2022
Figure 2Sequential Evaluation of Age Groups
PK=pharmacokinetics; yr =year.
†n represents number of PK -evaluable participants.
*PK analysis will occur at 3 intervals : when all evaluable participants have completed intensive PK in Age Group [ADDRESS_890067]: MK-8228 47
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890068] -2022
LET formulations : Oraland IV formulations of LET will be available (Section 6.1). LET 
should preferably be initiated asan oralformulation (tablets or oral granules), as long as the 
participant is able to swallow or receives oral granules via a gastric (G) tube or a nasogastric 
(NG) tube and does not have a condition that may interfere with the absorption of oral 
medication (eg, vomiting, diarrhea, or a malabsorptive condition) . Age Group 1 parti cipants 
preferably should be administered the tablet formulation; participants unwilling to or unable 
to swallow the tablet should receive the oral gra nules by [CONTACT_1966], instead. I nstructions for 
preparation and administration of all LET formulations are prov ided in the Pharmacy 
Manual.
As the primary objective of this study is to obtain PK data to s upport dosing 
recommendation sfor the pediatric oral granule formulation, allparticipants in Panel A of 
Age G roups 1 and 2 (and preferably all partic ipants in Age Group 3)must receive an
oral formulation from Day [ADDRESS_890069] 7 days may be switched; they will continue in the study, but will not have intensive PK 
samples drawn on the Day 7visit. The Sponsor should be notified immediately, as an 
additional participant may subsequently be enrolled in the corresponding panel, at the 
Sponsor’s discretion (Section [IP_ADDRESS] ). 
The IV fo rmulation should only be used when participants are either unable to 
swallow /cannot use a G tube/NG tube or have a condition that may interfere with the 
absorption of anoral form ulation. Use of the IV formulation should generally be limited to 4 
weeks or less in duration . However, it will be left to the investigator’s discretion to continue 
IV administration beyond 4 weeks if the b enefit/risk ratio supports continued administration . 
Simultaneous use of IV and oral LET is not allowed . The IV formulation should be switched 
to oral LET as soon as the condition necessitating the use of the IV formulation resolves.
Cyclosporin A coadministration : In clinical DDI studies in adult participant s, 
coadministration of CsA results in an approx imately 2 to 3- fold increase in LET exposures ,
necessitating lower doses of LET when coadministered with CsA (Section [IP_ADDRESS]) . The
appropriate dosage of LET for pediatric participants will be first assessed in the absence of 
CsA (Panel A) to build upon the PK model used for dose selection prior to adding an 
additional covariate . Table 6summarizes the enrollment requirements for LET formulation 
and CsA use as well as the PK sampling requir ements by [CONTACT_660196].
08C0PW
PRODUCT: MK-8228 48
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890070] -2022
Table 6 Enrollment Requirements and Pharmacokinetic Sampling by [CONTACT_660197] A Panel B
112 to 18 
yearsN=6 (PK evaluable)
Participants must receive oral 
formulation of LET (tablets 
preferably, or oral granule sa) 
from Day 1 through Day 7 
visit.
Participants cannot receive 
concomitant CsA.
Sparse and intensive PK 
sampling in all participantsN=20 participants
Participants may receive 
tablets or oral granules 
and/or IV formulation sof 
LET.
Participants may receive 
concomitant CsA
Sparse PK sampling in all 
participants . Additionally,
intensive PK if participant 
receives at least 5 
consecutive days of IV 
LETb.
22to 12 
yearsN=6 (PK evaluable)
-N=3 participants 2 years to 
<7 years
-N=3 participants 7 years to 
<12 years
Participants must receive 
Oral granule sof LETafrom 
Day 1 through Day 7 visit.
Participants cannot receive 
concomitant CsA .
Sparse and Intensive PK 
sampling in all participantsN=20 participants
-N=10participants 2 
years to <7 years
-N=10participants 7 
years to <12 years
Participants may receive 
oral granules and/orIV 
formulation of LET .
Participants may receive 
concomitant CsA. 
Sparse PK sampling in all 
participants . 
Intensive PK ,if participant 
receives at least 5 
consecutive days of IV 
LET.
3birth to <2 
yearsN=8 (PK evaluable)
Participants can receive oral granules (preferably) and/or IV 
formulation of LET .
Participants may receive concomitant CsA.
Sparse PK sampling in all participants 
Intensive PK s ampling in all participants, regardless of whether 
on oral or IV LET formulationb
HPCD PKsamplingc
08C0PW
PRODUCT: MK-8228 49
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890071] -2022
Age
GroupAge
Range Panel A Panel B
CsA=cyclosporin A; IV=intravenous; HPCD =hydroxypropyl -beta-cyclodextrin; LET=letermovir ; n=number 
of participants ; PK=pharmacokinetics.
aFor Age Group 1, tablets should be preferably administered unless the participant is unable or unwilling to 
swallow the tablet , in which case, the participant may receive oral granules. The oral granules may be 
administer edeither by [CONTACT_334572] a G tube/NG tube, provided the participant does not have a condition 
that may interfere with the absorption of oral medication (eg, vomiting, diarrhea, or a malabsorptive 
condition )
bIntensive PK on IV f ormulation will be collected from participants who have not had intensive PK on the 
oral formulations (oral granules/oral tablet) ; sample collection will start on the 5th consecutive day of IV 
dosing.
cHPCD PK s ampling will start on the 4thconsecutive day of IV dosing. HPCD PK sampling timepoints and 
additional creatinine clearance monitoring requirements aredetailed in Section s8.6.2 and [IP_ADDRESS] .
PK sampling: Intensive PK sampling for LET will be done at the Day 7 visit in all Panel A 
participants who received an oral formulation from Day 1 through Day 7 . Panel B 
participants, and p articipants who are not on the oral formulation through Day 7 (ie , switch to
IV during this period) will not u ndergo intensive PK sampling on Day 7. 
Any participant who receives IV LET for [ADDRESS_890072] intensive PK sampling done regardless of the 
formulation received (starting on either the fifth consecutive day of IV LET or the seventh 
consecutive day o foral LET , whichever comes first ).
The Sponsor should be notified if intensive PK cannot be done in a participant in Panels A of 
Age Groups 1 and 2, andall ofAge Group 3 . Enrollment ofparticipants in the sepanels will 
continue until the minimum number of evaluable participants for the interim PK analyses are 
enrolled in each panel . After a pause in enrollment for each interim PK analysis, enrollment 
of additional study participants will be resumed.
Sparse PK sampling will be done in all study participant s at the designated visits 
(Section 1.3–SoA). 
HPCD PKsampling : Whole blood will be collected from Age Group 3 participants starting 
on the fourth consecutive day of IV LET administration . Sections 8.6.2 and [IP_ADDRESS] contain 
details on timepoints for HPCD PK sampling and the additional creatinine clearance
monitoring requirements forAge Group 3 participants for whom HPCD PK sampling will be 
obtained.
Monitoring for CS -CMVi : All participants will receive LET from the day of enrollment
(Day 1) through Week 14 (~100 days) post-transplant, the period of highest risk for CMV 
reactivation, with the intent of preventing CS-CMVi . Participants will have study visits 
08C0PW
PRODUCT: MK-8228 50
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890073]-transplant , as the risk for CMV reactivation 
is considerably reduced during this interval . The incidence of CS -CMVi will also be assessed 
through Wee k 24 (~ 6 months) post-trans plant to evaluate the occurrence of late CS-CMVi
(between Weeks [ADDRESS_890074] -trans plant) . 
For participants who develop CS-CMVi through Week [ADDRESS_890075] a CMV Infection Visit . At this visit, LET should be discontinued (if 
applicable ) and all procedure sas outlined in the SoA (Section 1.3), including collection of a 
CMV DNA PCR sample ,should be performed immediately prior to the initiation PET or 
treatment of CMV disease . Such participa ntswill continue to be followed in the study and 
complete all remaining study visits). 
Participants who discontinue the study prior to Week [ADDRESS_890076]-trans plan tshould 
complete an Early Study Discontinuation Visit and complete all procedures as per the SoA 
(Section 1.3).
Following completion of the study period at Week 24 (~6 months) post-transplant, all study 
participants will remain in the study for an additional [ADDRESS_890077] ing safety information 
(Section 8.4). Mortality data will be collected throughout the participant s’enrollment in the 
study.
Following the conclusion of this study and the Clinical Study Report (CSR) for the study, a 
final PK model will be developed that includes all PK data from participants from birth to 
18years, in addition to relevant adult data previously collected in the program . The final 
model and proposed pediatric dosing regimen will be summarized in a separate m odeling 
report.
An independent external Data Monitoring Committee (DMC) will be established for safety 
evaluation. The DMC will review safety data ( at proposed time points outlined in Section 9.7 
and detailed in the DMC charter ), consider the overall risk and benefit of continuing the 
study to study participants, and make a recommendation to the Sponsor to continue, modify, 
or end the study. Some analyses may be combined at the request of the DMC . The DMC may 
review safety data at other time points (including after the last sche duled safety check) as 
needed .
Anindependent, Clinical Adjudication Committee (CAC) will be established for adjudicating 
all potential investigat or-reported cases of CMV end- organ disease, as defined i n Appendix 
8, throughout the study. For analysis purposes, t he adjudication of cases by [CONTACT_126526]’s assessment.
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each proced ure 
are provided in Section 8.
08C0PW
PRODUCT: MK-8228 51
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890078] -2022
4.2 Scientific Rationale for Study Design
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Pharmacokinetic Endpoints
The primary objective of this study is to evaluate the PK of LET in pediatric participants to 
support LET dose selection for use in preve ntion of clinically significant CMV infection in 
pediatric patients receiving an allogeneic HSCT . For thenoncompartmental analysis (NCA ), 
the primary PK endpoints for LET are:area under the concentration -time curve for the 
dosing period (AUC0 -24), maximum concentration observed (Cmax, for participants 
receiving oral formulations ), minimum concentration observed before next dose (Ctrough) , 
and concentration at the end of infusi on (Ceoi, for participants receiving IV formulation) . 
Additional PK parameter sfor participants receiving oral formulations aretime to maximum 
observed plasma drug concentration (Tmax ), half -life (t1/2), apparent clearance (CL/F), and 
apparent volume of distribution (Vd/F ). Additional PK parameters for participants receiving 
IVformulation are half -life (t1/2), clearance (CL ), and volume of distribution (Vd ). Plasma 
samples for PK evaluations will be collected at the time points described in the SoA 
(Secti on1.3). Refer to Section 8.6.1 for the PK sampling scheme.
[IP_ADDRESS] Safety Endpoints
Safety and tolerability arekey secondary objective sof this study. The safety and tolerability 
of LET will be assessed by a clinical evaluation of ad verse experiences and evaluation of 
other study parameters including vital signs, physical examination, [ADDRESS_890079] laboratory safety tests at appropriate time points as specified in the SoA 
(Section 1.3). 
Rationale for Specific Safety Endpoint Analyses: 
Renal function
The IV formulation of LET contains the excipi[INVESTIGATOR_660144] D,which can accumulate in patients 
with renal insufficiency. In this regard, cyclodextrin is also an excipie nt in other approved IV 
agents, including IV voriconazole (given with the excipi[INVESTIGATOR_841], sulfobutylether -β-cyclodextrin) . 
Recent data suggest that ,despi[INVESTIGATOR_660145], baseline renal function is not a p redictor of worsening renal function in patients 
receiving IV voriconazole [Neofytos, Dionissios, et al 2012] . Additionally, the quantity of 
cyclodextrin in the IV formulation of LET is less than that in the IV voriconazole 
formulation (1800 mg of cyclodextrin/vial for a 240 -mg dose of LET ascompared with
3200 mg of cyclodextrin/vial for a 200-mg dose of voriconazole ,which is administered twice 
a day) . 
The IV formulation of LET was used in a total of 99 participants (27%) in the pi[INVESTIGATOR_9205] 3 
study (P001) . The extent of exposure to IV LET was similar to IV placebo in P001 . The 
incidence of AEs reported in recipi[INVESTIGATOR_660146] 2
treatment groups . Further assessments of trends in blood urea nitrogen ( BUN )and serum 
08C0PW
PRODUCT: MK-8228 52
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890080] -2022
creatinine confirm that the use of the LET IV formulation had a similar renal safety profile 
compared with placebo, suggesting that the use of the cyclodextrin formulation in P001 was 
not associated with renal toxicit y.
Renal function will be closely monitored in this study (reported AEs as well as laboratory 
parameters of renal function including BUN ,serum creatinine levels and creatinine 
clearance ) to confirm the cyclodextrin -containing IV formulation is not associated with renal 
toxicity in the pediatric population . Additionally, HPCD PK sampling will be done in Age 
Group [ADDRESS_890081] 4 consecutive day s.See 
Section8.6.2 and Section 8.6.2 .1for sampling timepoints and additional creatinine clearance 
monitoring requirements inthese Age Group 3 study participants receiving the IV 
formulation. 
Based on the above, the use of IV LET is permitted in participants in this study with renal 
insufficiency, provided creatinine clearance is >10 mL/min as calculated by [CONTACT_16424] -
Gault equation (for participants ≥12 years of age) or >10mL/min/1.73 m2 by [CONTACT_660198] (for participant <12 years of age) or the participant is not on hemodialysis
(Appendix 12) . However, the IV formulation should only be used when participants are 
either unable to swallow or have a condition (eg,vomiting, diarrhea, or malabsorptive 
condition) t hat may interfere with the absorption of the oral form ulation. Participants on IV 
LET should be switched to the oral formulation as soon as they are able to swallow and/or 
the condition that warranted the use of the IV formulation has resolved.
[IP_ADDRESS] Efficacy Endpoint s
Theefficacy endpoint sof the study will be the proportion of participant s with CS-CMVi
through Week 14 (~100 days) and Week 24 (~6 months) post -trans plant , defined as the 
occurrence of either one of the following outcomes: 
onset of CMV end -organ disease 
OR
initiation of anti -CMV PET based on documented CMV viremia and the clinic al 
condition of the participant . Initiation of PET in this study refers to the practice of 
initiating therapy with the following anti -CMV agents when active CMV viral 
replication is documented: ganciclovir, valganciclovir, foscarnet, and/or cidofovir.
Note: Documented viremia is defined as anydetectable CMV viral DNA (including PCR 
results above or below the lower limit of quantification) .
CMV infection, as measured by [CONTACT_660199], is associated with considerable morbidity and 
mortality in H SCT recipi[INVESTIGATOR_660147] (the “direct” 
effects) and the “indirect” effects secondary to the effects of CMV on the immune system as 
described in Section 2.2.
Current ly, with most centers using PET for prevention of CMV dis ease, the overall incidence 
of CMV disease in HSCT recipi[INVESTIGATOR_660148] 5% in the first [ADDRESS_890082]: MK-8228 53
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890083] risk, from 20 % to 30% prior to the routine use of 
preventive measures [Boeckh, M. 2011] [ Boeckh, M. and Nichols, W. G. 2004] [Marty, F. 
M., et al 2011] [Craddock, C., et al 2001] [Boeckh, M., et al 1992] [Winston, D. J., et al 
2008] [Ljungman, P., et al 1998] [Snydman, D. R. 2011] . Therefore, the efficacy endpoint 
selected for this study –CS-CMVi –will be a composite endpoint of CMV infection 
warranting initiation of PET and/or CMV disease.
Assessment of Efficacy Endpoint
Detection of CMV in plasma or blood is associated with an increased risk of CMV disease 
[Gerna, G., et al 2011] [Lowance, D., et al 1999] [Gor, D., et al 1998] [Atkinson, C. and 
Emery, V. C. 2011] . CMV viral DNA as a measure of CMV infection is already used 
routinely in clinical practice to initiate and monitor PET [Boeckh, M. 2011] [ Boeckh, M. and 
Ljungman, P. 2009] [Winston, D. J., et al 2008] [Härter, G. and Michel, D. 2012] [Emery, V. 
C., et al 2000] . The decision to initiate PET should be guided by [CONTACT_660200]. 
Investigators will report all “probable ”and “ proven”cases of CMV disease using the 
definitions in Appendix 8 . All investigator -reported disease will be confirmed by [CONTACT_660201] . The CAC will review clinical, virological, and histopathological data as 
well as the investigator’s assessment for adjudicating all potential cases of end-organ CMV 
disease . For analysis purposes, the adjudication of cases by [CONTACT_660202]’s assessment.
[IP_ADDRESS] Palatability and Acceptance Assessment Endpoint
Palatability may play a n important role in adherence to treatment in the pediatric population . 
Palatability is an important element in the determination of acceptability, an d encompasses a 
product’s smell, taste, aftertaste, and texture . 
Acceptability, including palatability, of the oral 
granule formulation will be assessed in all participants using the Palatability Acceptance 
Assessment (PAA) . In previous studies, the most c ommonly reported assessment measured 
palatability preference using a visual analog scale that was modified by [INVESTIGATOR_3086] a facial 
hedonic scale (FHS; facial expression scale depi[INVESTIGATOR_542311] g various degrees of pleasure)
[Thompson, C., et al 2015] . The 5-point FHS for taste is one of the most frequently reported 
typesof palatability assessments used in pediatric clinical studiesand will be used in this 
study.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_890084] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug absorption, distribution, metabolis m, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and IRB/IEC allow, a sample will be collected for DNA analysis 
from consenting participants.
08C0PW
PRODUCT: MK-8228 54
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890085] -2022
DNA samples will be used for research related to the study intervention(s), the disease under 
study, and related diseases. They may also be used to develop tests/assays including 
diagnostic tests related to the disease under study, related diseases, and study intervention(s). 
Genetic research may consist of the analysis of 1 or more candidate genes or the analysis of 
genetic markers throughout the genome [or analysis of the entire genome] (as appropriate).
DNA samples will be analyzed for variation across the e ntire genome. Analyses may be 
conducted if it is hypothesized that this may help furthe r understand the clinical data.
The samples may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to understand study disease o r related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on specimens for which consent was provided during this 
study. This research may include genetic analyses (DNA), gene expression profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on which specimens are consented for FBR. 
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objectiv e of collecting/retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective dru
gs/vaccines, and/or to ensure that participants receive the correct dose of 
the correct drug/vaccine at the correct time. The details of FBR research are presented in
(Appendix 6) .
4.3 Justification for Dose
4.3.1 Starting Dose for This Study
Table 7 and Table 8show doses for initiating LET prophylaxis with the oral or IV 
formulations of LET, respectively ,when LET is administered with or without CsA ,for 
Age Group s 1to 3. Age Group 1 (age 12 to < 18years ),Panel A started with the adult dose of 
480mg once daily. For Age Group 2 (age 2 to <12 years ), the LET doses shown are the 
starting doses .The starting doses for Age Groups 1 and 2  were confirmed based on the 
review of interim analyses of PK , safety ,and tolerability from Age Group 1, Panel A. Doses 
for Age Group 3 (birth to <2 years) are based on the accumulated PK,safety, andtolerability
data from Age Group 1 (Panels A and B) and Age Group [ADDRESS_890086] 3 participants from Age Group 3. (Note: for weight -based dosing, weight recorded at 
enrollment [ Day 1 ]will be used to determine initial dosing . Dose may need to be 
adjusted according to the most recent body weight taken per the SoA). In the event the 
starting doses listed here need to be modified, this information will be communicated to 
investigators and sites via a PCL . The rationale for these starting doses is described below in 
Section [IP_ADDRESS]. See Sec tion6.1for full dosing instructions.
08C0PW
PRODUCT: MK-8228 55
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890087] establish 
the oral LET pediatric PK profile and subsequent model predictions . However, participants 
initially enrolled in Panel A, but requiring a switch to IV administration after the Day 7 visit 
will still be included in the populati on PK analysis.
Table 7 Oral Letermovir Dosing Table
Age 
Group Age RangeBW limits 
(kg)Oral dose LET
(mg)Oral dose LET (mg) 
with CsA
1 12 to<18 years Any weight 480 240
2 2to<12 years≥30 480 240
18 to <30 240 120
10 to <18 120 60
3 birth to <2 years10 to ≤15 120 60
7.5 to <10 120 60
5.0 to <7.5 60 40
2.5 to <5.0 40 20
BW = body weight recorded at enrollment (Day 1) will be used to determine the initial dosing. Dose may be 
adjusted according to the most recent body weight taken per the SoA. CsA = Cyclosporin A; IV = intravenous; 
LET = letermovir; PK = pharmacokinetics; S oA=Schedule of Activities.
Table 8 I ntravenous Letermovir Dosing Table
Age 
Group Age Range BW limits (kg) IV dose LET (mg)IV dose LET (mg) 
with CsA
1 12 to <18 years Any weight 480 240
2 2to <12 years≥30 240a240b
18 to <30 120a120b
10 to <18 60a60b
3 birth to <2 years10 to ≤15 60a60b
7.5 to <10 60c60b,c
5.0 to <7.5 40c40b,c
2.5 to <5.0 20c20b,c
BW=body weight recorded at enrollment (Day 1) will be used to determine the initial dosing. Dose may be 
adjusted according to the most recent body weight taken per the SoA ; CsA=Cyclosporin A; IV=intravenous; 
LET=letermovir; PK =pharmacokinetics; SoA=Schedule of Activities.
aBased on modeling, for Age Group 2, the IV dose of LET is reduced by 50% compared with oral LET in 
order to maintain target exposures.
bNo further reduction of IV LET is necessary when co administered with CsA.
cBased on interim analyses res ults, doses are increased for participants weighing  <[ADDRESS_890088]: MK-8228 56
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890089] -2022
[IP_ADDRESS] Dose Justifications
Using modeling and simulation in the adult clinical program, the relationship between LET
exposure and response (efficacy and safety) in adult HSCT recipi[INVESTIGATOR_660149] . In 
addition, t he pathogenesis of CMV infection (viremia) and disease ,and the mechanism of 
action of LET, arenot anticipated to be different in pediatric scompared with adults. Thus, 
achieving LET exposures in pediatric HSCT recipi[INVESTIGATOR_660150].
Exposure t argets:
Exposure targets and bounds for the pediatric HSCT population were established using the 
typi[INVESTIGATOR_660151]. 
The Phase 3 population PK model predicted steady -state median exposures (AUC0- 24h) in 
adult HSCT recipi[INVESTIGATOR_660152] 480 mg without CsA (Table4), 
respectively, were chosen as the target range (34,400 to100,000 ng.hr/mL) for the pediatric 
median exposures . In addition, the 5thpercentile exposure following 480 mg oral LET, and 
the 95thpercentile exposure following 480 mg IV LET, respectively, were chosen as the 
(16,900 to 148,000 ng·hr /mL) lower and upper bound for the pediatric exposure range .
Simulations with both thePBPK model combined with the Simcyp pediatric module and the
Phase [ADDRESS_890090] optimal LET doses 
and weight bounds within each of the 3age groups, with the goal of keepi[INVESTIGATOR_660153] e predicted exposures within theprespecified bounds. The pediatric p atients had 
an assumed weight distribution at each age according to CDC (2 to 17years ) and WHO (0 to 
23months) growth tables . Figure 3andFigure [ADDRESS_890091] the predicted pedia tric AUC in Age Groups 1 and 2 ,as a function of Age Group 
and body weight, for the 4 regimens of oral or IV route of LET administration, and with or 
without concomitant CsA. Figure 3is the dosing paradigm using oral and IV LET (without 
CsA) interchangeably for both Age Groups 1 and 2 . 
Figure 4shows the dosing paradigm for this study ,where participants in Age Group 2 (2 to 
<12 y ears) without co administration of CsA require a 50% reduction in LET IV dose relative 
to oral.
Figure 5shows the Age Group [ADDRESS_890092]: MK-8228 57
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890093] -2022
Figure 3LET Median AUC (With 5th and 95thPercentile Prediction Intervals) by [CONTACT_660203], Based on the Phase 3 Population PK Model With Allometric Scaling. 
Age Group 1 (12 to <18 y rs) and Age Group 2 (2 to <7 yrsand 7 to <12 yrs), Without 
Coadministration of CsA, are Given LET IV at the Same Dose as Oral
AUC=area under the concentration -time curve; CsA= cyclosporin A; LET=letermovir (MK- 8228); 
IV=intravenous; po=by [CONTACT_1966] ; yrs=years.
08C0PW
PRODUCT: MK-8228 58
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890094] -2022
Figure 4LET Exposure Predictions Corresponding to the Dosing Paradigm for This Study, 
Showing LET Median AUC (With 5thand 95thPercentile Prediction Intervals) by [CONTACT_660204], Based on the Phase 3 Population PK Model With Allometric Scaling. Age 
Group 2 (2 to <7 yrs and 7 to <12 yrs), Without Coadministration of CsA, has a 50% 
Reduction in LET IV Dose Relative to Oral
See Table 7 for initial dosing paradigm ( oral) and Table 8for initial dosing paradigm (IV) . Green dotted lines 
are the median exposures (50th percentile) following the 480 mg oral and IV LET dose (without CsA) of 34,400 
to 100,000 ng.hr/mL, respecti vely, and represent the target exposure range for the pediatric median exposures.
Brown dotted lines are the 5thpercentile exposure of 16,900 ng·hr/mL following 480 mg oral LET and the 95th 
percentile exposure of 148,000 ng·hr/mL following 480 mg IV LET, and represent the lower and upper bound 
targets, respectively, for the pediatric exposure range. 
Red dotted line is the maximal AUC exposure achieved in the Phase 1 program . 
AUC=area under the concentration -time curve; CsA= cyclosporin A; LET=letermovir (MK -8228); 
IV=intravenous; po=by [CONTACT_1966]; yrs=year s.
08C0PW
PRODUCT: MK-8228 59
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890095] -2022
Figure 5Age Group 3 LET Exposure Predictions Corresponding to the Initial Dosing 
Paradigm, Showing LET Median AUC (With 5thand 95thPercentile Prediction Intervals) by
[CONTACT_5122], Based on the Phase 3 Population PK Model With Allometric Scaling. 
Solid lines are medians and shaded regions are 90% prediction intervals.
AUC=area under the concentration -time curve; CsA =cyclosporin; IV=intravenous; Ph=Phase; po=by [CONTACT_1966].
LET is transported by [CONTACT_448662]1B 1/3, for which limited maturation data are available . In the 
literature, relative protein expression of OATP1B1 was highly variable among individuals, 
and no statistically si gnificant difference was observed among the studied age groups 
[Thomson, M. M., et al 2016] [Prasad, B., et al 2016] . For OAT P1B3, protein expression was 
not significantly different between adults and children >1 year, but was significantly different 
for children <1 year [Prasad, B., et al 2016] . However, it is unknown how much of the 
measured protein represents active transporter . Therefore, dose predictions fo r Age Group 3 
(birth to <2 years) exhibit a higher uncertainty than the older pediatric age groups . As such ,
dose predictions for Age Group 3 were determined by[CONTACT_660205] 2 Panel A PK data ,along with all cumulative PK, safety ,and 
tolerability data . The resulting oral and IV dose selections for all Age Groups are presented 
inTable 7 andTable 8, respectively.
LET administered without CsA:
The adult clinical program included patients with a body weight range of 35.1 to 141.5 kg 
who demonstrated favorable PK, safety, and efficacy . Based on the comparable body weight 
and OATP1B maturation in participants aged 12 to <18 y ears (Age Group 1), it is anticipated 
that the PK of LET in this age group will behave similarly to those of adults receiving the 
08C0PW
PRODUCT: MK-8228 60
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890096] -2022
adult 480-mg oral dose of LET. The adult clinical program supports that the IV and oral LET 
dose are interchangeable . This approach was model edfor Age Group 1, and although the 
predicted exposure sforIV and/or CsA regimens exceeds the median and upper bound
exposure targets for simulated adolescents approaching the lowest 5thpercentile weight of 
30kg, the exposures are generally within the target exposures overall, and are below t he 
highest exposure achieved in the entire clinical program ( ~ 328,000 ng.hr/mL) ( Figure 4 , 
rows 2-4 , column 3). Exposures in the lowest weight adolescents will be carefully monitored, 
and an additional weight band in Age Group 1may be added in the event actual exposures 
exceed the clinical experience in adults.
During the model ingof the dose selections for Age Group 2, when using interchangeable 
doses for IV and o ral LET , the predicted exposures for IV without CsA exceeded both the 
median and upper bound exposure targets ( Figure 3, row 2, columns 1 -2). In order to 
maintain predi cted exposure swithin target bounds for IV, 2 options forAge Group 2 were 
considered: (1) add additional weight bands with a narrower weight range and maintain 
interchangeable IV and oral doses; or (2) maintain the current weight bands and reduce the 
IV dose by 50%. Given that there is less known about drug disposition in this age group, and 
that the children with the lowest body weight were at the highest risk to exceed the upper 
limit of the exposure target, in order to achieve the target exposure range in Age Group 2, the 
initial IV dose of LET is reduced by 50% . 
LET administered with CsA:
As the PBPK model s are not currently validated to predict drug- drug interactions for CsA, 
the Phase 3 p opulation PK model alone was used to estimate LET exposures with CsA, 
suggesting a reduction of oral LET dose by 50% when given with CsA for ages 
2to<18years , due to the expected increase in bioavailability and decrease in clearance with 
CsA. No furthe r reduction in the LET IV dose is anticipated when coadministered with CsA
(Figure 3).
[IP_ADDRESS] Dose in Age Group 1 (12 to <18 years ),Panel A
For the initial dose for Age Group 1 Panel A, t he LET PBPK model simulations assume the 
same OATP1B 1/3 abundance for hepatic uptake and effects of physiology as estimated for 
adult patients. The PBPK and the p opulation PK model suggests that the adult dose of LET
of 480 mg oral or IV will result in comparable exposures in ages 12to <18 years as in adults. 
The adult tablet s will be used in this age group, thus establishing continuity with the body of 
adult PK data from the adult studie s. For participants unable or unwilling to swallow the 
adult tablets, oral granules may be used (see Section 6.1 for dosing instructions) . No dose 
modifications for Age Group 1 were necessary based on the interim PK analysis of all 
evaluable participants in Age Group 1 Panel A.
[IP_ADDRESS] Dose in Age Group 2 (2 to <12 years ), Panel A
The doses for Age Group 2 Panel A shown in Table 7and Table 8 were estimate d,as 
described in Section4.3.1. 2. The doses were confirmed by[CONTACT_660206], safety, 
and tolerability data.Age G roup 2 (2 to <12years )issubdivided into weight bands . For 
08C0PW
PRODUCT: MK-8228 61
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890097] -2022
participants weigh ing≥30kg, an oral dose of [ADDRESS_890098] pat ients. For participants weighing 18 to <30kg, a n 
oral dose of 240mg of oral granules of LET is estimated to result in comparable exposures as 
the adult HSCT patients. For participants weighing 10to<18kg, an oral dose of 120 mg of 
LET is estimated. In the event t hat a participant is switched to IV LET, the IV dose is 
reduce din this age group and the estimated IV doses are described in Table 8.
A minimum of 3 evaluable participants per age range (2years to <7 years , and 7 years
<12years ) are required prior to initiating interim PK analysis, in order to assess maturation 
effect on the PK disposition of LET. No dose modifications for Age Group 2 were necessary 
based on the planned interim PK analysis of all evaluable participants in Age Group 2 Panel 
A.
All participants in Age Group 2 Panel A will receive oralgranules sprinkled on soft food or 
administered via a G tube/NG tube (see supporting study documentation [eg, Pharmacy 
Manual ] for details on preparation and administration of oral granules by [CONTACT_660207]/NG tube).
[IP_ADDRESS] Dose in Age Group s [ADDRESS_890099] recipi[INVESTIGATOR_840] . The Day 7 intensive PK 
data from Age Group 1 or 2 of Panel A was used to estimate exposures using NCA . The 
range of exposures estimated by [CONTACT_660208] ;no adjustments to the doses specified in Table 7 and Table 8 were
made for P anel B. The final determination of doses for Panel B was based on the composite 
assessment of cumulative PKandsafety and tolerability results through Panel A.
Recommendations for dose modifications will be communicated to investigators and sites via 
a PCL as soon as they are available . The interim and final analyses will be described in a 
separate Modeling and Simulation Plan, and reported in separate Modeling and Simulation 
Reports.
[IP_ADDRESS] Age Groups 1 and 2 P harmacokinetic Exper ience Through Interim 
Analysis 2
The initial dose selections for Age Groups 1 and 2 were evaluated by [CONTACT_660209] A (n=6 per Age Group) following oral administration of LET 
without CsA for at least [ADDRESS_890100]: MK-8228 62
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890101] exposure observed in the LET Phase 1 program (328000 
h.ng/mL). Figure 6shows the steady -state exposures (AUC24) determined by 
[CONTACT_469436] (NCA) for the (n=20) participants who had intensive PK as of 
Interim Analysis 2.Overall, 17/20 participants had exposures in the adult exposure target 
range, comprising 4/6 participants in Age Group 1 Panel A, 7/8 participants in Age Group 1 
Panel B, and 6/6 participants in Age Group 2 Panel A . Of the 3/20 participants who had 
exposu res outside the adult exposure target range, one participant receiving oral LET (Age 
Group 1 Panel A) had an exposure below the target range, another receiving oral LET (Age 
Group 1 Panel A) had an exposure above the target range, but 1.46 -fold below the u pper 
clinical bound, and one participant receiving IV LET (Age Group 1 Panel B) had an exposure 
above the target range, but 2.11 -fold below the upper clinical bound . Overall, these results 
support the validity of the method used to determine the doses for Age Groups 1 and 2 , and 
the continuation of the same method for Age Group 3.
Figure 6Letermovir Exposure (AUC24) in AllParticipants F rom Age Groups 1 and 2 who 
had Intensive PK (N=20)
AUC 24=area u nder the concentration -time curve for the dosing interval (0 to 24 hours); CsA=cyclosporin; 
IV=intravenous; NG=nasogastric; po=by [CONTACT_1966]; y=year.
CsA above the symbol indicates CsA was coadministered with the LET dose. Vertical dotted lines show the 
dosing weight band boundaries for Age Group 2 (there are no dosing weight boundaries for Age Group 1) .
a  The relative size of each symbol reflects the dose of LET : small=120 mg;medium=240 mg;large=[ADDRESS_890102]: MK-8228 63
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890103] -2022
[IP_ADDRESS] Dose in Age Group 3
The initial doses in Age Group 3 were determined based on ananalysis of the accumulated 
PK data from Age Group 1 (Panels A and B) and Age Group 2 Panel A ,as described above
in Section4.3.1.4 .Having validated the dose selection for Age Groups 1 and 2, the method 
of allometric scaling of the adult Phase 3 pop ulation PK model was applied to Age Group 3. 
A metabolic maturation adjustment to the allometric scaling coefficient for glucuronidated 
drug clearance was used, as well as a small adjustment to exposure for granules consumed 
with food. The Age Group 3 participants ha vean assumed weight distribution according to 
WHO (0 to 23 months) growth tables. As for all a ge groups , doses and weight band s were 
selected to keep the predicted pediatric exposures within the adult target range . The resulting 
simulated exposures in Figure [ADDRESS_890104] exposures in the adult target range with the proposed doses in Table 7and Table 8 .
Following the collection of intensive PK in 3 evaluable participants in Age Group 3, 
enrollment waspaused until after the analysis of intensive PK and reevaluation of the initial 
dose for t his age group.Changes in dosesfor Age Group 3 w ascommunicated to
investigators and sites via a PCL.
4.3.2 Maximum Dose/Exposure for This Study
The maximum dose of LET in this study will not exceed [ADDRESS_890105] participant (or their legally acceptable representative) 
provides documented informed consent/assent. The overall study ends when the last 
participant completes the last study- related contact, withdraws co nsent, or is lost to follow -up 
(Section 7.3) .
4.4.1 Clinical Criteria f orEarly Study Termination
Early study termination will be the result of the criteri onspecified below:
1.The eDMC recommends termination of the study and the Executive Oversight 
Committee (EOC) agrees as stated in the DMC charter.
2.The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects is such that the risk/benefit ratio to the study population as a whol e 
is unacceptable .In addition, further recruitment in the study or at ( a) particular study 
site(s) may be stopped, as described in Appendix [ADDRESS_890106] between the ages of birth and <18 years 
of age (on the day of documenting informed consent /assent ) will be enrolled in this study.
08C0PW
PRODUCT: MK-8228 64
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890107] for Clinical Trials (Appendix 1.1), this study includes 
participants of varying age, race, ethnicity, and sex. The collection and use of these 
demographic data will follow all local laws and participant confidentiality guidelines while 
supporting the study of the disease, its related factors, and the IMP under investigation .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
An individual is eligible for inclusion in this study if the individual meets all of the following 
criteria :
1.All Age Group [ADDRESS_890108] documented positive CMV serostatus (CMV IgG 
seropositive) for the recipi[INVESTIGATOR_841] (R+) within [ADDRESS_890109] documented positive CMV serostatus
(CMV IgG seropositive) for the recipi[INVESTIGATOR_841] (R+) within 90 days prior to enrollment and/or 
for the donor (D+); the donor serostatus should be documented within [ADDRESS_890110] (bone marrow, peripheral blood stem cell, or 
cord blood transplant).
3.Have undetectable CMV DNA from a plasma or whole blood sample collected within [ADDRESS_890111] at the time of enrollment.
Demographics
1.Participant is aged from birth to <18years of age at the time of providing documented
informed consent /assent .
Female Participants
2.A female participant is eligible to participate if she is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of the following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b.A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_890112]: MK-8228 65
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890113] -2022
Informed Consent /Assent
3.The participant (or legally acceptable representative )has provide ddocumented informed 
consent /assent for the study. The participant or legally acceptable representative may also 
provide consent /assent for FBR . However, the participant may participate in the study 
without participating in FBR.
Additional Categories
4.Study participants in Panel A of Age Groups 1and [ADDRESS_890114] be able to take (as assessed by [CONTACT_093]) LET tablets or the oral granule s
(either by [CONTACT_334572] G tube/NG tube ), provided the participant does not have a 
condition that may interfere with the absorption of oral medication (eg, vomiting, 
diarrhea, or a malabsorptive condition) from the day of enrollment until the intensive PK 
sampling is completed in these panels (Day 7 Visit, see SoA, Section 1.3) .
5.For Age Group 2, the participant’s weight should be at least 10 kg; and for Age Group 3, 
the participant’s weight should be at least 2 .5kgand less than or equal to 15kgat the 
time of enrollment.
5.2 Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1.Has received a previous allogeneic HSCT (Note: receipt of a previous autologous HSCT 
is acceptable) . 
2.Has a history of CMV end -organ disease within [ADDRESS_890115] procedure, whichever is earlier, until the time o f enrollment . (Note: Evidence of 
CMV viremia will include any test result reported as “positive ”on a qualitative assay; 
“detectable ” including “detectable , not quantifiable ,” or “detected” with a numeric value 
provided by a quantitative assay.)
4.Has suspec ted or known hypersensitivity to active or inactive ingredients of LET
formulations.
5.Has severe hepatic insufficiency (defined as Child -Pugh Class C; see Appendix 9) within 
5days prior to enrollment .
6.Has serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 x the 
upper limit of normal (ULN) or serum total bilirubin >2.[ADDRESS_890116] within 5days prior to 
enrollment . 
Note : Participants who meet this exclusion criterion may, at the discretio n of the 
investigator, have repeat test ingdone one time prior to enrollment . If the repeat value 
08C0PW
PRODUCT: MK-8228 66
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890117] -2022
does not meet this criterion, they may continue in the screening process . Only the specific 
out of range value should be repeated (not the entire panel).
7.Isa) onrenal replacement therapy (eg ,hemodialysis, peritoneal dialysis )
OR 
b) has end-stage renal impairment with a creatinine clearance ≤10mL/min, as 
calculated by [CONTACT_16424] -Gault equation (for participants ≥12 years of age) or ≤10 
mL/min/1.73 m2 by [CONTACT_660210] (for participant s <12 years of 
age) using serum creatinine within 5days prior to enrollment (Appendix 12 ).
Note : Participants who meet this exclusion criterion may, at the discretion of the 
investigator, have repeat testing done one time within 5days prior to enrollment . If 
the repeat value does not meet this criterion, they may continue in the screening 
process . Only the specif ic out of range value should be repeated (not the entire panel).
8.Has both moderate hepatic insufficiency AND moderate -to-severe renal insufficiency. 
Note: Moderate hepatic insufficiency is defined as Child -Pugh Class B ( Appendix 8 ); 
moderate- to-severe renal insufficiency is defined as a creatinine clearance <50mL/min, 
as calculated by [CONTACT_16424] -Gault equation (for participants in Age Group 1 )or 
<50mL/min per 1.73 m2calculated using the modified Schwartz equation (for 
participants in Age Group 2 ). Participants in Age Group [ADDRESS_890118] moderate hepatic insufficiency and creatinine clearance <20mL/min per 1.73 m2
calculated using the modified Schwartz equation; see Appendix 12 for Cockcroft -Gault 
andmodified Schwartz equ ations ).
9.Has an uncontrolled infection on the day of enrollment.
10.Requires mechanical ventilation or is hemodynamically unstable at the time of 
enrollment.
11.Has a documented positive result for ahuman immunodeficiency virus antibody (HIV-
Ab) test at any time prior to enrollment, or for hepatitis C virus antibody (HCV -Ab) with 
detectable HCV RNA, or hepatitis B surface antigen (HBsAg) within 90days prior to 
enrollment.
12.Has active solid tumor malignancies with the exception of localized basal cell or 
squamous cell skin cancer or the condition under treatment ( eg,lymphomas).
13.Has a preexisting cardiac condition a) for which the patient is currently being treated or 
b)which required hospi[INVESTIGATOR_854] 6 months or c) that may be expected to 
recur during the course of the trial . Examples of pre existing cardiac conditions that would 
preclude enrollment include atrial fibrillation and atrial flutter.
08C0PW
PRODUCT: MK-8228 67
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890119] -2022
Prior/Concomitant Therapy
14.Received with in 7days prior to enrollment any of the following :
ganciclovir
valganciclovir
foscarnet
acyclovir (at doses greater than those recommended for HSV/VZV prophylaxis; see 
Appendix 10 )
valacyclovir (at doses greater than those recommended for HSV/VZV prophyla xis: 
seeAppendix 10 ) 
famciclovir
15.Received within 30days prior to enrollment of any of the following:
cidofovir
CMV immunoglobulin 
any investigational CMV antiviral agent/biologic therapy
Rifampin and other strong inducers (such as phenytoin, carbamazepi[INVESTIGATOR_050], St John’s 
wort ( Hypericum perforatum ), rifabutin and phenobarbital) and moderate inducers 
such as nafcillin, thioridazine, modafinil and bosentan.
16.Received letermovir at any time prior to enrollment in this study.
Prior/Concurrent Clinical S tudy Experience 
17.Is currently participating or has participated in a study with an unapproved
investigational compound or device within 28days, or 5X half -life of the investigational 
compound (excluding monoclonal antibodies), whichever is longer, of init ial dosing in 
this study. Participant s previously treated with a monoclonal antibody will be eligible to 
participate after a 28 -day washout period. 
Note : Investigational chemotherapy regimens involving approved agents and 
investigational antimicrobial regimens involving approved 
antibacterial/antifungal/antiviral age nts, investigational radiotherapy studies, or other 
observational studies are allowed.
18.Has previously participated in this study or any other study involvin g LET.
08C0PW
PRODUCT: MK-8228 68
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890120] dose of study intervention .
22.Has clinically relevant drug or alcohol abuse within 12 months of screening that may 
interfere with participant treatment, assessment, or compliance with the protocol , as 
assessed by [CONTACT_093] .
23.Has a history or current evidence of any condition, therapy, lab abnormality, or other 
circumstance that might confound the results of the study, interfere with the participant 's 
participation for the full duration of the study, or would be put at undue risk as judged by 
[CONTACT_093], such that it is not in the best interest of the participant to participate in 
this study.
24. Is or has an immediate family m ember (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.[ADDRESS_890121] circular for meal and dietary restrictions .
5.4 Screen Failures
Screen failures are defined as participants who consent /assent to participate in the clinical 
study, but are not subsequently entered in the study. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities . Minimal information includes demography, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
08C0PW
PRODUCT: MK-8228 69
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890122] -2022
5.5 Participant Replacement Strategy
If a participant enrolled in Panel A of Age Group 1 or 2 or in Age Group 3 discontinues from 
study intervention or withdraws from the study prior to intensive PK sampling, or is 
considered not evaluable for intensive PK, a replacement participant may be en rolled in the 
corresponding panel to ensure n=6 PK -evaluable participants in each Panel A,and n=8
PK-evaluable participants in A ge Group 3. Enrollment of replacement participants will be at 
the discretion of the Sponsor and may occur at any active study site . The replacement
participant will be assigned a unique allocation number . 
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protocol.
Clinical supplies study interventions provided by [CONTACT_210638] .Clinical supplies will be affixed with a 
clinical label in accordance with regulatory requirements.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study areoutlined inTable 9.  In this study, 
approximately 60 participants will be enrolled in three age groups to receive LET once a day 
from the day of enrollment (Day 1, within [ADDRESS_890123] -transplant) through 14 weeks (~100 
days) post -transplant.  Both oral (adult tablet and capsul es containing oral granules) and IV 
formulations of LET willbe used i n this study.  Simultaneous use of IV and oral study 
therapy is not allowed .
Dosing for all age groups will be based on age and most recent weight (SoA 1.3.1) . Dosing 
recommendations for all Age Groups are provided in Table [ADDRESS_890124]: MK-8228 70
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890125] -2022
Table 9 Study Intervention
Arm TypeIntervention 
NameTypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationaRegimen/ Treatment 
PeriodUseIMP/
NIMP/
AxMPSourcing
1Experimental letermovir Drug Tablet 240 mg Age/
weight based Oral QD from Day 1 through 
week 14 (~100 days) 
post-transplant Test 
ProductIMP Sponsor
2Experimental letermovir Drug Capsule (oral 
granules)a120 mg Age/
Weight basedOral QD from Day 1 through 
week 14 (~100 days) 
post-transplantTest 
ProductIMP Sponsor
3Experimental letermovir Drug Capsule (oral 
granules)a30 mg Age/
Weight basedOral QD from Day 1 through 
week 14 (~100 days) 
post-transplantTest 
ProductIMP Sponsor
4Experimental letermovir Drug Capsule (oral 
granules)a10 mg Age/
Weight basedOral QD from Day 1 through 
week 14 (~100 days) post 
transplantTest 
ProductIMP Sponsor
5Experimental letermovir Drug Intravenous 20 mg/mL 
vialAge/
Weight basedIntravenous QD from Day 1 through 
week 14 (~100 days) post 
transplantbTest 
ProductIMP Sponsor
EEA=European Economic Area; IMP=investigational medicinal product; NIMP/AxMP=noninvestigational medicinal product/auxiliary medicinal product.
The classification of IMP and NIMP/AxMP in this table is based on guidance issued the European Commission and applies to countries in the EEA. Country differences wi th 
respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circumstances, local legislation is followe d.
aThe oral granules may be administered either by[CONTACT_334572] G tube/NG tube, provided the participant does not have a condition that may interfere with the 
absorption of oral formulation (eg, vomiting, diarrhea, or a malabsorptive condition).
bUse of IV formulation should generally be limited to 4 weeks or less in duration . The IV formulation should be switched to oral study intervention (ie, at the 
next planned visit) as soon as such participants are able to swallow and/or the condition necessitating the use of IV formulation resolves.
08C0PW
PRODUCT: MK-8228 71
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890126] -2022
Dosing of Oral F ormulation :
For Age Group 1 : Either the currently marketed oral 240-mg tablets (or multiples thereof) for 
adults will be used (preferably) or, the oral granules will be used for participants unable or 
unwilling to swallow the adult tablets. The adult tablets may be taken with or without food.
For Age Group s 2and 3 : The only oral formulation that will be used in th esegroup swill be 
oral granules .
Oral Granule Administration : 
Oral granules are encapsulated and may be administered either by [CONTACT_120728] a soft food 
vehicle, or as a suspension using a G tube/NG tube . Please see Pharmacy Manual for further 
details on preparation and administration of oral granules.
Table 10 Dosing for Oral Formulations of LET
Age 
GroupAge 
RangeBW limits
(kg)Oral dose 
LET
(mg)Clinical supplies 
for oral dosea, cOral dose 
LET (mg) 
with CsAClinical supplies for 
oral dose with CsA
112 to <18 
yearsAny weight 4802x240 mg tablets
OR
4x120 mg capsulesb2401x240 mg tablet
OR
2x120 mg capsulesb
2 2 to <12 
years≥30 480 4x120 mg capsules 240 2x120 mg capsules
18 to<30 240 2x120 mg capsules 120 1x120 mg capsule
10to<18 120 1x120 mg capsule 60 2x30 mg capsules
3Birth to <2 
years10 to ≤15 120 1x120 mg capsule 60 2x30 mg capsules
7.5 to <10 1201x12 0 mg capsules
or 
4x30 mg capsules60
2x30 mg capsules
5.0 to <7.5 60 2x30 mg capsules 404x10 mg capsules
2.5 to <5.0 40 4x10 mg capsules 20 1x10 mg capsule
BW=body weight recorded at enrollment (Day 1) will be used to determine initial dosing . Dose may be 
adjusted according to the most recent body weight taken per the SoA ;CsA=cyclosporin A; LET=letermovir.
aCapsules refer to the capsules containing oral granules for administration with soft food or via G tube/NG
tube.
bFor participants unable to swallow tablets.
cAlternate combinations may be used to achieve doses , if necessary . These alternate combinations will be 
communicated separately to investigator s. 
08C0PW
PRODUCT: MK-8228 72
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890127] -2022
Dosing of IV Formulation :
For study participants who cannot swallow and/or have a condition that may interfere with 
the absorption of an oral formulation ( eg,vomiting, diarrhea, or a malabsorptive condition), 
study intervention can be initiated with or switched to the IV formulation (Table 11) . The IV 
formulation should be administered over a period of 60 minutes . A sterile 0.2- micron or 
0.22- micron polyethersulfone ( PES)in-line filter and diethylhexyl phthalate ( DEHP )-freeIV 
bags and infusion set materials must be used . Use of the IV formulation should generally be 
limited to 4 weeks or less in duration . However, it will be left to the investigator’s discretion 
to continue IV administration beyond 4 weeks.
Administration of IV Formulation :
Please see Pharmacy Manual for details on preparation and administration of the IV 
formulation.
Table 11 Dosing for Intravenous Formulation LET
Age Group Age RangeBW limits
(kg)IV dose LETa
(mg) IV dose LET (mg) with CsAa
1 12 to <18 years Any weight 480 240
2 2 to <12 years≥30 240b240
18 to <30 120b120
10 to <18 60b 60
3 Birth to <2 years10 to ≤15 60b60
7.5 to <10 60c60b,c
5.0 to <7.5 40c40b,c
2.5 to <5.0 20c20b,c
BW=body weight recorded at enrollment (Day 1) will be used to determine initial dosing . Dose may be 
adjusted according to the most recent body weight taken per the SoA; CsA=cyclosporin A; 
LET=letermovir.
aIV formulation concentrate to be diluted per the Pharmacy Manual .
bBased on model ingfor Age Group s 2and 3 , the IV dose of LET is reduced by 50% compared with oral 
LET in order to maintain target exposures and no further reduction of IV LET is necessary when 
coadministered with CsA.
cBased on interim analysis results for Age Group 3, dose increase for BW limi ts <10 kg.
As additional PK analyses are performed during the study, the dose proposed for participants 
will be confirmed or modified. Recommendations for dose modifications will be 
communicated to investigators and sites via a PCL.
All supplies indicated in Table 9will be provided per the “ Sourcing ”row depending upon 
local country operational requirements. Every attempt should be made to source these 
supplies from a single lot/batch number .
08C0PW
PRODUCT: MK-8228 73
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890128] -2022
Refer to Section 8.1.9 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_890129] be stored 
in a secure, environmentally controlled, and monito red (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The s tudy site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and sh all take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomiz ation and Blinding
6.3.[ADDRESS_890130]: MK-8228 74
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890131] -2022
6.3.2 Stratification
Participants in this study will be stratified by [CONTACT_551] (birth to <2 years, 2 to <12 years, and 
12 to <18 years).
6.3.3 Blinding
This is an open -label study; therefore, the Sponsor, investigator, an d participant will know 
the intervention administered.
6.4 Study Intervention Compliance
Interruptions from the protocol specified treatment plan for > 7 consecutive days require 
consultation between the investigator and the Sponsor and written documentation of the 
collaborative decision on participant management.
6.5 Concomitant Therapy
It is important for investigators to review each medication (prescription and nonprescription) 
the part icipant is taking before starting the study and at each study visit.
At each visit, participants should be questioned about any new drug they are taking.
To minimize the risk of adverse drug interactions, every effort should be made to 
limit the number of concomitant drugs to those that are truly essential.
Given that the lists below are not comprehensive, the investigator should use his/her medical 
judgment when a participant presents with a medication not on the list and consult with the 
Sponsor when appr opriate.
6.5.1 Allowed Medications/Therapi[INVESTIGATOR_014]
[IP_ADDRESS] Allowed Medications/Therapi[INVESTIGATOR_660154] C an be Administered W ithout 
Monitoring
The following medications/therapi[INVESTIGATOR_660155].
Standard antimicrobial prophylaxis (eg,levofloxacin for bacteria, fluconazole/
posaconazole for fungi ; see Section [IP_ADDRESS] for recommendation s on voriconazole use
when coadministered with LET )
acyclovir , or valacyclovir, for prophylaxis of herpes simplex virus (HSV) or varicella 
zoster virus ( VZV) infections at doses no greater than prohibited doses of these 
medications ( Appendix 10)
All types of prior conditioning regimens (including myeloablative, reduced -intensity, 
or nonmyeloablative regimens)
08C0PW
PRODUCT: MK-8228 75
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890132] -2022
Prior/Ongoing graft manipulation regimens (incl uding various ex-vivo or invivo
T-cell depletion or selection regimens)
GVHD prophylaxis regimens , other than those outlined below in Section [IP_ADDRESS] .
[IP_ADDRESS] Allowed Medications/Therapi[INVESTIGATOR_126500] C linical and/or 
Drug -level M onitoring
The following medications/therapi[INVESTIGATOR_660156] , but should 
be used with clinical monitoring for adverse events related to these agents and/or drug -level 
monitoring of these agents. 
When using an allowed concomitant medication please refer to the pediatric prescribing 
information of each local product circular . Note that all allowed medications in this section 
have pediatric prescribing information, but not all these agents have prescribing information 
covering the wide age ran ge of participants (from birth to <18years of age ) that will be 
evaluated in this protocol . 
Note : Since the DDIs may be different when LET is coadministered with CsA , the 
combined effect on CYP3A substrates may be similar to a strong CYP3A inhibitor , 
please refer to Section [IP_ADDRESS] for additional recommendations when LET is 
coadministered with CsA.
CYP3A substrates:
oCoadministration of LET with drugs that are CYP3A substrates may result in 
clinically relevant increases in the plasma concentrations of coadministered CYP3A 
substrates (examples : alfentanil, fentanyl, and midazolam ). Therefore, frequent 
monitoring for adverse reactions related to these agents is recommended during 
coadministration. 
oDose adjustment of CYP3A substrates with narrow therapeutic range ( NTR) may be 
needed when coadministered with LET (a moderate CYP3A inhibitor). P lease consult 
current prescribing information for monitoring and dosing these products with 
moderate inhibitors of CYP3A.
Cyclosporin A (CsA) : Coadministration of LET with CsA increases CsA 
concentrations . Frequent monitoring of CsA whole blood concentrations should 
be performed during and at discontinuation of LET and the dose of CsA adjusted 
accordingly.
Sirolimus : Coadministration of LET with sirolimus increases concentrations of 
sirolimus. Frequent monitoring of sirolimus whole blood concentrations should be 
performed during and at discontinuation of LET and the dose of sirolimus 
adjusted accordingly. When LET is coadministered with CsA, refer to the 
sirolimus prescribing information for specific dosing recommendations for use of 
sirolimus with CsA.
08C0PW
PRODUCT: MK-8228 76
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890133] -2022
Tacrolimus : Coadministration of LET with tacrolimus increases tacrolimus 
concentrations . Frequent monitoring of tacrolimus whole blood concentrations 
should be performed during and at discontinuation of LET and the dose of 
tacrolimus adjusted accordingly.
Everolimus: Coadministration of LET with everolimus may increase everolimus 
concentrations . Frequent monitoring of everolimus blood concentrations should 
be performed during and at discontinuation of LET and the dose of everolimus 
adjusted accordingly. ( Note : Please see Section [IP_ADDRESS] for recommendation s for
everolimus when LET is coadministered with CsA ).
Note: LET dose adjustment is not necessary when coadministered with tacrolimus, sirolimus, 
everolimus or mycophenolate mofetil.
Certain HMG -CoA reductase inhibitor s (also referred to as S tatins) as s ubstrates of 
organic anion -transporting polypeptide 1B1/3 (OATP1B1/3) and/or CYP3A:
oAtorvastatin: The dos e of atorvastatin should not exceed a daily dose of 20 mg.
(Note : Please see Section [IP_ADDRESS] for recommendation s for the administration of 
atorvastatin when LET is coadministered with CsA) . 
oFluvastatin, rosuvastatin, lovastatin, or pravastatin : The dose of fluvastatin, lovastatin, 
or pravastatin may need to be adjusted when coadministered w ith LET . Monitoring 
for statin- associated adverse reactions (eg, myalgias , rhabdomyolysis ) is 
recommended during coadministration with LET . 
Substrates of CYP2 C9 and CYP2C19:
oVoriconazole : Coadministration of LET with voriconazole decreases the plasma 
concentrations of voriconazole likely due to induction of CYP2C9 and/or 2C19 . If 
concomitant administration is necessary, close monitoring for reduced effectiveness 
of voriconazole is recommended.
oWarfarin: LET may decrease the plasma concentrations of CYP2C9 and/or CYP2C19 
substrates (eg, warfarin). Frequent monitoring of international normalized ratio (INR) 
should be performed while warfarin is coadministered with LET.
oProton Pump Inhibitors, such as omeprazole and pantoprazole : LET may decrease the 
plasma concentrations of CYP2C19 substrates . Clinical monitoring and dose 
adjustment may be needed.
6.5.2 Prohibited Medication s
Medications/therapi[INVESTIGATOR_660157] [IP_ADDRESS]. Since the DDI on coadministered 
drugs may be different when LET is coadministered with CsA than when dru gs are 
08C0PW
PRODUCT: MK-8228 77
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890134] -2022
coadministered with LET without CsA, additional prohibited medications when LET is 
coadministered with CsA are outlined in Section [IP_ADDRESS] . 
Letermovir should be administered in a manner consistent with the LET local product 
circular, including the complete list of prohibited medications (ie, those that are 
contraindicated or not recommended) in the circular . The local product circular for LET 
supersedes this section when the product circular is more restrictive .While the participant 
is enrolled in the study, only LET provided by [CONTACT_660211] .
If there is a clinical indication for one of these or other medications specifically prohibited 
during the study, discontinuation from LET may be required . The investigator should 
discuss any questions regarding this with the Clinical Director . The final decision on any 
supportive therapy rests with the investigator and/or the participant 's primary physician . 
However, the decision to continue the participant on LET requires the mutual agreement of 
the investigator, the Sponsor , and the participant .
[IP_ADDRESS] Medications Prohibited with LET
A. Prohibited Anti -CMV Medications
The following antiviral drugs or therapi[INVESTIGATOR_126503]/treatment of CMV are 
prohibited through Week [ADDRESS_890135]-transplant unless required for the initiation of PET or 
treatment of CMV disease at a CMVi visit :
oGanciclovir orvalganciclovir
oFoscarnet
oCidofovir
Note: these agents may be used for other indications while participants are on study 
therapy (eg, foscarnet for the treatment of human herpes virus 6 [HHV-6] ). 
B. Other Prohibited A gents With Anti-CMV Activity
The following a ntiviral drugs or therapi[INVESTIGATOR_126503]/treatment of CMV are prohibited 
through Week [ADDRESS_890136] -transplant :
oAcyclovir , valacyclovir (at doses greater than those recommended for HSV/VZV 
prophylaxis: seeAppendix 10), famciclovir , or letermovir (not provided by [CONTACT_660212]).
oCMV hyper -immune globulin or intravenous immune globulin.
oAny investigational CMV antiviral agent/biologic therapy, including CMV vaccines .
Note: these agents may be used for other indications while parti cipants are on study 
therapy (eg, acyclovir for treatment of disseminated zoster) . 
08C0PW
PRODUCT: MK-8228 78
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890137] -2022
C. Other M edication s Prohibited W ith LET
The following medications/therapi[INVESTIGATOR_660158] [ADDRESS_890138] dose of study medication:
Investigational Agents : Unapproved investigational agents or investigational 
regimens involving combinations of approved agents are not permitted except
oInvestigational chemotherapy regimens involving approved agents and 
investigational antimicrobial regimens involving approved 
antibacterial/antifungal/antiviral age nts, investigational radiotherapy studies, or 
other observational studies are allowed.
oInvestigational vaccines (ie, those not licensed or approved for emer gency use) 
are not allowed. 
Note: any licensed COVID- 19 vaccine (including for emergency use) in a particular 
country is allowed in the study as long as they are mRNA vaccines, adenoviral 
vaccines, or inactivated vaccines. These vaccines will be treated j ust as any other 
concomitant therapy. 
Herbal Supplements : Herbal supplements are not permitted.
CYP3A substrates with NTR that can lead to SAEs, including but not limited to:
opi[INVESTIGATOR_3924] :Concomitant administration of LET may result in increased 
concentrations of pi[INVESTIGATOR_126505]3A by [CONTACT_126532], which may lead 
to QT prolongation and torsade de pointes.
oergotalkaloids: Concomitant administration of LET may result in increased 
concentration of ergot alkaloids (ergotamine and dihydroergotamine) due to 
inhibition of CYP3A by [CONTACT_126532], which may lead to ergotism.
Certain Statins (Note: See Section [IP_ADDRESS] for additional statins that are prohibited for 
use when LET is coadministered with C sA):
osimvastatin and pi[INVESTIGATOR_2830]. 
oFixed -dose combinations of statins.
• Rifampin and other strong inducers (such as phenytoin, carbamazepi[INVESTIGATOR_050], St John’s 
wort [ Hypericum perforatum ], rifabutin and phenobarbital) and moderate inducers 
such as nafcillin, thioridazine, modafinil, and bosentan.
[IP_ADDRESS] Additional Medications Prohibited when LET is Coadminist ered with CsA
Themagnitude of CYP3A- and OATP1B1/[ADDRESS_890139]: MK-8228 79
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890140] -2022
section pertain to coadministration with LET with CsA. In addition to the prohibited 
medications listed above in Section [IP_ADDRESS], medications listed in this section are additional 
medications that are prohibited when coadm inistered with LET and CsA.
When used together, they should be administered in a manner consistent with the local 
product circulars (for CsA and if available, for LET), including the complete list of 
prohibited medications including those that are contrain dicated or not recommended. For
example ,the SmPC for LET has additional contr aindications when LET and CsA are 
administered; the local product circular for LET supersedes this section when the product 
circular is more restrictive .
Certain s tatins: When LET is coadministered with CsA, the magnitude of the increase 
in statin plasma concentrations is expected to be greater than with LET alone . 
oatorvastatin and lovastatin (Note: please see Section 6.5.2 .1for additional 
prohibited statins when coadministered with LET alone ). 
everolimus (Note: please see Section [IP_ADDRESS] for recommendation for everolimus 
when coadministered with LET alone).
repaglinide 
6.5.3 Rescue Medications and Supportive Care
In the event of CS-CMVi (CMV disease or initiation of PET based on CMV viremia and the 
clinical condition of the participant [see Section [IP_ADDRESS]] ) at any time during the 14-week 
post-trans plant period, study intervention will be discontinued ,and the participant may be 
treated according to the local standard of care ( outside the context of the study ). In this 
setting, any of the prohibited anti -CMV medications (outlined in Section 6.5) may be used.
6.6 Dose Modification (Escalation/Titration/Other)
See Section 4.3.1 for the LET dose to be used with or without coadministered CsA.
If CsA is initiated after starting study i ntervention, the next dose of LET (administered up to 
24 hours later) should be decreased as applicable . If CsA is discontinued permanently or for 
the long term in a participant already receiving LET, the next dose of LET (administered up 
to 24 hours later ) should be increased as applicable . If CsA is temporarily withheld due to 
high levels detected by [CONTACT_126548], the dose of LET need not be adjusted.
6.[ADDRESS_890141]: MK-8228 80
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890142] -2022
6.8 Clinical Supplies Disclosure
This study is open- label; therefore, the participant, the study site personnel, the Sponsor, 
and/or designee are not blinded. Study intervention (name, strength, or potency) is included 
in the label text; random code/disclosure envelop es or lists are not provided.
[ADDRESS_890143] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore , all participants 
who discontinue study intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 1.[ADDRESS_890144] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1. 10.
A participan t must be discontinued from study intervention but continue to be monitored in 
the study for any of the following reasons:
The participant or participant’s legally acceptable representative requests to 
discontinue study intervention.
The participant has a medical condition or personal circumstance which, in the 
opi[INVESTIGATOR_11922]/or Sponsor, placed the participant at unnecessary risk 
from continued administration of study intervention.
The participant has a confirmed positive pregnancy test.
The participant develops CS-CMVi as determined by [CONTACT_093] (Section 
[IP_ADDRESS]).
The participant develops (one or more of the following) :
o An elevated AST or ALT lab value that is ≥ 3 × ULN and an elevated total 
bilirubin lab value that is ≥2 × ULN and, at the same time, an alkaline 
08C0PW
PRODUCT: MK-8228 81
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890145] -2022
phosphatase lab value that is <2 × ULN, as determined by [CONTACT_13149] -
specified laboratory testing or unscheduled laboratory testing
o Both moderate hepa tic insufficiency (Child -Pugh Class B; Appendix 9 ) and 
moderate- to-severe renal insufficiency (defined as creatinine clearance
<50mL/min as calculated by [CONTACT_16424] -Gault equation (for Age Group 1 ) 
or<50mL/min per 1.73 m2 as calculated using the modified Schwartz 
equation ( for Age Group 2) ;Participants in Age Group [ADDRESS_890146] moderate hepatic insufficiency and creatinine 
clearance <20mL/min per 1.73 m2 calculated using the modified Schwartz 
equation; see Appendix 12 for Cockcroft -Gault and modified Schwartz 
equations .
o Severe hepatic insufficiency ( Child -Pugh Class C; Appendix 9 ).
o Either 
a) a needfor renal replacement therapy (eg , hemodialysis, peritoneal dialysis)
OR
b) has e nd-stage renal impairment with creatinine clearance ≤10mL/min as 
calculated by [CONTACT_16424] -Gault equation (for participants ≥12 years of age) 
or ≤10mL/min per 1.73 m2as calculated using the modified Schwartz 
equation (for pa rticipants <12 years of age ; Appendix 12).
For Age Group 3 participants only, the IV formulation of LET should be 
discontinued when the creatinine clearance (as determined by [CONTACT_660213]) meets the following criteria:
•decreases by ≥50% from the baseline value (ie, on the day IV LET wa s 
initiated) 
AND
•is below the lower bound of normal creatinine clearance for the age at the time 
of assessment ( Table 12).
•Note: The decrease in creatinine clearance should be confirmed by [CONTACT_254108] . The confirmatory sample should be obtained no later than [ADDRESS_890147]: MK-8228 82
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890148] -2022
Table 12 Lower Bound of Creatinine Clearance by [CONTACT_660214], b
18 months to <2 years ≥76 mL/min/1.73m2
12 to <18 months ≥73 mL/min/1.73m2
8 to <12 months ≥65 m L/min/1.73m2
14 weeks to<8 months ≥57 m L/min/1.73m2
6 to <14 weeks ≥47 m L/min/1.73m2
2 to <6 weeks ≥41 m L/min/1.73m2
1 to <2 weeks ≥35 m L/min/1.73m2
Birth to <1 week ≥20 m L/min/1.73m2
aModified Schwartz equation used to calculate creatinine clearance (Appendi x 12.1 ).
bLower bound of normal creatine clearance taken from published lower bound standard deviation of age -
appropriate means (Biron, Schwartz).
[Brion, L. P., et al 1986] [Schwartz, G. J. 2009]
7.[ADDRESS_890149] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from t he 
study, as well as specific det ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.10. The procedures to be performed should a participant repeatedly 
fail to return for scheduled visits and/or if the study site is unabl e to contact [CONTACT_63517] 7.3.
7.[ADDRESS_890150] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or de signee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_660215]’s medical record.
08C0PW
PRODUCT: MK-8228 83
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890151] -2022
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_148198]. Delegatio n of study site personnel responsibilities 
will be documented in the Investigator Study File Binder (or equivalent).
•All study- related medical decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be compl eted and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as app licable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be used for screening or baseline purposes 
provided the procedures meet the protocol -specified criteria and were performed within 
the time frame defined in the SoA .
•Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent, and assent if applicable, be obtained from 
the participant. In these cases, such evaluations/testing will be performed in accordance 
with those reg ulations.
•The maximum amount of blood collected from each participant over the duration of the 
study will vary ;see Appendix 2.
•Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent /Assent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent, and assent if applicable, from each potential 
participant or their legally acceptable representative prior to participating in this clinical 
study or FBR .If there are changes to the participant’s status during the study (eg, health or 
age of majority requirements), the investigator or medically qualified designee must e nsure 
the appropriate documented consent/assent is in place .
08C0PW
PRODUCT: MK-8228 84
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890152] -2022
[IP_ADDRESS] General Informed Consent/Assent
Informed consent/assent given by [CONTACT_351921] a consent /assent form. The form must include the trial protocol 
number, trial protocol title, dated signature, and /agreement of the participant (or his/her 
legally acceptable representative) and of the person conducting the consent discussion. 
A copy of the signed and dated informed consent/assent form should be given to the 
participant (or their legally acceptable representative) before participation in the study.
The initial informed consent/assent form, any subsequent revised consent/assent, and any 
written information provided to the participant mus t receive the IRB/IEC’s 
approval/favorable opi[INVESTIGATOR_19349]. The participant or his/her legally acceptable 
representative should be informed in a timely manner if new information becomes available 
that may be relevant to the participant’s willingn ess to continue participation in the study. 
The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the participant’s or their 
legally acceptable representative ’s dated signature.
Specifics about the study and the study population are to be included in the study informed 
consent form. 
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements. 
The assent, as applicable, will adhere to IRB/IEC requirements, applicable laws and 
regulations and Sponsor requirements.
[IP_ADDRESS] Consent /Assent and Collection of Specimens for Future Biomedical 
Research
The investigator or medically qualified designee will explain the FBR conse nt/assent to the 
participant, or the participants legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent/assent before performing any procedure 
related to FBR. A copy of the informed consent/assent will b e given to the participant before 
performing any procedure related to FBR .
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_660216].
8.1.[ADDRESS_890153] informa tion 
(including direct telephone numbers) to be utilized in the event of an emergency. The 
investigator or qualified designee will provide the participant with a participant identification 
08C0PW
PRODUCT: MK-8228 85
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890154] immediately after the participant provides documented informed consent/assent. At the 
time of intervention allocation/randomization, site personnel will add the 
treatment/randomization number to the participant identification card.
The participant ID card also contains contact [CONTACT_93307] a health care provider can obtain information about study intervention in 
emergency situations where the investigator is not available .
8.1.4 Medical History
A medical history will be obtained by [CONTACT_660217] .
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement . Prior medication taken by [CONTACT_78772] 30 
days prior to enrollment will be recorded.
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by [CONTACT_19432].
All concomitant medications should be reviewed and documented while participants are on 
study intervention.
Anti-CMV medications administered for treatment of CMV disease or for initiation of PET , 
medications used for HSV/VZV prophylaxis, and all drug/biologic therapi[INVESTIGATOR_660159]/treat GVHD should be recorded at every visit through Week [ADDRESS_890155]-trans plant.
During the follow -up period ( after Week [ADDRESS_890156] -
transplant ), concomitant m edication review is limited to the above and all antimicrobials 
(antibacterials, antifungals, antiparasitic agents and antivirals), chemotherapy agents, and 
immunosuppressant agents.
8.1.[ADDRESS_890157] will be collected on Day 1 (enrollment ). This includes 
details regarding the conditioning regimen used, the date and type of transplant , primary 
reason for transplant, the source of stem cells, type of graft manipulation, presence of 
GVHD, and GVHD prophylaxis regimen (if any) used.
08C0PW
PRODUCT: MK-8228 86
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890158] the testing repeated one 
time as described in Section 5.2 . Only the exclusionary lab is to be retested . Any indivi dual 
who has mo re than one screening will retai n the original screening number assigned at the 
original screening visit.
8.1.8 Assignment of Treatment/Randomization Numb er
All eligible participants will be allocated, by [CONTACT_148195], and will receive a 
randomization number. The randomization number identifies the participant for all 
procedures occurring after randomization. Once a randomization number is assigned to a 
participant, it can never be re -assigned to another participant .
A single participant cannot be assigned more than [ADDRESS_890159] dose of study intervention will be administered at the study site on Day 1 after 
enrollment/allocation . A sample for CMV DNA PCR must be collected prior to initiating
study intervention.
The oral granules may be administered by [CONTACT_1966] (with a soft food vehicle ), or via a G
tube/NG tube . Refer to Pharmacy Manual for further details on preparation and 
administration of oral granules . 
For IV formulation, the study pharmacist (or appropriately qualified designee) will be 
responsible solely for the preparation of the IV study intervention. The IV formulation will 
be administered by [CONTACT_660218] a sterile 0.2 -micron or 0.22- micron PES in -line 
filter and using DEHP -freeIV bags and infusion set materials . Refer to the Pharmacy Manual 
for further details on preparation and administration of the IV formulation.
Please refer to Section 6.1 for details regarding a dministration of oral granules.
[IP_ADDRESS] Timing of Dose Administration
Study intervention should be taken at approximately the same time each day for the duration 
of the treatment period of the study ( once daily for LET) . Treatment compliance is further 
described in Section 6.4.
If a participant misses a dose of LET, the missed dose should be taken as soon as possible 
during the same day. Then, the next dose should be taken at the normally scheduled time . 
However, if more than 12hours have elapse d after the regular dosing time, then the missed 
08C0PW
PRODUCT: MK-8228 87
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890160] -2022
dose should be skipped ,and the normal dosing schedule should be resumed . The next dose 
should not be doubled in order to “make up” what has been missed.
If a participant vomits within 2hours of an administ ration oftablets or oral granules ,the full 
dose can be repeated one time within 6 hours of vomiting . If a participant vomits and it has 
been longer than 2 hours from the time of an administration of tablets or oral granules , the 
dose should not be repeat ed. Instead, the next dose should be taken at the usual time the 
following d ay.
[IP_ADDRESS] Study Medication Diary 
For hospi[INVESTIGATOR_660160], study intervention 
will be recorded in the participant’s chart; this will serve as the source document . For 
participants receiving oral tablets or granules outside of the hospi[INVESTIGATOR_6885] (ie, receiving oral 
LET at home), study intervention will be recorded in a paper study medication diary (SMD) . 
The investigator/study co ordinator will review and provide instructions to the 
participant/legally acceptable representative on the use of the SMD, which is to be completed 
during the treatment period of the study. The investigator/study coordinator will be 
responsible for enterin g the participant’s identification ( randomization/allocation number), 
visit weeks , the diary distribution date, and the information to indicate the appropriate dosage 
form and quantity before giving the SMD to the participant/legally acceptable representat ive. 
The participant/legally acceptable representative will be instructed on proper storage, 
preparation and administration of LET oral granules and to use the SMD to record 
dates/times and the number of tablets/capsules of LET dosed for the entire treatm ent period;
participants on oral granule formulation given by [CONTACT_660219], whether the entire dose was consumed and the timeframe over which the dose 
was consumed . Participants on oral granules administered via G tube/NG tube will record 
whether the entire dose was given . In addition, the reason for any missed or incorrect doses 
or entire dose not being consumed/given will need to be recorded. Only the 
participant/legally acceptable representative should enter information into the SMD . The 
participant/legally acceptable representative is to return the completed SMD at each 
scheduled visit . 
Forall visits during the treatment period, site personnel are required to verify the accuracy of 
the dosing recorded in the SMD by [CONTACT_660220] . If a discrepancy is noted, the investigator/study coordinator must discuss the 
discrepancy with the participant, and the explanation must be documented . The 
investigator/study coordinator will be respon sible for transferring the appropriate information 
from the SMD to the appropriate CRF.
Training participants/ legally acceptable representative on administration of oral 
granules
Forparticipants discharged on oral granules to be administered either by [CONTACT_334572]
G tube/NG tube on an outpatient basis, site personnel must provide training to the 
08C0PW
PRODUCT: MK-8228 88
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890161] -2022
participant/ legally acceptable representative on preparation and administration of the 
oral granules prior to discharge, preferably during the preceding week (refer to the 
Pharmacy Manual on detailed instructions; instructions are also briefly provided in the 
SMD) . Such training also should be provided when the route of administration of oral 
granules chang es (eg, from G tube/NG tube to administration by [CONTACT_1966]) . Documentation of 
such training and that the participant/caregiver has understood the instructions and will be 
able to take the oral granules correctly must be entered in the participant’s chart ,whic h will 
serve as the source document . 
8.1.10 Discontinuation and Withdrawal
Participants who discontinue study intervention prior to completion of the treatment period 
should be encouraged to continue to be followed for all remaining study visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the Early Study Discontinuation V isitshould be performed (at the time of 
withdr awal). Any AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4 .
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
A Participant’s consent for Future Biomedical Research may be with drawn by [CONTACT_171589]’s legally acceptable representative (as appropriate) .A participant’s consent 
may be withdrawn at any time by [CONTACT_59554] [INVESTIGATOR_63472]. If 
medical records for the main study are st ill available, the investigator will contact [CONTACT_63527] (clinical.specimen.management@m sd.com). 
Subsequently, the participant's consent for future biomedical r esearch will be withdrawn. A 
letter will be sent from the Sponsor t o the investigator confirming the withdrawal. It is the 
responsibility of the investigator to inform the participant of completion of withdrawal. Any 
analyses in progress at the time of request for withdrawal or already performed prior to the 
request being received by [CONTACT_264831]. No new analyses would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg , if the 
investigator is no longer required by [CONTACT_180631]) 
or the specimens have been completely anonymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed. 
8.1.11 Participant Blinding/Unblindi ng
This is an open -label study; there is no blinding for this study.
08C0PW
PRODUCT: MK-8228 89
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890162] -2022
8.1.12 Domiciling
For participants who will undergo intensive PK sampling, the investigator should make 
arrangements (including local accommodations outside the context of hospi[INVESTIGATOR_059], if 
needed/warranted) such that all PK sampling at specified time points canbe perfor med as 
scheduled.
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentati on at the 
study site.
8.[ADDRESS_890163] should be repeated 
one more tim e within 5 days of the planned enrollment date to ensure the result is still 
negative . Thereafter, samples will be collected as indicated in the SoA (Section 1.3). CMV 
DNA PCR testing may be conducted within 3 days prior to a scheduled study visit and no 
later than the day of the scheduled study visit . (This CMV DNA PCR testing window is not 
applicable to a CMV Infection Visit) .
For participants who develop CS -CMVi (through [ADDRESS_890164]-trans plant) : When the 
investigator intends to initiate either treatment for CMV disease or PET, the participant 
should have a CMV Infection Visit . It is very important to ensure that all procedures, as 
outlined in the SoA (Section 1.3), are performed at the CMV Infection Visit immediately 
prior to the initiation of treatment of CMV diseases or initiation of PET (ie, on the same day 
anti-CMV therapy or PET is initiated) . Thereafter, the participant should be discontinued 
from LET (if applicable) and treated according to the local standard of care (outside the 
context o f the study) . Such participants will continue to be followed in the study (despi[INVESTIGATOR_660161] -CMV therapy) and complete all 
remaining study visits (including all subsequent treatment period visits) . At such subsequ ent 
visits, all procedures specified in the SoA (Section 1.3)should be completed with the 
exception of study intervention administration, PK assessments and palatability assessments. 
Additional CMVi Visit (s)arealso required for every new epi[INVESTIGATOR_660162]-CMVi following the 
initial epi[INVESTIGATOR_251138] [ADDRESS_890165]: MK-8228 90
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890166] -2022
Note on re-initiation of study intervention :There may be instances when lab test results 
for CMV DNA PCR obtained on the day of PET initiation may be negative (CMV DNA 
undetectable) and the investigator may wish to discontinue PET . The decision to stop PET in 
the event of a negative (CMV DNA undetectable ) result collected on the day of PET 
initiation resides with the investigator caring for the participant . Therefore, in the event the 
CMV DNA sample at PET initiation is negativ e for CMV viremia, the Sponsor will allow for 
LET to be restarted at the investigator’s discretion, once PET is discontinued . In such 
instances, study intervention should be restarted within 7 days from the date on which study 
intervention was stopped . It is important to note that the status of the participants’ study 
intervention in IRTshould NOT be changed until the investigator i s certain that LET 
prophylaxis will be permanently discontinued.
Assessment of CMV Disease
CMV disease will be assessed at every visit from screening through Week 24post-trans plant . 
Diagnostic criteria for the evaluation of CMV disease are outlined in Appendix 8. If CMV 
Disease is suspected, site should perform the CMV Infection Visit instead of the scheduled 
visit assessments (Section 1.3). The investigator will ensure that clinical information, 
radiology results, and specimens for the appropriate diagnostic tests (including, but not 
limited to, viral culture, histopathology, immunohistochemical analysis, in situ hybridization, 
CMV DNA PCR) as outlined in Appendix 8 will be collected. Both “probable” or “proven” 
cases of CMV disease should be reported.
8.2.2 CMV DNA Sequ ence Analysis
Sample collection, storage, and shipment instructions for plasma samples wil l be provided in 
the central laboratory manual.
CMV DNA s equence a nalysis willbe performed on samples from participants who meet the 
criteria for CS -CMVi at the CMV infection visit. Resistance to LET will be assessed by 
[CONTACT_660221] s (UL56 , UL89, and UL51) in DNA 
extract edfrom plasma samples collected as indicated in the SoA (Section 1.3)with 
detectable CMV viral DNA . Samples will be analyzed by [CONTACT_660222] . In 
participants with multiple CMV -positive samples, the last on- therapy and/or follow -up 
samples will be used for analysis. 
Because plasma volume collection is limited in the pediatric population compared with 
adults, actual sample volume collected may be less than expected . If insufficient plasma is 
available for resistance genoty pi[INVESTIGATOR_660163] [ADDRESS_890167]: MK-8228 91
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890168] not been previously characterized via phenotypic 
analysis . 
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided below . The total amount of blood/tissue to be drawn/collected over the course of 
the study for research testing ,including approximate blood/tissue volumes drawn/collected 
by [CONTACT_126541], can be found in Appendix 2.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) as per institutional standard at visit sspecified 
in the SoA (Section 1.3). The complete physical exam ination includes the following 
assessments: general appearance, head, eyes, ears/nose/ throat, neck, lymph nodes, skin, 
lungs, heart, abdomen, musculoskeletal, and neurologic evaluations. Breast, rectal, and 
genitourinary/pelvic exams should be performed when clinically indicated.
A brief directed physical examination may be conducted by [CONTACT_113803] (consistent with local requirements) as per institutional standard atany 
other visit when clinically indicated.
Height and weight will be measured and recorded per the SoA . We ight will be used to guide 
LET dosing. Body weight recorded at enrollment (Day1) will be used to determine the 
initia l dosing. Dose may be adjusted according to the most recent body weight taken per 
the SoA . Height and weight will be measured per SoA to monitor creatinine clearance, as 
calculated by [CONTACT_16424] -Gault equation (for participants ≥12 years of age) or by [CONTACT_660223] (for participants <12 years of age) using serum creatinine 
(Appendix 12).
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
8.3.2 Vital Signs
Vital signs will be assessed as indicated in the SoA (Section 1.3) . 
Vital signs will include heart rate, blood pressure, respi[INVESTIGATOR_697], and body temperature 
(oral) . Participants should be resting for at least 5 minutes prior to measurement of vital 
signs.
Note : Temperatures should be taken orally, but if oral is not possible, tympanic, rectal, and 
axillary temperatures ar e acceptable .
08C0PW
PRODUCT: MK-8228 92
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890169] -2022
Vital signs will be measured after 5 minutes’ rest and will include temperature, systolic and 
diastolic blood pressure, pulse, and respi[INVESTIGATOR_697].
8.3.3 Electrocardiograms
Single 12- lead electrocardiogram (ECG) will be obtained and reviewed locally by [CONTACT_111959] (consistent with local requirements) as outlined 
in the SoA ( Section 1.3) using an ECG machine that automatically calculates the heart rate 
and measures PR, QRS, QT, and QTc intervals. 
Participants should be shaved (ifnecessary) for proper lead placement . Participant s should be 
resting for at least 5minutes prior to having ECG readings obtained.
8.3.4 Clinical Safety Laboratory Assessments
•Refer to Appendix 2for the list of clinical laborat ory tests to be performed and to the 
SoA for the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements)
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_78259]'s condition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_890170] be 
conducted in accordance with the laboratory manual and the SoA .
•If laborator y values from nonprotocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), t hen the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 28days after the last dose of study intervention, every 
attem pt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
8.3.[ADDRESS_890171] previously expe rienced 
menarche . Once a date of menarche has been confirmed, the participant is considered to be a 
woman of child bearing potential ( WOCBP ). For prepubescent females, site staff should 
continue to review and record, as appropriate, at each visit during th e treatment period.
08C0PW
PRODUCT: MK-8228 93
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890172] -2022
8.3.6 Confirmation of Contraception (WOCBP O nly)
Throughout the screening and treatment periods, precaution must be taken to avoid 
pregnancy in WOCBP . Confirmation must be obtained and documented by [CONTACT_542342] ( Appendix 5). This assessment 
must be documented in the participant's study chart at each specified visit.
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE, as well as other reportable safety events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3. Investigators need to document if an AE 
and/or SAE was associated with a medication error, misuse, or abuse.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality.
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the participant provides 
docu mented informed consent , but before intervention allocation/randomization must be 
reported by [CONTACT_660224], is receiving placebo run -in or other run -in 
treatment, if the event cause sthe participant to be excluded from the study, or is the result of 
a protocol -specified intervention, including , but not limited to washout or discontinuation of 
usual therapy, diet, or a procedure.
From the time of treatment allocation/randomization through [ADDRESS_890173]: MK-8228 94
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890174] promptly notify the Sponsor .
All initial and follow -up AEs, SAEs, and other reportable safety events will be rec orded and 
reported to the Sponsor or designee within the time frames as indicated Table 13.
Table 13 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/
AllocationReporting Time 
Period:
Randomization/
Allocation through 
Protocol -Specified 
Follow- up Period
([ADDRESS_890175] dose of study 
medication )Reporting Time 
Period:
After the Protocol -
Specified Follow -
up Period (from [ADDRESS_890176]-
transplant )Timeframe to 
Report Event 
and Follow- up 
Information to 
SPONSOR:
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusionReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
- death due to any 
cause 
-due to protocol -
specified 
interven tion
-causes exclusionReport all Report only if:
-drug related. OR
-SAEs leading to 
death, regardless of 
causality Within 24 hours 
of learning of 
event
Pregnancy/
Lactation ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported 
–Follow to 
completion/termina
tion; report 
outcomeWithin [ADDRESS_890177] (ECI) 
(require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-Potential drug-
induced liver injury 
(DILI ) 
-Require 
regulatory 
reportingNot required Within [ADDRESS_890178] (Do not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-non-DILI ECIs 
and those no t 
requiring 
regulatory 
reportingNot required Within [ADDRESS_890179]: MK-8228 95
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890180] -2022
Type of EventReporting Time 
Period:
Consent to 
Randomization/
AllocationReporting Time 
Period:
Randomization/
Allocation through 
Protocol -Specified 
Follow- up Period
([ADDRESS_890181] dose of study 
medication )Reporting Time 
Period:
After the Protocol -
Specified Follow -
up Period (from [ADDRESS_890182]-
transplant )Timeframe to 
Report Event 
and Follow- up 
Information to 
SPONSOR:
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days of 
learning of event
Overdose Report if:
-receiving placebo 
run-in or other run -
in medication Report all Not required Within 5 
calendar days of 
learning of event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial A E/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safety events 
including pregnancy and exposure during breastfeeding, events of clinical interest (ECI), 
cance r, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follow- up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AE s that occur in 
randomized participants for outcome. Further information on follow -up procedures is given 
in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_88701] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. All 
AEs will be reported to regulatory authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topi c E6 (R2) Guidelines for 
Good Clinical Practice [GCP] ).
08C0PW
PRODUCT: MK-8228 96
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890183] be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if ap propriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy. 
Pregnancy outcomes of spontaneous abortion, missed aborti on, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reporte d.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not Applicable.
8.4.[ADDRESS_890184] (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study include:
Potential DILI events defined as an elevated AST or ALT lab value that is greater than or 
equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is 
greater than or equal to 2X the upper limit of normal and, at the same time, an alkaline 
phosphatase lab value that is less than 2X the upper limit of normal, as determined by 
[CONTACT_13149] -specified laboratory testing or unscheduled laboratory testing .*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underlying etiology. The study site guidance for 
assessment and follow -up of these cri teria can be found in the Investigator Study File 
Binder (or equivalent).
8.5 Treatment of Overdose
In this study, an overdose is any dose higher than 2times the prescribed dose specified in 
Section 6.6 (Dose Modification [Escalation/Titration/Other]).
08C0PW
PRODUCT: MK-8228 97
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890185] -2022
Sponsor does not recommend specific treatment for an overdose . Overdose during the study 
will be a reportable safety event (see Section 8.4.1 and Appendix 3 for further details) .
Decisions regarding dose interruptions or modifications will be made by [CONTACT_660225].
8.6 Pharmacokinetics
Plasma samples for sparse PK will be collected in all participants . 
Plasma samples for intensive PK ( oralformulation ) will be collected from a ll participants in 
Panel A of Age Groups 1 and 2 who receive oral LET formulation (by [CONTACT_469100] G tube/NG 
tube) from Day 1 until D ay 7 visit . Additionally, plasma samples for intensive PK (IV 
formulation) will be collected for any study participant who receives at least 5 consecutive 
days of IV dosi ng and has not had prior intensive PK collected on the oral formulation. The 
proposed PK sampling scheme for sparse PK and intensive PK across all age groups is 
provided inTable 14.
8.6.1 Blood Collection for L etermovir Pharmacokinetic Sampling
Sample collection, storage, and shipment instructions for PKsamples will be provided in the 
laboratory manual . PK samples should not be collected in participants after discontinuation 
of study intervention.
On all PK visits where a predose sample will be collected, the visit should occur prior to the 
participant’s regular time for taking their study intervention and the participant should 
withhold their dose until after the predose sample is drawn. If it is not feasible to schedule the 
visit prior to the participant’s regular time for taking their study intervention, the participant 
should withhold their dose until reporting to the clinic . The predose PK sample will be 
obtained and the next scheduled dose will then be administered at the cli nic. The date and 
time of each PK sample as well as the date and time of the last dose of study medication prior 
to the PK sample will be recorded.
For participants receiving oral granule sin soft food, the soft food vehicle used to administer 
the last dose of study medication prior to the PK sample as well as the day of the PK sample 
will also be recorded. For participants receiving oral granules via G tube or NG tube, the use 
of these tubes will be recorded.
If a participant vomits following administration of oral LET while intensive PK sampling is 
ongoing, nofurther samples should be collected, and the Sponsor should be informed to
determine further course of action. 
08C0PW
PRODUCT: MK-8228 98
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890186] -2022
Table 14 Pharmacokinetic Sampling for Protocol 030
PK TypeLET Route of 
Administration Study Visit PK Sample TimesaPrimary 
PK 
ParametersOther 
PK 
Parameters
Intensive 
PK for 
LETOral 
FormulationsbDay 7c
(Days 7 -9)Predose (0 to 20 min before 
dose)
1 h (± 10 min)
2.5 h (± 30 min)
8 h (± 2 h)
24 h (0 to 2 h before next 
dose)AUC0 -24h
Cmax
CtroughTmax
t1/2
CL/F
Vd/F
IVdAny Predose (0 to 20 min before 
IV infusion begins)
1 h (0 to 10 min after IV 
infusion ends)
2.5 h (± 30 min)
8 h (± 2 h)
24 h (0 to 2 h before next 
dose)AUC0 -24h
Ceoi
Ctrought1/2
CL
Vd
Sparse 
PK for 
LETOral 
FormulationsbWeeks 2, 4, 6, 
8, 10, 12, 14, 
CMVieor 
Early Discone
VisitsPredose (0 to 2 h before dose) Ctrough
IV Weeks 2, 4, 6, 
8, 10, 12, 14Predose (0 to 2 h before IV 
infusion begins)Ctrough
HPCD 
PK
samp lingIV See notef1 h after initiating the IV 
infusion (within 10 mins of 
ending a 60 min IV infusion)
on the 4thconsecutive day of 
IV infusion
24 h after initiating the IV 
infusion (0 to 2 hours before 
the next dosing) on the 5th
consecutive day of IV LET 
administrationPK
exploratory 
parametersIV
08C0PW
PRODUCT: MK-8228 99
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890187] -2022
PK TypeLET Route of 
Administration Study Visit PK Sample TimesaPrimary 
PK 
ParametersOther 
PK 
Parameters
AUC0 -24h=area under the concentration -time curve from time 0 to 24 hours; CEIO=concentration at the end 
of infusion; CL= clearance; Cmax=maximum concentration; CMVi=cytomegalovirus infection; Ctrough= 
trough concentration; Discon=discontinuation; F=bioavai lability; h=hour (s); HPCD=hydroxypropyl -beta-
cyclodextrin; IV=intravenous; LET=letermovir: min=minute; min(s)=minute(s); PK=pharmacokinetics; 
t1/2=apparent half -life; Tmax=time to maximum concentration; Vd=apparent volume of distribution.
aSample collecti on times for IV formulation are relative to start of IV infusion, with acceptable ranges 
noted.
bThe oral formulations may be tablets or oral granules. Oral granules may be administered either by [CONTACT_660226] G tube/NG tube, provided the participant does not have a condition that may interfere with the 
absorption of oral formulation (eg, vomiting, diarrhea, or a malabsorptive condition).
cAll participants in Panel A of Age Groups [ADDRESS_890188] intensive PK 
sampling done regardless of the formulation received (starting on either the fifth day of IV LET or the 
seventh consecutive day of oral LET, whichever comes first) .
dIntensive PK on IV formulation will be collected from participants who have NOT had intensive PK on the 
oral formulations (oral granules/oral tablet); sample collection will start on the 5thconsecutive day of IV 
dosing.
eCollected only if the participant is still on LET at the CMVi or Early Discontinuation Visit and the visit 
occurs on or before Week 14.
fStart on the 4thconsecutive day of IV dosing for participants in Age Group 3.
8.6.2 Blood Collection for HPCD Pharmacokinetic Sampling
Whole blood will be collected from Age Group 3 participants starting on the fourth
consecutive day ofIV LET administration , as follows:
The first sample on that day will be taken 1 hour after initiating the IV infusion 
(within 10 minutes of ending the 60 minute infusion). 
The second sample must be taken 24 hours after initiating the IV infusion (0 to 2 
hours before the next dosing)on the fifth consecutive day of IV LET administr ation. 
The central laboratory manual contains instruction for sample handling and processing.
All A ge Group 3 participants, for whom HPCD sampling is collected, will also need 
local laboratory testing for serum creatinine levels to correlate any changes i n creatinine 
clearance with HPCD level sas outlined in Section [IP_ADDRESS] .
[IP_ADDRESS] Additional Creatinine Clearance Measurements for Participants in Age 
Group 3 Receiving I ntravenous Letermovir Formulation
Timepoints for c ollection of HPCD PK and creatinine clearance measurement s(which would 
require local laboratory testing for serum creatinine) depend on the number of consecutive 
days of IV LET and whether it is the initial or subsequent IV LET dose ( Table 15). 
Creatinine clearance measurement sshould be repeated every time a subsequent course of IV 
formulation is initiated.
08C0PW
PRODUCT: MK-8228 100
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890189] -2022
Table 15 Creatinine Clearance Timepoints for Age Group 3 Participants Receiving 
Intravenous Letermovir
Course and Duration 
of IV LETCollection of 
HPCD PK 
Sampling
(Yes/No)Collection of 
Creatinine 
for Creatinine Clearance
First course ≥4 days at 
any time during 
treatmentYes 1stday of IV LET administration (prior to initiating IV LET)
0 to 2 hours before the next dose of LET (at the same time as 
the second HPCD PK sample is collected)
last day of IV LET (immediately after discontinuing the 
infusion, if IV LET continues beyond 5 consecutive days)
All other course (s)
regardless of durationNo 1stday of IV LET administration (prior to initiating LET)
last day of IV LET (immediately after discontinuing the IV)
HPCD= hydroxypropyl -beta-cyclodextrin ; IV=intravenous; LET= letermovir.
8.7 Pharmacodynamics
No p harmacodynamic parameters will be evaluated in this study.
8.8 Future Biomedical Research Sample Collection
If the participan t provides documented informed consent /assent for FBR, the following 
specimens will be obtained as part of future biomedical r esearch:
Residual DNA from buccal swab for future research
Leftover plasma from CMV viral resistance samples stored for future research.
8.9 Planned Genetic Analysis Sample Collection
The planned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for FBR if the participant provides documented 
informed consent for FBR. If the planned genetic analysis is not approved, but FBR is 
approved and consent is given, this sample will be collected for the purpose of FBR.
Sample collection, storage, and shipment instructions for buccal swabs will be provided in 
the laboratory manual .
8.10 Palatability and Acceptance Assessment
The PAA ( Appendix 11) is to be completed for all participants on the first day of oral granule 
administration and repeated one week later. The PAA should be implemented with the 
following recommendations: 
From Birth to Age 4 years: Completion by [CONTACT_206091] (legally accept able 
representative/caregiver/health care provider).
08C0PW
PRODUCT: MK-8228 101
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890190] -2022
Ages 5 to 13 years: Combined completion where the participant completes the faces 
question, and the observer completes the remaining questions .
Ages 14 to less than 18 years : Completion directly by [CONTACT_941] p articipant, preferred when 
possible.
Observer assessments should be based on what the legally acceptable 
representative /caregiver /health care provider has observed directly during and after 
medication administration, including the participant’s facial expressions, behavior, and what 
the participant says. Only individuals who have actually observed the participant taking the 
medication should complete the assessment.
8.11 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.11.1 Screening
Screening of potentially eligible participants may begin within 15 days prior to 
transplantat ion, but enrollment/allocation must occur no later than [ADDRESS_890191]-trans plant . 
The informed consent and assent (as applicable) must be obtained before any study -specific 
procedure is performed. Potential participants will be evaluated to determine if the y fulfill the 
Inclusion/Exclusion entry requirements as described in Sections 5.1 and 5.2 . All screening 
procedures listed under Visit 1 of the Study SoA (Section 1.3)will be performed. Laboratory 
tests including chemistry, hematology, urinalysis , prothro mbin time ( PT)/coagulation, HIV, 
and hepatitis B and C tests will be performed locally. As noted in Section 5.2, p articipants
who meet laboratory exclusion criterion [ADDRESS_890192] dose 
of study intervention (or longer i f dictated by [CONTACT_427]) . Participants will also be 
instructed about the restrictions for concomitant medications, as noted in Section 6.5 .
Presence of CMV disease in the screening period will be assessed according to Appendix 8.
8.11.2 Treatment Period Visits
Study intervention (LET) may begin as early as the day of transplant and no later than [ADDRESS_890193] -trans plant . Study intervention will continue through Week 14 (~100 days) 
post-trans plant . Study visits will occur weekly through Week 14 (~100 days) post-trans plant . 
For the purposes of this study, “Treatment Period” refers to the period from Day [ADDRESS_890194]: MK-8228 102
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890195] -2022
The Day 1 Visit (as shown in the SoA, Section 1.3.1) will be day the participant is 
enrolled/ allocated and LET is initiated . Study intervention will continue through the End of 
Treatment Visit . The End of Treatment Visit may occur at the Week 10, 11, 12, [ADDRESS_890196]-trans plant 
window . For example, if LET is started on the day of transplant, the End of Treatment Visit 
will be the Week 14 Visit (which corresponds to Week [ADDRESS_890197]-transp lant). If LET is started 
[ADDRESS_890198]-trans plant, the End of Treatment Visit will be the Week 10 Visit (which 
corresponds to Week [ADDRESS_890199]-trans plant).
All procedures listed under the study visits in the SoA (Section 1.3.1) will be performed at 
the corresponding visit . After allocation , a complete physical examination does not need to 
be performed at every visit; a targeted physical exam ination should be performed only when 
clinically indicated. 
[IP_ADDRESS] Day 1 Visit
Day 1 procedures/assessments listed on the SoA (Section 1.3.1) must be performed prior to 
initiation of study intervention. The weight of the participant on Day 1 will be used to 
determine LET dose (Se ction 6.1).
For female participants of childbearing potential, a urine or serum pregnancy test will be 
performed at the site prior to the initiation of study intervention. If the urine or serum
pregnancy test result is negative, the participant will be eligible for allocation and the 
remainder of the Day 1 testing/procedures will be performed. If the urine or serum pregnancy 
result is positive, the participant must not be allocated.
[IP_ADDRESS] Study Intervention Administration Visit
Following completion of the Day 1 procedures/as sessments and confirmation of eligibility, 
the participant will be allocate d/enrolled. Sites should not allocate the participant for study 
intervention (LET) administration until the participant has met all eligibility criteria for the 
study and is ready t o receive the first dose of LET on D ay 1. The site pharmacist or study 
coordinator will contact [CONTACT_660227]. The dose 
ofLET will be determined by [CONTACT_2299]’s weight at Day 1, the formulation 
administered, and by [CONTACT_660228] (see Section 6.1 
for specific details of dose selection and administration instructions ). Dose may be adjusted 
thereafter, according to the most recent body weight taken per the SoA
Participants in Panel A of Age Groups 1 and 2 :
Must initiate LET using an oral formulation (either tablets or oral granules ; oral 
granules may be administered by [CONTACT_334572] G tube/NG tube ) from the day of 
enrollment through the completion of the intensive PK sampling at the Day 7 visit . 
May not receive concomitant administration of CsA from the day of enrollment 
through the completion of the intensive PK sampling at the Day [ADDRESS_890200]: MK-8228 103
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890201] -2022
These restrictions are not applicable to participants enrolled in Age Group 1 (Panel B 
only), Age Group 2 (Panel B only) ,or for participants in Age Group 3 ;although all 
participants should preferably be initi ated on oral LET formulation. In the event that a 
participant enrolled in Panel A has a need to either (1) switch to IV formulation 
administration or (2)to have CsA coadministered prior to the Day [ADDRESS_890202] intensive PK samples drawn at the Day 7 visit . If a 
participant switches to IV formulation or has a new requirement for CsA 
coadministration, the site is required to notify the Sponsor immediately . The Sponsor 
will make arrangements for an additional participant to be enrolled in the 
corresponding panel to maintain n=6 PK -evaluable participants.
In the event that p articipants who were initiated on an oral formulation subsequently develop 
a condition ( eg,vomiting, diarrhea, or a malabsorptive condition) that may interfere with the 
absorption of the tablets , these participants can be switched to the IV formulation . For 
participants who are switched to the IV formulation ( Panel A or B) ,or who initiated with the 
IV formulation ( Panel B only), these participants should be switched to oral LET as soon this
participant is able to swallow and/or the condition necessitating the use of the IV formulation 
resolves (ie , at the next planned dose ). Use of the IV formulation should generally be limited 
to 4 weeks or less in durati on; h owever, it will be left to the investigator’s discretion to 
continue IV administration beyond 4 weeks, if the benefit/risk ratio supports continued 
administration.
LET may be used with or without concomitant CsA. See Section 6.1 for the LET dose to be 
used with or without coadministered CsA and for details of study drug modification if 
concomitant CsA is initiated or discontinued .
[IP_ADDRESS] Additional Treatment Period Visits
Procedures/assessments listed on the SoA (Section 1.3.1) must be performed at all the 
weekly study visits during the treatment period.
Throughout the treatment period p recaution must be taken to avoid pregnancy in WOCBP . 
Confirmation must be obtained and documented by [CONTACT_542347] ( Appendix 5). This assessment must be documented in 
the participant's study chart at each specified visit .
From Day 1, through Week 14 (~100 days) post-trans plant participants will be assessed for 
CMV disease and CMV DNA PCR should be tested at the loca l laboratory as per the SoA 
(Section 1.3.1) . 
8.11.3 Follow -upPeriod/Visits
As stated in Section 8.11.2, participants will receive study intervention with LET for [ADDRESS_890203]-trans plant (ie , participants will receive approximately 10 to 14 weeks of LET 
depending on initiation of study intervention in relation tothe date of transplant) . After the 
last day of study intervention , participant s will be followed via study visit sat the site from 
08C0PW
PRODUCT: MK-8228 104
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890204] -trans plant . These v isits will occur every 2 weeks and all 
procedures listed in the SoA (Section 1.3.2) corresponding to the visits will be performed . 
All participants will continue to be assessed for CMV disease through Week 24 pos t-
transplant and CMV DNA PCR should be tested at the loca l laboratory as per the SoA 
(Section 1.3) . 
Subsequent post treatment follow -up visits will occur at Weeks 32, 40, and [ADDRESS_890205] -trans plant 
(telephone c ontact )and all procedures listed in the SoA (Section 1.3.2) corresponding to the 
visits will be performed. 
Adverse event monitoring should include the collection of all adverse events while on study 
intervention and for [ADDRESS_890206]-transplant . 
8.11.4 Participants Discontinuing Study Intervention but Continuing to be 
Monitored in the Study
Participants who discontinue study intervention (LET) for any reason will continue to be 
followed in the study as outlined in the Study SoA (Section 1.3 .1), provided informed 
consent has not been withdrawn. 
[IP_ADDRESS] Discontinuation of Study Intervention Due to CS -CMVi
As all participants in the study will receive the study intervention ( LET) through Week [ADDRESS_890207]-transplant, LET should be discontinued when the CMV infection V isit occurs prior to 
the End of Treatment Visit . A sample for CMV DNA PCR should be collected 
immediately prior to the initiation of PET or treatment of CMV disease . Such 
participants will continue to be followed in the study (despi[INVESTIGATOR_660164] -CMV therapy) and complete all re maining study visits (including all 
subsequent treatment period visits) . All procedures as outlined in the SoA (Section 1.3.1 ),
with the exception of study intervention administration, PK sampling, collection of samples 
for PT/INR, Child -Pugh score assessm ents,and study medication diary review ,will be 
performed for the remainder of the study.
[IP_ADDRESS] Discontinuation of Study Intervention for Reasons Other Than CS-CMV i
Participants who discontinue study intervention (LET) prior to the last scheduled treatment 
visit for reasons other than CS-CMVi (eg,for an AE) will continue to be followed in the 
study and complete all remaining study visits regardless of when cessation of study 
intervention occurs . All procedures as outlined in the SoA (Section 1.3.1), with the exception 
of study intervention administration, PK sampling, collection of samples for PT/INR, Child -
Pugh score assessments ,and study medication diary review, will beperformed for the 
remainder of the study.
08C0PW
PRODUCT: MK-8228 105
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890208] -2022
8.11.5 Disco ntinuation from Study
[IP_ADDRESS] Study Discontinuation Prior to Week [ADDRESS_890209] -transplant:
Participants who prematurely discontinue the study (eg ,withdrawal of consent) prior to 
Week [ADDRESS_890210] an Early Study Discontinuation Visit . It is important to
ensure that all procedures, as outlined in the Study SoA (Section s 1.3.1 and 1.3. 2), are 
performed for such participants at this visit prior to discontinuing the participant from the 
study. A sample for CMV DNA PCR testing should be collected at this visi t.
[IP_ADDRESS] Study Discontinuation After Week [ADDRESS_890211] visit (as outlined in the Study SoA, Section 1.3.2), 
prior to discontinuing the participant from the study.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study . Changes to 
analyses made after the protocol has been finalized will be documented in a supplemental 
SAP (sSAP) and referenced in the Clinical Study Report (CSR) for the study . Post hoc 
exploratory analyses will be clearly identified in the CSR.
9.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below ; the comprehensive plan 
is provided in Sections 9.2to 9.12. 
Study Design Overview A Phase 2b open -label, single- arm study to evaluate pharmacokinetics, 
safety , efficacy and acceptability/palatability of LET in pediatric 
participants from birth to less than 18 years of age at risk of developi[INVESTIGATOR_660165]/or disease following allogeneic haematopoietic 
stem cell transplantation (HSCT).
Treatment Assignment This will be an open -label, nonrandomized study . 
Analysis Populations Pharmacokinetics: Per Protocol (PP) 
Safety: All Participants as Treated (APaT)
Efficacy: Full Analysis Set (FAS)
Primary Endpoint(s) AUC0 -24, Cmax , (for participant s receiving oral formulation), Ceoi, 
(for participants receiving IV formulation), and Ctrough
Key Secondary Endpoints Safety: Number of participants experiencing 
•Adverse Events (AEs)
•AEs Resulting in Study Medication Discontinuation
Efficacy: Clinic ally significant CMV infection (CS-CMVi )through 
Week [ADDRESS_890212]-trans plant .
Palatability: Score on a palatability scale
08C0PW
PRODUCT: MK-8228 106
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890213] -2022
Statistical Methods for Key 
Pharmacokinetic /Efficacy
AnalysesAUC 0-24, Cmax, and Ctrough will be calculated, and g eometric means 
and 95% confidence intervals (CIs) will be provided for AUC 0-24, 
Cmax, and Ctrough by [CONTACT_660229].
The proportion of participants with CS-CMVi through Week 14 
(~100 days) post- trans plant and through Week 24 ( ~6 months) 
post-trans plant will be estimated using a 95% CI (via the Clopper -
Pearson method) . The missing data approach will be Non-Completer= 
Failure (NC=F) approach .
Statistical Methods for Key 
Safety AnalysesSafety and tolerability will be assessed by [CONTACT_660230], laboratory tests , vital signs and ECG 
parameters . Descriptive statistics will be provided for these safety 
parameters.
Interim Analyses An external DMC will be appointed and will review the safety and 
tolerability data . The DMC will periodically review the safety data at the 
following time points : 1)when [ADDRESS_890214] completed intensive PK sampling . 2)when [ADDRESS_890215] completed 
intensive PK sampling . 3)when ~10(which is ~50%) of participants in 
Age Group 1, Panel B have completed th e Week 4 visit . 4)when ~10
(which is ~50%) of participants in Age Group 2, Panel B have 
completed th e Week 4 visit . 5)when at least [ADDRESS_890216] completed intensive PK sampling . This will supplement routine 
in-house medical monitoring.
Multiplicity No multiplicity adjustment is planned .
Sample Size and Power PK: A sample size of 6 in Age Group 1 and 2 has approximately 95% 
power to show that the 95% confidence interval of the geometric mean 
of AUC 0-24in this age group will be within 60% and 140% of the 
geometric mean estimates of the AU C0-24of LET. A sample size of 8 in 
Age Group 3 has approximately 99% power to show that the 95% 
confidence interval of the geometric mean of AUC 0-24in this age group 
will be within 60% and 140% of the geometric mean estimates of the 
AUC 0-24of LET.
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor . The statistical analyses of the PK data will 
be conducted in col laboration with the Pharmacokinetics, Pharmacodynamic and Drug 
Metabolism and Clinical Research departments of the S ponsor .
This study is being conducted as a nonrandomized, open -label study, ie,participants, 
investigators, and S ponsor personnel will be a ware of participant treatment assignments after 
each participant is enrolled and treatment is assigned.
The Clinical Biostatistics department will generate the allocation schedule for study 
intervention assignment . Allocation number will be assigned via anIRT.
Planned interim analyses for ongoing safety monitoring are described in Section 9.[ADDRESS_890217]: MK-8228 107
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890218] -2022
9.3 Hypotheses/Estimation
There are no hypotheses to be tested in this study. Objectives of the study are stated in 
Section 3.
9.4 Analysis Endpoints
Pharmacokinetics, safety ,and efficacy endpoints that will be evaluated are listed below.
9.4.1 Pharmacokinetics Endpoints
An initial description of PK endpoints is provided in Section 4.2 .1.1. The primary PK 
endpoints for LET are: AUC0 -24, Cmax (for participant s receiving oral formulation), Ceoi 
(for participant s receiving IV formulation), and Ctrough . Additional PK parameters for 
participants receiving oral formulations are time to maximum observed plasma drug 
concentration (Tmax) , half -life (t1/2), apparent clea rance (CL/F), and apparent volume of 
distribution (Vd/F) . Additional PK parameters for participants receiving IV formulation are 
half-life (t1/2), clearance (CL ), and v olume of distribution (Vd).
9.4.[ADDRESS_890219] dose of study medication in all 
participants . Thereafter, only drug- related serious adverse events (SAEs) and SAEs leading 
to death will be collected through Week [ADDRESS_890220]-transplant . 
Safety endpoints will be analyzed using a 3 -tiered approach ( Section 9.6.3).
9.4.3 Efficacy Endpoints
An initial description of efficacy endpoints is provided in Section [IP_ADDRESS] . 
The key efficacy endpoint swill be the proportion of participants with CS-CMVi through 
Week 14 (~100 days) post-trans plant and through Week 24 (~6 months) post -trans plant , 
defined as the occurrence of either one of the following outcomes: 
•onset of CMV end -organ disease 
OR
•initiation of anti -CMV PET based on documented CMV viremia and the clinical 
condition of the participant .
CMV end -organ disease will be determined using the definitions in Appendix 8and 
confirmed by [CONTACT_660231] . For analysis purposes, the adjudication of cases by [CONTACT_126553] (ie, the final CAC assessment) will take precedence over the investigator’s assessment. 
Only the CAC -confirmed cases of CMV end- organ disease will be included in the CMV end-
08C0PW
PRODUCT: MK-8228 108
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890221] -2022
organ disease category. However, investigator -assessed CMV end -organ disease cases ,which 
were not confirmed by [CONTACT_660232] -CMV therapy was initiated (in the setting 
of documented CMV viremia) will be included in the initiation of PET category and, 
therefore, qualify as having CS -CMVi . Conc ordance/discordance between CAC and 
investigator assessment will be summarized.
In this study, any detectable CMV viral DNA result using a local CMV PCR assay is 
acceptable for documenting viremia as a component of the efficacy endpoint . Documented 
viremia is defined as any detectable CMV viral DNA obtained immediately prior to (ie, on 
the day of) the initiation of treatment for CMV disease or PET . In the event that the 
confirmatory result is not available, a subsequent laboratory result collected from a sa mple 
obtained within [ADDRESS_890222] -trans plant
will also be presented separately. 
9.5 Analysis Populations
9.5.1 PK Analysis Population
PerProtocol (PP): The Per -Protocol Population will serve as the primary population for the 
analyses of PK data in the study . The PP population consists of the subset of participant s who 
comply with the protocol sufficiently to ensure that these data will be likely to exhibit the 
effects of treatmen t, according to the underlying scientific model.
Compliance covers such considerations as exposure to t reatment (participants’ dosing 
compliance should be such that their PK is expected to be approaching steady state at the 
time of intensive PK sampling, availability of measurements and absence of major protocol 
deviations that may affect the PK assessment .Major protocol deviations will be identified 
prior to final database lock . Any participant s or data values excluded from analysis will be 
identified, along with their reason for exclusion, in the CSR . At the end of the study, all 
participant s who are compliant with the study procedure as aforementioned and have 
available data will be included in the Per -Protocol dataset . This population will be used for 
the PK analyses.
9.5.2 Safety Analysis Population
Safety Analyses will be conducted in the All Participant s as Treated (APaT) population, 
which consists of all allocated participants who received at least one dose of study 
intervention. The safety analyses will include all participants who receive any dose of study 
intervention, but participants who receive di fferent doses in Panel sA and B will also be 
reported separately.
08C0PW
PRODUCT: MK-8228 109
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890223] one dose of 
study intervention is required for inclusion in the analysis of the respective safety parameter . 
To assess change from baseline, a baseline measurement is also required.
9.5.3 Efficacy Analysis Population
The Full Analysis Set (FAS) population will serve as the primary population for the analysis 
of efficacy data in this study. The FAS population consists of all allocated participants who 
receive at least one dose of study intervention and had no detectable CMV viral DNA on 
Day 1 (when study intervention is initiated) . Participants who receive different doses in 
Panels A and B wi ll also be reported separately.
9.[ADDRESS_890224] (AUC 0-24, Cmax, Ctrough, Ceoi ) will be summarized by [CONTACT_660233] , with geometric means ( GMs ) and 95% CI s based on natural log-
transformed values and the t distribution . Individual AUC 0-24, Cmax, Ctrough, and Ceoi 
values will be plot ted by [CONTACT_31365] G roup and dose level as appropriate . 
Individual values will also be listed for each PK parameter by [CONTACT_660234], and the following (nonmodel -based) descriptive statistics will be provided: N 
(number of participants with non -missing data), arithmetic mean, standard deviation, 
arithmetic percent coefficient of variation (CV) (calculated as 100 × standard 
deviation/arithmetic mean), median, minimum, maximum, GM, and geometric percent CV
(calculated as 100 × sqrt(exp(s2) - 1), where s2 is the observed variance on the natural log 
scale). Descriptive statistics will also be provided for concentrations/PK parameters obtained
at other time points, as appropriate.
9.6.2 Pharmacokinetic Modeling an d Simulation for Dose Selection
Population PK analysis will be performed on all participants who undergo PK sampling ,
while noncompartmental analysis (NCA) will be performed on the subset of participants w ho 
undergo intensive PK in Age Group s [ADDRESS_890225]: MK-8228 110
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890226] likely to result in 
exposures that are within the predetermined bounds.
A final p opulation PK analysis using all cumulative pediatric PK data will be used to 
establish the PK properti es of LET in pediatric patients, enable exposure -efficacy and 
exposure- safety analyses, and to make final dosing recommendations in the pediatric 
population for all regimens, age groups , and relevant intrinsic/extrinsic covariates .
An exploratory exposure- response analysis will be conducted relating the HPCD NCA PK 
parameters to changes in creatinine -based renal function metrics during IV LET 
administration.
The methodology and employment for both the p opulation PK and NCA methods will be 
detailed in a separate Modeling & Analysis Plan, and PK -related results reported in a
Modeling and Simulation report.
9.6.[ADDRESS_890227] categories of any AE ,a drug -related AE, a serious AE, an 
AE,which is both drug- related and serious, and who discontinued study medication due to an 
AEwill be provided along with the corresponding 95% CIs . In addition, deaths will b e 
summarized in the same manner . The 95% CI s for the safety parameters will be estimated 
using the Clopper -Pearson method [Clopper, C. J. 1934] .
The primary safety analysis will summarize the safety data for participants through 28 days
following the las t dose of study medication . Safety results will be summarized for the APaT 
population and will also be presented by [CONTACT_660235] ( 12 years to <18years , 2 years to
<12years, birth to <2 years) . If doses in Panel A and Panel B are different, results of 
participants in the Panel B will also be reported separately from those in Panel A. Limited 
summaries of safety may be provided in participants in Panel A if the starting doses in 
Panel A and Panel B are different . Adverse event swill also be summarized through 
Week [ADDRESS_890228]: MK-8228 111
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890229] -2022
Table 16 Analysis Strategy for Safety Parameters
Safety Endpoint Within Group 95% CI Descriptive Statistics
Any AE X X
Any Serious AE X X
Any Drug -Related AE X X
Any Serious and Drug -Related AE X X
Discontinuation due to AE X X
Death s X X
Specific AEs , SOCs or PDLCs X
Change from Baseline results ( Labs, ECGs, Vital Signs ) X
AE=adverse event; ECG=electrocardiogram; labs= laboratory values; SOC=System Organ Class; 
PDLC= Predefined Limit of Change; SOC=System Organ Class ;X=results will be provided . 
95% CIs will be calculated using the Clopper -Pearson method.
For continuous measures such as changes from baseline in laboratory, vital signs, and ECG
parameters, summary statistics for baseline, on -treatment, and change from baseline values 
will be provided in table format .
Missing safety laboratory ,ECGs, or vital signs will be handled using the Data -As-Observed
approach, that is, any missing value will be excluded from the analysis . The only exception is 
when a Baseline/Day 1 result is missing ;this will be replaced with the latest pretreatment
result, if availabl e.
9.6.4 Statistical Methods for Efficacy Analyses
For the efficacy analysis to estimate the proportion of participants with CS-CMVi through 
Week 14 (~100 days) post-trans plant and through Week 24 (~6 months) post-trans plant , a 
95% CI will be calculated based on the exact binomial method proposed by [CONTACT_193442] (1934) [Clopper, C. J. 1934] . The same method will be used to analyze all binary 
endpoints. 
The primary efficacy analysis will be performed on the FAS population . A sensitivity 
analysis including those participants who had detectable CMV viral DNA on Day 1 will be 
provided . The primar y missing data approach will be the Non- Completer= Failure (NC=F ) 
approach (see below for details) . Supportive analyses using different missing data approaches 
will also be conducted ( Table 17).
For the analyses of efficacy, results of participants in the Panel B will also be reported 
separately from those in Panel A , if doses in Panel A and Panel B are different . Limited 
summaries of efficacy may be provided in partic ipants in Panel A if the starting doses in 
Panel A and Panel B are different . In addition, key summaries of efficacy will be provided 
separately by [CONTACT_660236] 9.10.
08C0PW
PRODUCT: MK-8228 112
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890230] -2022
Table 17 Analysis Strategy for k ey Efficacy Variables
Endpoint/Variable
(Description, 
Time Point)Primary vs. 
Supportive 
Approach Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Proportion of 
participants with 
clinically significant 
CMV infection through 
Week 14 (~100 days) 
post-trans plantP 95% CI (Clopper -Pearson) FAS NC= F
S 95% CI (Clopper -Pearson) FAS OF
S 95% CI(Clopper -Pearson) FAS DAO
Proportion of 
participants with 
clinically significant 
CMV infection through 
Week 24 (~ 6months) 
post-trans plantP 95% CI (Clopper -Pearson) FAS NC=F
S 95% CI (Clopper -Pearson) FAS OF
S 95% CI (Clopper -Pearson) FAS DAO
CI=confidence interval; CMV=cytomegalovirus; DAO=Data -as-observed; FAS=full analysis set; NC=F: Non-completer 
equal failure.(non -completers refer to participants who prematurely discontinued from the study); OF= observed failure; 
P=primary approach; S=supp ortive approach. 
Missing Data Handling
The primary missing data approach will be the Non-Completer = Failure (NC=F) approach to 
be consistent with the adult study (P001) . Non- completers refer to participants who 
prematurely discontinued from the study. A participant who had missing efficacy measures at 
the study time point (eg, Week [ADDRESS_890231] -transplant) will be considered as a failure . A 
participant who discontinued study medication ,but remained in the study follow -up will not 
be considered as a N on-C ompleter . 
Two secondary missing data approaches will be used for supportive analyses . The first is the 
Observed Failure (OF) approach . Using this approach, participants who were failing (ie ,had 
viremia) when they discontinue dprematurely from the study for any reason willbe
considered as failures , and participants who were not failing (ie ,had no viremia) when they 
discontinue dprematurely from the study for any reason w illnot be considere d as failures .
The second is the Data -As-Observed (DAO) approach . With this approach, any participant
with missing value for a particular endpoint will be excluded from the analysis.
9.6.5 Summaries of Baseline Characteristics, Demographics, and Other Analyses
[IP_ADDRESS] Demographic and Baseline Characteristics
Baseline characteristics for all allocated and treated partic ipants will be summarized by [CONTACT_660237]. No statistical hypothesis tests will be performed on these 
characteristics . The number and percentage of participants screened and allocated, and the 
08C0PW
PRODUCT: MK-8228 113
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890232] -2022
primary reasons for screen failure and dis continuation will be displayed. Demographic 
variables (eg, age, gender, race), indication for HSCT, prior and concomitant therapi[INVESTIGATOR_660166], as appropriate .
[IP_ADDRESS] Palatability and Acceptance Assessment
Each part icipant will rate the palatability and respond to questions on the acceptability of
treatment with oral granules on the first day of oral granule administration and one week 
later. This will be based on the FHS facial expression scale depi[INVESTIGATOR_660167] (Section [IP_ADDRESS] and Section 8.10).
Descriptive statistics will be used to summarize the palatability and acceptability responses . 
Missing data will not be imputed, and the analyses will be based on observed data only . 
These analyses will be based on the APaT population.
9.7 Interim Analyses
Initial PK evaluations will be conducted as described in Section 4.3.1.
To supplement the routine safety monitoring outlined in this protocol, an external DMC will 
beappointed to monitor ongoing safety data and provide recommendations to discontinuation 
of the study or protocol modifications to the EOC (see Appendix 1 Committees Structure –
Executive Oversight Committee) . The DMC will periodically review the safety data at the 
following proposed time points:
1)when [ADDRESS_890233] completed intensive 
PK sampling at the Day 7 visit
2)when [ADDRESS_890234] completed intensive 
PK sampling at the Day 7 visit
3)when ~10(which is ~50% ) of participants in Age Group 1, Panel B have completed 
the Week 4 visit 
4)when ~10(which is ~50% )of participants in Age Group 2, Panel B have completed 
the Week 4 visit 
5)when at least [ADDRESS_890235] of the DMC . The DMC may review 
safety data at other time points (including after the last scheduled safety check) as needed. 
DMC reviews are primarily based on safety, but any available efficacy data willbe provided 
upon request to facilitate a benefit -riskevaluation.
Study enrollment for an age group will be paused until after the interim PK analyses, and
reevaluation of the initial dose for th e age group at the indicated time points ,as shown in
Figure 2are completed independent of DMC review of safety data . An internal statistician 
08C0PW
PRODUCT: MK-8228 114
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890236] analyses and present results to the DMC . 
Additional logistical details will be provided in the DMC Charter.
9.8 Multiplicity
There will be no multiplicity adjustments in the analysis of this study.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for PK Analysis
A sample size of 6 in A ge Group 1 and 2 has approximately 95% power to show that the 
95% confidence interval of the geometric mean of AUC 0-24in this age group will be within 
60% and 140% of the geometric mean estimates of the AUC 0-24of LET. A between -subject 
standard deviation of 0.325 in log scale for AUC 0-24that was obtained from previous studies 
(P003 and P004) was used for these calculations . This calculation is based on the pediatric 
guidance proposed by [CONTACT_38874] [Wang, Y., et al 2012] .
A sample size of 8 in A ge Group 3 has approximately 99% power to show that the 
95% confidence interval of the geometric mean of AUC 0-24in this age group will be within 
60% and 140% of the geometric mean estimates of the AUC 0-24of LET. A between -subject 
standard deviation of 0.325 in lo g scale for AUC 0-24that was obtained from previous studies 
(P003 and P004) was used for these calculations . This calculation is based on the pediatric 
guidance proposed by [CONTACT_38874] [Wang, Y., et al 2012] .
9.9.[ADDRESS_890237] one of a particular AE in this study depends on the 
number of participants treated and the underlying percentage of participants with that AE in 
the study population . If the underlying incidence of a particular AE is 1% (1 of every 100 
participants receiving the drug), there is a 45% chance of observing at least one of that 
particular AE among 60 participants. For analyses by [CONTACT_70566] , there is a 23% chance of 
observing at least one of that particular AE among 26 participants or an8% chance of 
observing at least one of that particular AE among 8 participants . If no AE of that particular 
type are observed among the 26participants ,this study will provide 95% confidence that the 
underlying percentage of participants with that particular AE is <13.2% (one in every 8
participants ). If no AE of that particular type are observed among the 8participants ,this 
study will provide 95% confidence that the underlying percentage of participants with that 
particular AE is<36.9% (one in every 3 participants) . 
The estimate of and the upper bound of the 95% confidence interval for the underlying 
percentage of participants with a particular AE given various hypothetical ob served number 
08C0PW
PRODUCT: MK-8228 115
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890238] binomial method proposed by [CONTACT_93325] (1934) [Clopper, C. J. 1934] .
Table 18 Estimate of Incidence of AEs and 95% Upper Confidence Bound Based on
Hypothetical Numbers of Participants With AEs
Hypothetical Number of Participants with 
an AE (Estimate of Incidence, %) 95% Upper Confidence Bounda
N=80 (0) 36.9
1 (12.5) 52.7
2(25.0) 65.1
N=260 (0) 13.2
1 (3.8) 19.6
2 (7.7) 25.1
N=600 (0) 6.0
1 (1.7) 8.9
2 (3.3) 11.5
5 (8.3) 18.4
AE(s)=adverse event(s); N=number of participants.
aBased on the two -sided exact confidence interval of a binomial proportion (Clopper and Pearson, 1934).
9.9.[ADDRESS_890239] age groups . The key efficacy objective will be assessed 
based on the proportion of participants with CS-CMVi through Week 24 (~6 months) 
post-trans plant . The expected rate of participants with CS-CMVi through Week [ADDRESS_890240]-trans plant is ~ 18% based on P001 data and assuming LET is expected to be similarly 
active in adults and pediatric participants. Since the primary missing data approach will be 
NC=F approach, 25% was added to the expected incidence of CS -CMVi through Week [ADDRESS_890241]-transplant with the assumption that higher discontinuation rate will be observed in the 
more vulnerable pediatric participants than adults. In terms of estimation with the proposed 
sample size, with 26 participants, the maximum half-width of the 95% exact confidence 
interval will be no greater than 21%. The calculation is based on the exact binomial method 
proposed by [CONTACT_93325] ( 1934) [Clopper, C. J. 1934] and is carried out using SAS 
v9.4. Table 19 shows the 95% CIs for CS-CMVi given varying assumptions of number of
failures for8, 26, and [ADDRESS_890242]: MK-8228 116
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890243] -2022
Table 19 Two-sided 95% Confidence Intervals for the Proportion of Participants With 
Clinically Significant CMV Infection Through Week 2 4 (~6 Months ) Post-transplant
(FAS Population)
Number of Fail uresa(%) Two-Sided 95% Confidence Intervalb
N=82(25.0) (3.2, 65.1)
3 (37.5) (8.5, 75.5 )
4 (50.0) (15.7, 84.3 )
N=269 (34.6) (17.2, 55.7 )
10 (38.5) (20.2, 59.4 )
11(42.3) (23.4, 63.1 )
12(46.2) (26.6, 66.6 )
N=6019 (31.7) (20.3, 45.0)
21 (35.0) (23.1, 48.4)
23 (38.3) (26.1, 51.8)
25(41.7) (29.1, 55.1)
27(45.0) (32.1, 58.4 )
CMV= -cytomegalovirus; FAS=full analysis set; N=number of participants .
a Based on Non-Completer = Failure approach.
b Based on the two -sided exact confidence interval of a binomial proportion (Clopper and Pearson, 1934).
9.10 Subgroup Analyses
To assess the consistency of the response across various subgroups , the proportion of 
participants with CS-CMVi through Week 14 (~100 days) post-trans plant and associated 
95% CIs will be estimated within each category of the following classification variables:
Age category (birth to <2 years, 2 years to <12 years, 12 years to <18 years)
Sex (female, male)
Race (white, black, Asian, other )
Donor and/or Recipi[INVESTIGATOR_660168] . Other clinically relevant variables may 
be identified for which additional subgroup analyses may be performed . 
08C0PW
PRODUCT: MK-8228 117
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890244] -2022
9.11 Compliance (Medication Adherence)
Drug accountability data for LET will be collected during the study . A day within the study 
will be considered an “On -Therapy” day if the participant takes at least one dose . For a 
participant who is followed for the entire study period, the “Number of Days Should be on 
Therapy” is the total number of days from treatment allocation to the last scheduled day for 
treatment administration for that participant. For a participant who discontinued from the 
study permanently, the “Number of Days Should be on Therapy” is the total number of days 
from treatment allocation to the date of the last dose of study intervention.
For each participant, percent compliance w ill then be calculated using the following formula:
Summary statistics will be provided on percent compliance for the APaT population.
In addition, percent of participants on CsA and duration of CsA use will be reported.
9.12 Extent of Exposure
The extent of exposure to study intervention will be evaluated by [CONTACT_148216] (N, 
mean, and range) for the “Number of Days on Therapy”.
08C0PW
PRODUCT: MK-8228 118
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890245] -2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considera tions
10.1.[ADDRESS_890246] for Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest e thical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, Interna tional Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical int erventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in natur e, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in th e trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious G CP-noncompliance is suspected, the issues 
08C0PW
PRODUCT: MK-8228 119
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890247] -2022
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commi ts to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of o ther analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since t he trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to protect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or representative), ethics committee, and/or regulator y authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant refer rals. However, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
08C0PW
PRODUCT: MK-8228 120
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890248] -2022
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meeti ngs, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commitment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to d etermine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
08C0PW
PRODUCT: MK-8228 121
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890249] -2022
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furni shed to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF report form data. By [CONTACT_17317], the participant agrees 
to this process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/ initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulat ions.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496].
10.1.4 Committees Structure
[IP_ADDRESS] Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d of members of Sponsor Senior 
Management. The EOC will receive and decide upon any recommendations made by [CONTACT_126562].
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, the y cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
08C0PW
PRODUCT: MK-8228 122
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890250] -2022
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants ( Section9.7 Interim 
Analysis ) and recommend to the EOC whether the study should continue in accordance with 
the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documenta tion 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
[IP_ADDRESS] Clinical Adjudication Committee (CAC)   
A Clinical Adjudication Committee (CAC) will evaluate the following events for the 
purposes of confirming them according to the criteria in Appendix 8 , as well as evaluating 
the presence of confounding factors.
The CAC will review clinical, virological, and histopathological data as well as the 
investigator’s assessment for adjudicating all potential cases of CMV end -organ disease . 
CMV end-organ disease will be determined using the definitions in Appendix 8.
10.1.[ADDRESS_890251] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directiv e 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to id entify potentially appropriate studies for their 
08C0PW
PRODUCT: MK-8228 123
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890252] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally 
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules a nd regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
Theinvestigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on cl inical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or des ignee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management proce dures for this protocol will be 
provided separately.
08C0PW
PRODUCT: MK-8228 124
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890253] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_660238] i nspection, 
copying, review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing sou rce data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is bein g conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants, documented informed consent, pertaining to 
the conduct of thi s study must be retained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of t he 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor .
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study site participation in the study for
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor will 
promptly notify that study site’s IRB/IEC.
08C0PW
PRODUCT: MK-8228 125
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890254] -2022
10.2 Appen dix 2: Clinical Laboratory Tests
•The tests specified in Table 20will b e performed by [CONTACT_779]’s local laboratory. The tests 
specified in Table [ADDRESS_890255] be entered into the CRF.
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Sections 5.1 and 5.2 ,respec tively.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 20 Protocol -require d Laboratory Assessm ents(Local Laboratory)
Laboratory 
AssessmentsParameters
Hematology Platelet Count White Blood Cell ( WBC )count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsHemoglobin
Hematocrit
Chemistry Blood Urea Nitrogen 
(BUN)
If BUN testing is not 
available at the local 
laboratory , blood urea must 
be measured and reported.Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic- Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin
and direct
bilirubin
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic- Pyruvic 
Transaminase (SGPT)Total Protein
Glucose [ nonfasting] Calcium Alkaline phosphatase
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase by 
[CONTACT_19508] (if blood or protein is abnormal)
Other Tests Urine or serum β human chorionic gonadotropin (β hCG ) pregnancy test (for WOCBP) .
Serology : (HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus 
(HCV) antibody (screening only) . 
HCV RNA PCR : to be done only in participants who test pos itive for HCV antibody
(screening only)
Coagulatio n: PT/INR
Creatinine Clearance; calculated using the Cockcroft -Gault equation for participants ≥12 
years of age or the modified Schwartz equation for participants <12 years of age
(Appendix 12 )
CMV DNA PCR using plasma or whole blood
pp65 antigen test (to be only reported by [CONTACT_660239] )
08C0PW
PRODUCT: MK-8228 126
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890256] -2022
Table 21 Protocol -require d Laboratory Assessments ( Central Laboratory)
Laboratory Assessments/Parameters
Plasma sample for cytomegalovirus ( CMV )DNA Sequence Analysis: CMV DNA Sequence 
Analysis to be performed only in participants with clinically significant cytomegalovirus infection 
(CS-CMVi )and who have detectable CMV DNA.
PKsamples testing 
Planned genetic analysis specimen (bucc al swab)
Future Biomedical Research will be conducted on residual DNA collected from buccal swab as 
well as l eftover main study plasma from CMV viral resistance
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
Table 22, Table 23, and Table 24 summarize the approximate blood volumes collected by 
[CONTACT_660240] (central labs), in separate tables by [CONTACT_243677].
08C0PW
PRODUCT: MK-8228 127
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890257] -2022
Table 22 Approximate Blood Volumes Drawn/Collected by [CONTACT_660241] –Research Testing (Age Group 1)
Treatment Period Follow -up Period
Expected 
Maximum 
Total Blood 
Volume per 
participantVisit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 25 26
Visit Name [CONTACT_444087] D1 D7 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 W13 W14 W16 W18 W20 W22 W24CMV 
Infec -
tion 
VisitEarly 
Study 
Discon 
Visit
Research Testing (Central Labs) 
CMV DNA 
Sequence Analysis3a3
Sparse PK 3 3 3 3 3 3 3 3b3c21
Intensive PKc15 15
Expected Total 
(mL)0 0 15 3 0 3 0 3 0 3 0 3 0 3 0 3 0 0 0 0 0 6 3 39
CMV=cytomegalovirus; CS -CMVi=clinically significant cytomegalovirus infection ; Discon=discontinuation; PK=pharmacokinetics.
Note: This table is based on the estimated maximum volume (in mL) to be required for each test . 
a Performed only in part icipants with CS -CMVi . Plasma samples required.
bDone only if the visit occurs during the Treatment Period . No subsequent Sparse PK samples would be taken.
cRefer to Section 8.[ADDRESS_890258]: MK-8228 128
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890259] -2022
Table 23 Approximate Blood Volumes Drawn/Collected by [CONTACT_660241] –Research Testing (Age Group 2)
Treatment Period Follow -up Period
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 25 26 Expected 
Maximum 
Total Blood 
Volume per 
participant Visit Name [CONTACT_444087] D1 D7 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 W13 W14 W16 W18 W20 W22 W24CMV 
Infec -
tion
VisitEarly 
Study 
Discon
Visit
Research Testing (Central Labs) 
CMV DNA 
Sequence Analysis2a2
Sparse PK 1 1 1 1 1 1 1 1b1b7
Intensive PKc5 5
Expected Total 
(mL)0 0 5 1 0 1 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 3 1 14
CMV=cytomegalovirus; CS -CMVi=clinically significant cytomegalovirus infection ; PK=pharmacokinetics.
Note: This table is based on the estimated maximum volume (in mL) to be required for each test . 
aPerformed only in part icipants with CS -CMVi .Plasma samples required.
bDone only if the visit occurs during the Treatment Period . No subsequent Sparse PK samples would be taken.
cRefer to Section 8.[ADDRESS_890260]: MK-8228 129
PROTOCOL/AMENDMENT NO.: 030-[ADDRESS_890261] -2022
Table 24 Approximate Blood Volumes Drawn/Collected by [CONTACT_660241] –Research Testing (Age Group 3)
Treatment Period Follow -up Period
Visit
Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 25 26 Expected 
Maximum 
Total Blood 
Volume per 
participant Visit Name [CONTACT_444087] D1 D7 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 W13 W14 W16 W18 W20 W22 W24CMV 
Infec -
tion 
VisitEarly 
Study 
Discon 
Visit
Research Testing (Central Labs) 
CMV DNA 
Sequence 
Analysis1a1
Sparse PK 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25b0.25b2.25
Intensive
PK c 1.251.25
HPCD PK
samplingd0.50.5
Expe cted 
Total (mL)0 0 1.75 0.25 0.25 0.25 0.25 0.25 0.25 0.25 1.25 0.25 5.0
CMV=cytomegalovirus; CS -CMVi=clinically significant cytomegalovirus infection ; Discon=discontinuation; HPCD= hydroxypropyl -beta-cyclodextrin;
LET=letermovir; PK=pharmacokinetics.
Note: This table is based on the estimated maximum volume (in mL) to be required for each test . 
aPerformed only in participants with CS -CMVi.
bDone only if the visit occurs during the Treatment Period . No subsequent Sparse PK samples would be taken.
cRefer to Sec tion8.6 for details . Collection will start on the 5thconsecutive day of IV dosing.
d Start on the 4thconsecutive dayofIVdosing. See Sections8.6.2 and [IP_ADDRESS] for additional sampling for serum creatinine with HPCD PK sampling .
08C0PW
PRODUCT: MK-8228 130
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890262] -2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_890263].
10.3.2 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•NOTE: An AE can therefore be any unfavorable and unintended sig n (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study intervention includes any pharmaceutical 
product, biological produ ct, vaccine, device, diagnostic agent, or protocol specified 
procedure whether investigational (including placebo or active comparator product) or 
marketed, manufactured by, licensed by, provided by, or distributed by [CONTACT_660242].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
08C0PW
PRODUCT: MK-8228 131
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890264] -2022
•New condit ions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
Any new cancer or progression of existing cancer.
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day flu ctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgery planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
•Refe r to Section 8.4.[ADDRESS_890265] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
• The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
08C0PW
PRODUCT: MK-8228 132
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890266] -2022
c.Requi res inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_660169] a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly /birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition . These events should usually be 
considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_1916], or development of drug dependency 
or drug abuse.
10.3.4 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reporta ble to the Sponsor.
•Is a cancer
•Is associated with an overdose
08C0PW
PRODUCT: MK-8228 133
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890267] -2022
10.3.5 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to t he Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be bli nded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
-The investigator will m ake an assessment of intensity for each AE and SAE (and 
other reportable safety event) reported during the study and assign it to 1 of the 
following categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort, 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category used f or rating the 
intensity of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely distressed or unable to do usual activities).
Assessment of c ausality
•Did the study intervention cause the AE?
08C0PW
PRODUCT: MK-8228 134
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890268] -2022
•The determination of the lik elihood that the study intervention caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
study intervention and the AE ; the greater the correlation with the components and 
their resp ective elements (in number and/or intensity), the more likely the study 
intervention caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the study 
intervention such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], 
diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in 
bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the study intervention? Is the time of onset of the AE c ompatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental fact ors.
-Dechallenge: Was the study intervention discontinued or dose/exposure/frequency 
reduced?
-If yes, did the AE resolve or improve?
-If yes, this is a positive dechallenge.
-If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_19364]; (3) the study is a single -dose drug study; or (4) study intervention(s) 
is/are only used 1 time.)
-Rechallenge: Was the participant re -exposed to the study intervention in this study?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
08C0PW
PRODUCT: MK-8228 135
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890269] -2022
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) study 
intervention(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_19512], OR IF RE -
EXPOSURE TO THE STUDY INTERVENTION POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE 
APPROVED IN ADVANCE BY [CONTACT_93333], AND IF 
REQUIRED, THE IRB/IEC .
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the study intervention or drug class 
pharmacology or toxicology?
•The assessment of relationship will be reported on the case report forms/worksheets by 
[CONTACT_19427] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indica tive of a study intervention relationship).
-Yes, there is a reasonable possibility of study intervention relationship:
-There is evidence of exposure to the study intervention. The temporal sequence of 
the AE onset relative to the administration of the stud y intervention is reasonable. 
The AE is more likely explained by [CONTACT_14355].
-No, there is not a re asonable possibility of study intervention relationship:
-Participant did not receive the study intervention OR temporal sequence of the AE 
onset relative to administration of the study intervention is not reasonable OR the 
AE is more likely explained by [CONTACT_14354]. (Also 
entered for a participant with overdose without an associated AE.)
•The invest igator must review and provide an assessment of causality for each AE/SAE 
and document this in the medical notes .
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Spon sor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242]- up inf ormation 
and send an SAE follow- up report with the updated causality assessment.
•The causality assessment is [ADDRESS_890270]: MK-8228 136
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890271] -2022
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or invest igations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the inf ormation.
10.3.6 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Refere nce Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic system as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new da ta or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE for m or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of t he SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
08C0PW
PRODUCT: MK-8228 137
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890272] -2022
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting proc edures can be found 
in the Investigator Study File Binder (or equivalent).
08C0PW
PRODUCT: MK-8228 138
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890273] -2022
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not Applicable . 
08C0PW
PRODUCT: MK-8228 139
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890274] -2022
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile.
Women in the following categories are not considered WOCBP:
• Premenarchal
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
10.5.[ADDRESS_890275]: MK-8228 140
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890276] -2022
Table 25 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when u sed consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1% per year when used consistently and correctly.
●Combined (estrogen -and progestogen -containing) hormonal contraceptionb
○Oral
○Intravaginal
○Transdermal
○Injectable
●Progestogen only hormonal contraceptionb
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb
●Intrauterine hormone- releasing system (IUS)
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception sho uld be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants of 
clinical studies.
a   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
b   If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
hormonal contracept ives are limited to those , which inhibit ovulation.
08C0PW
PRODUCT: MK-8228 141
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890277]: MK-8228 142
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890278] -2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal o r abnormal process or of a condition or disease. A biomarker may 
be used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vacci ne response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research3,4
The specimens consented and/or collected in this study as outlined in Section 8.8 will be 
used in various experiments to understand:
•The biology of how drugs/vaccines work
•Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
•Other pathways with which drugs/vaccines may interact
•The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimatel y 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3. Summary of Procedures for Future Biomedical Researc h3,[ADDRESS_890279]: MK-8228 143
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890280] -2022
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc .) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved informed consent will be stored in th e 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical rese arch, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research3,4
In order t o optimize the resea rch that can be conducted with future b iomedical research
specimens, it is critical to link participant s' clinical information with future test results. In 
fact,little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific a nalyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical resear ch
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will
appear on the specimen tube.
08C0PW
PRODUCT: MK-8228 144
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890281] party (eg, a university investigator) designated by [CONTACT_429]. The investigator conducting the analysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope of analysis outlined in future biomedical research protocol and consent. 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research3,[ADDRESS_890282] the Sponsor using the designated mailbox 
(clinical.specimen.management@ msd.com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from stud yparticipants specifically for FBR , these specimens will be removed 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawal and/or destruction, 
if applicable. Any analyses in progress at the time of request for withdrawal/destruction 
or already performed before the request being received by [CONTACT_619647] b e 
used as part of the overall research study data and results. No new analyses would be 
generated after the request is received.
If the medical records for the study are no longer available (eg , if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens3,[ADDRESS_890283]: MK-8228 145
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890284] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentic ation is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants3,4
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: lack of relevance to participant health, limitations of predictive 
capability, and conc erns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_111939] a nd participants. Participants will not be 
identified by [CONTACT_88726].
10. Future Biomedical Research Study Population3,[ADDRESS_890285] security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In thi s highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly to 
clinical.specimen.management@ msd.com.
08C0PW
PRODUCT: MK-8228 146
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890286] -2022
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmonisation [Internet]: E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, G enomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry Pharmacogenomic s Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08C0PW
PRODUCT: MK-8228 147
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890287] -2022
10.7 Appendix 7: Country -specific Requirements
Not Applicable.
08C0PW
PRODUCT: MK-8228 148
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890288] -2022
10.8 Appendix 8 Definition of CMV Disease in Hematopoietic Stem Cell Transplant 
(HSCT) Recipi[INVESTIGATOR_660170]/or symptoms of 
pneumonia
AND
Detection of CMV by [CONTACT_140176], rapid culture of BAL 
fluid, or the quantitation of 
CMV DNA in BAL fluidSigns and/or symptoms of 
pulmonary disease
AND
Detection of CMV in lung 
tissue by [CONTACT_126568], rapid 
culture, histopathology, 
immunohistochemistry, or 
DNA hybridization techniquesPCR may be too 
sensitive, so detection 
of CMV by [CONTACT_660243].
Superinfection or 
coinfection with other 
pathogens may occur 
and should be noted 
when present.
GI Disease Symptoms of upper and/ or 
lower GI disease
AND
Evidence of CMV in tissue but 
without the requirement for 
macroscopic mucosal lesionsSymptoms of upper and/ or 
lower GI disease
AND
Macroscopic mucosal lesions 
AND
Detection of CMV in GI tissue 
by [CONTACT_26745], virus 
isolation, rapid culture, 
immunohistochemistry, or 
DNA hybridizationDetection of CMV by 
[CONTACT_660244].
Hepatitis N/A Abnormal liver function tests
AND
CMV documented in tissue by 
[CONTACT_26745], 
immunohistochemistry, virus 
isolation, rapid culture, or DNA 
hybridization techniques
AND
Absence of other documented 
cause of hepatitisDetection of CMV by 
[CONTACT_660245] . Hence, 
PCR is insufficient to 
diagnose CMV 
hepatitis.
Documentation of 
CMV in liver biopsy 
specimen ( ie, by 
[CONTACT_921], 
histopat hology, 
immunohistochemical 
analysis or in situ
hybridization) is 
needed. 
Coinfection with other 
pathogens like HCV 
may be present 
without excluding the 
diagnosis of CMV 
hepatitis.
08C0PW
PRODUCT: MK-8228 149
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890289] -2022
CMV Disease 
Type Probable Proven Notes
Encephalitis / 
ventriculitisCNS symptoms 
AND
Abnormal imaging results or 
evidence of encephalitis on 
electroencephalography
AND
Detection of CMV in CSF 
without visible contamination 
of bloodCNS symptoms
AND
Detection of CMV in CNS 
tissue by [CONTACT_126568], rapid 
culture, immunohistochemistry, 
in situ hybridization , or 
(preferably) quantitative PCRN/A
Retinitis N/A Lesions typi[INVESTIGATOR_660171].N/A
Nephritis N/A Detection of CMV by [CONTACT_140175], rapid culture, 
immunohistochemistry, or in 
situhybridization in a kidney 
biopsy specimen obtained from 
a patient with renal dysfunction
AND
Identification of histologic 
features of CMV infectionDetection of CMV in 
urine by [CONTACT_660246] .
Cystitis N/A Detection of CMV by [CONTACT_140175], rapid culture, 
immunohistochemistry, or in 
situhybridization in a bladder 
biopsy specimen obtained from 
a patient with cystitis
AND
Identification of conventional 
histologic features of CMV 
infectionDetection of CMV in 
urine by [CONTACT_660247].
Myocarditis N/A Detection of CMV by [CONTACT_140175], rapid culture, 
immunohistochemistry, or in 
situhybridization in a heart 
biopsy specimen obtained from 
a patient with myocarditis
AND
Identification of conventional 
histologic features of CMV 
infectionN/A
08C0PW
PRODUCT: MK-8228 150
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890290] -2022
CMV Disease 
Type Probable Proven Notes
Pancreatitis N/A Detection of CMV by [CONTACT_140175], rapid culture, 
immunohistochemistry, or in 
situhybridization in a 
pancreatic biopsy specimen 
obtained from a patient with 
pancreatitis
AND
Identification of conventional 
histologic features of CMV 
infectionN/A
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BAL=bronchoalveolar lavage; 
CMV=cytomegalovirus; CNS=central nervous system; CSF=cerebrospi[INVESTIGATOR_872]; DNA=deoxyribonucleic 
acid; GI=gastrointestinal; HCV=hepatitis C virus; PCR=polyme rase chain reaction; ULN=upper limit of 
normal.
[Ljungman, P., et al 2016] [National Cancer Institute 2009]
08C0PW
PRODUCT: MK-8228 151
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890291] -2022
10.9 Appendix 9 Child -Pugh Classification for Severity of Liver Disease
Scoring by [CONTACT_126575] 1 point 2 points 3 points 
Hepatic encephalopathyaabsent Grade 1 or Grade 2 Grade 3 or Grade 4 
Ascites absent mild moderate /severe
Bilirubin ( mg/dL ) <2mg/dL 2 – 3mg/dL >3mg/dL 
Albumin (g/dL) >3.5 g/dL 2.8 –3.5g/dL <2.8 g/dL
INR <1.7 1.7 –2.3 >2.3 
INR=international normalized rati o
aHepatic encephalopathy grading: 
Grade 1 : Altered mood/confusion
Grade 2 : Inappropriate behavior, impending stupor, somnolence
Grade 3 : Markedly confused, stuporous but arousable
Grade 4 : Comatose/unresponsive
Child -Pugh Score Interpretation
5 –6 pointsChild -Pugh Stage A(mild hepatic insufficiency)
7 –9 pointsChild -Pugh Stage B(moderate hepatic insufficiency*)
>10 pointsChild -Pugh Stage C(severe hepatic insufficiency)
*If hypoalbuminemia is the only abnormality noted, the participant will need to have a score of ≥[ADDRESS_890292]: MK-8228 152
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890293] -2022
10.10 Appendix 10: Medications Allowed for HSV/VZV Prophylaxis
10.10.1 Acyclovir
[IP_ADDRESS] HSV Prophylaxis
Prevention of e arly reactivation
Note: Begin at conditioning and continue until engraftment or resolution of mucositis; 
whichever is longer (~[ADDRESS_890294]) .
Infants, Children, and Adolescents <40 kg:
IV: 250 mg/m2/dose every 8 hours or 125 mg/m2/dose every 6 
hours; maximum daily dose: 80 mg/kg/ day
Oral: 60 to 90 mg/kg/ dayin 2 to 3 divided doses; maximum 
dose: 800 mg/dose twice daily
Children and Adolescents ≥40kg:
IV: 250 mg/m2 /dose every 12 hours
Oral: 400 to 800 mg twice daily
Prevention of l ate reactivation
Note: Treatment during first year after HSCT.
Infants, Children, and Adolescents <40 kg:
Oral: 60 to 90 mg/kg/ dayin 2 to 3 divided doses; maximum 
daily dose: 800 mg twice daily
Children and Adolescents ≥40kg:
Oral: 800 mg twice daily
[IP_ADDRESS] Varicella (C hickenpox) or Herpes Z oster ( Shingles), Prophylaxis
Hematopoietic s tem c ell transplant (HSCT): Prophylaxis of disease r eactivation
Note: Continue therapy for [ADDRESS_890295] [Tomblyn, M, et al 2009] .
Infants, Children, and Adolescents <40 kg:
Oral: 60 to 80 mg/kg/day in [ADDRESS_890296]: MK-8228 153
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890297] -2022
Children and Adolescents ≥40kg:
Oral: 800 mg twice daily
10.10.2 Valacyclovir
[IP_ADDRESS] Herpes S implex Virus (HSV), Prophylaxis
Immunocompromised patients (eg, HSCT or leukopenic oncology patients)
Limited data available ( [Tomblyn, M, et al 2009] )
Children and a dolescents, o ral:
Early reactivation prevention
Begin at initiation of conditioning and continue until engraftment or resolution of 
mucositis (IDSA [Tomblyn, M, et al 2009] )
Patient weight <40 kg:
250mg twice daily
Patient weight ≥40kg:
500mg once or twice daily; twice daily dosing should be 
considered in patients who are highly suppressed
Late reactivation prevention
Continue throughout the first year following HSCT ( [Tomblyn, M, et al 2009] )
Patient weight <40 kg:
250mg twice daily
Patient weight ≥40kg:
500mg once or twice daily; twice daily dosing should be 
considered in patients who are highly suppressed
[IP_ADDRESS] Varicella (C hickenpox), Prophylaxis
Immunocompromised patients (eg, HSCT or leukopenic oncology)
Limited data available
08C0PW
PRODUCT: MK-8228 154
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890298] -2022
Children and a dolescents:
Weight -directed: 
Oral: 15 to 30 mg/kg/dose 3 times daily ( [Bomgaars, L., et 
al 2008] )
Fixed dosing:
Patient weight <40 kg: 
Oral: 250 or 500 mg twice daily ( [Tomblyn, M, et al 2009] )
Patient weight ≥40kg:
Oral: 500 mg twice daily ( [Tomblyn, M, et al 2009] )
Post exposure prophylaxis (IDSA [Tomblyn, M, et al 2009] ):
Note: Continue for [ADDRESS_890299] exposure.
Patient weight <40 kg:
Oral: 500 mg 3 times daily
Patient weight ≥40kg:
Oral: 1,[ADDRESS_890300]: MK-8228 155
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890301] -2022
10.11 Appendix 11: Palatability and Acceptance Assessment Form
08C0PW
PRODUCT: MK-8228 156
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890302] -2022
10.12 Appendix 12: Calculation of Creatinine Clearance by [CONTACT_660248]-Gault equation in 
adolescents ≥ 12years of age and the modified Schwartz equation for infants and children 
<12 years of age [Food and Drug Administration (CDER) 2014] .
Cock croft-Gault Equation (for Participants ≥12 Y ears of age):
Creatinine clea rance (males) = (weight in kg) × (140 minus age)     
       (72) × (creatinine in mg/dL)
Creatinine clearance (females) = 0.85 × the value obtained using the equation above
Modified Schwartz E quation (for Participant s<12 Years of age):
Creatinine clearance =     K × (height in cm) ___  
(creatinine in mg/dL)
K (proportionality constant):
Infant (term <1 year): K=0.45
Female child ( ≥1 year and <12 years): K=0.55
Male child ( ≥1year and <12 years): K=0.[ADDRESS_890303]: MK-8228 157
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890304] -2022
10.13 Appendix 13: Abbreviations
Abbreviation Expanded Term
ADME absorption, distribution, metabolism, and excretion
AE adverse event 
ALT alanine aminotransferase
APaT All Participants as Treated
AST aspartate aminotransferase
AUC0 -24 area under the concentration -time curve for the dosing period (0 to 24 hours)
AUC0 -inf area under the concentration -time curve for the dosing period (0 to infinity)
CAC Clinical Adjudication Committee
Ceoi concentration at the end of infusion
CI confidence interval
CL clearance
CL/F apparent clearance
Cmax maximum concentration observed
CMV Cytomegalovirus
CMVi Cytomegalovirus infection
CNS central nervous system 
COVID -[ADDRESS_890305]: MK-8228 158
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890306] hematopoietic stem cell transplantation
HSV herpes simplex virus
IA(s) Interim Analysis (ses)
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International C ouncil onHarmoni zation of Technical Requirements for 
Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IgG immunoglobulin G
IND Investigational New Drug 
IRB Institutional Review Board 
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
LET Letermovir
NC=F Non-Completer=Failure
NCA Noncompartmental analysis
NG tube Naso gastric tube
NTR narrow therapeutic range
OF observed failure
PAA Palatability Acceptance Assessment
PCL Protocol Clarification Letter
PCR polymerase chain reaction
PES polyethersulfone 
PET preemptive therapy
PBPK physiologically based pharmacokinetic s
PK pharmacokinetic s
PP Per Protocol
PT prothrombin time
QD once daily
QP2 department of quantitative pharmacology and pharmacometrics
R+ CMV -seropositive recipi[INVESTIGATOR_660172]
t1/[ADDRESS_890307]: MK-8228 159
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890308] upper limit of normal
Vd volume of distribution
VZV varicella zoster virus
WOCBP woman/women of childbearing potential 
08C0PW
PRODUCT: MK-8228 160
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890309] -2022
11 REFERENCES
[Ariza -Heredia, E. J., 
et al 2014]Ariza -Heredia EJ, Nesher L, Chemaly RF. 
Cytomegalovirus diseases after hematopoietic 
stem cell transplantation: a mini -review. Cancer 
Lett. 2014 Jan 1;342(1):1 -8.[04J8SD]
[Atkinson, C. and 
Emery, V. C. 2011]Atkinson C, Emery VC. Cytomegalovirus 
quantification: Where to next in optimising 
patient management? J Clin Virol 2011;51:219-
24.[03RVNJ]
[Barrow, P. C., et al 
2011]Barrow PC, Barbellion S, Stadler J.  Preclinical 
evaluation of juvenile toxicity.  In: Gautier J -C, 
editor.  Drug safety evaluation: methods and 
protocols, methods in molecular biology, 
vol.691.  [LOCATION_001]: Humana Press, c/o Springer 
Science+Business Media, LLC; 2011.  p. 17 -35.[03W8ZF]
[Bate, S. L., et al 
2010]Bate SL, Dollard SC, Cannon MJ. 
Cytomegalovirus seroprevalence in the United 
States: the National Health and Nutrition 
Examination Surveys, [ADDRESS_890310] 
Dis 2010;50:1439- 47.[03RMF9]
[Boeckh, M. 2011] Boeckh M. Complications, diagnosis, 
management, and prevention of CMV i nfections: 
Current and future. Am Soc Hematol 2011:305 -
9.[03RVMQ]
[Boeckh, M. and 
Geballe, A. P. 2011]Boeckh M, Geballe AP. Cytomegalovirus: 
Pathogen, paradigm, and puzzle. J Clin Invest 
2011;121(5):1673 -80.[03RVMS]
[Boeckh, M. and 
Ljungman, P. 2009]Boeckh M, Ljungman P. How we treat 
cytomegalovirus in hemtopoietic cell transplant 
recipi[INVESTIGATOR_840]. Blood 2009;113:5711- 9.[03RSYS]
[Boeckh, M. and 
Nichols, W. G. 2004]Boeckh M, Nichols WG. The impact of 
cytomegalovirus serostatus of donor and 
recipi[INVESTIGATOR_660173] e hematopoietic stem cell 
transplantation in the era of antiviral prophylaxis 
and preemptive therapy. Blood 2004;103:2003-
8.[03RVMR]
08C0PW
PRODUCT: MK-8228 161
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890311] -2022
[Boeckh, M., et al 
1992]Boeckh M, Bowden RA, Goodrich JM, Pettinger 
M, Meyers JD. Cytomegalovirus antigen 
detection in peripheral blood leukocytes after 
allogeneic marrow transplantation. Blood 
1992;80(5):1358 -64.[03RVND]
[Bomgaars, L., et al 
2008]Bomgaars L, Thompson P, Berg S, Serabe B, 
Aleksic A, Blaney S. Valacyclovir and acyclovir 
pharmacokinetics in immunocompromis ed 
children. Pediatr Blood Cancer. 2008;51:504- 8.[04X7GN]
[Brion, L. P., et al 
1986]Brion LP, Fleischman AR, McCarton C, 
Schwartz GJ. A simple estimate of glomerular 
filtration rate in low birth weight infants during 
the first year of life: noninvasive assessment of 
body composition and growth. J Pediatr. [ADDRESS_890312];109(4):698 -707.[04JMK0]
[Cannon, M. J., et al 
2010]Cannon MJ, Schmid DS, Hyde TB. Review of 
cytomegalovirus seroprevalence and 
demographic characteristics associated with 
infection. Rev Med Virol 2010;20:202- 13.[03RRN6]
[Castagnola, E., et al 
2004]Castagnola E, Cappelli B, Erba D, Rabagliati A, 
Lanino E, Dini G. Cytomegalovirus infection 
after bone marrow transplantation in children. 
Hum Immunol 2004;65:416 -22.[03WK5G]
[Center for 
International Blood 
and Marrow 
Transplant Research 
2017]Center for International Blood and Marrow 
Transplant Research (C IBMTR). Transplant 
activity report covering [ADDRESS_890313] performed in the United 
States and reported to CIBMTR by [CONTACT_660249]; includes 
sex, disease at transplant, age at transplant, broad 
race, and state of transplant center: For calendar 
year 2014 [Internet]. Minneapolis: CIBMTR; 
2014. Available from: https://www.cibmtr.org/.[04THJF]
[Clopper, C. J. 1934] Clopper CJ, Pearson ES. The use of confidence 
or fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404- 13.[03Q0LW]
08C0PW
PRODUCT: MK-8228 162
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890314] -2022
[Craddock, C., et al 
2001]Craddock C, Szydlo RM, Dazzi F, Olavarria E, 
Cwynarski K, Yong A, et al. Cytomegalovirus 
seropositivity adversely influences outcome after 
T-depleted unrelated donor transplant in patients 
with chronic myeloid leukaemia: The case for 
tailored graft -versus -host disease prophylaxis. Br 
J Haematol 2001;112:228 -36.[03RVN2]
[Emery V, Zuckerman 
M, Jackson G, Aitken 
C, Osman H 2013]Emery V, Zuckerman M, Jackson G, Aitken C, 
Osm an H, Pagliuca A, et al. Management of 
cytomegalovirus infection in haemopoietic stem 
cell transplantation. Br J Haematol 2013;162:25-
39.[03V285]
[Emery, V. C., et al 
2000]Emery VC, Sabin CA, Coppe AV, Gor D, 
Hassan -Walker AF, Griffiths PD. Application of 
viral-load kinetics to identify patients who 
develop cytomegalovirus disease after 
transplantation. Lancet 2000;355:2032 -6.[03RT9M]
[Food and Drug 
Administration 
(CDER) 2014]Food and Drug Administration (CDER). General 
clinical pharmacology considerations for 
pediatric studies for drugs and biological 
products [Internet]. Silver Spring, MD: U.S. 
Department of Health and Human Services; 
2014. Available from: 
http://www.fda.gov/downloads/drugs/guidancec
omplianceregulatoryinformation/guidances/ucm
425885.pdf.[04JMPW]
[Gerna, G., et al 2011] Gerna G, Lilleri D, Furione M, Baldanti F. 
Management of human cytomegalovirus 
infection in transplantation: Validation of 
virologic cut -offs for preemptive therapy and 
immunological cut -offs for protection. New 
Microbiol 2011;34:229 -54.[03RVNF]
[Gor, D., et al 1998] Gor D, Sabin C, Prentice HG, Vyas N, Man S, 
Griffiths PD, et al. Longitudinal fluctuations in 
cytomegalovirus load in bone marrow transplant 
patients: Relationship between peak virus load, 
donor/recipi[INVESTIGATOR_660174], acute gvhd and cmv 
disease. Bone Marrow Transpl 1998;21:597 -605.[03RT9N]
08C0PW
PRODUCT: MK-8228 163
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890315] -2022
[Green, M. L., et al 
2016]Green ML, Leisenring W, Xie H, Mast TC, Cui 
Y, Sandmaier BM, et al. Cytomegalovirus viral 
load and mortality after haemopoietic stem cell 
transplantation in the era of pre -emptive therapy: 
a retrospective cohort study. Lancet Haematol. 
2016 Mar;3(3):e119 -27.[04HYZH]
[Härter, G. and 
Michel, D. 2012]Härter G, Michel D. Antiviral treatment of 
cytomegalovirus infection: An update. Expert 
Opin Pharmacother 2012;13(5):623- 7.[03RVQH]
[Just -Nubling, G., et al 
2003]Just-Nubling G, Korn S, Ludwig B, Stephan C, 
Doerr HW, Preiser W. Primary cytomegalovirus 
infection in an outpatient setting --laboratory 
markers and clinical aspects. Infection. [ADDRESS_890316];31(5):318- 23.[04GCTX]
[Larsson, K., et al 
2004]Larsson K, Aschan J , Remberger M, Ringdén O, 
Winiarski J, Ljungman P. Reduced risk for 
extensive chronic graft -versus- host disease in 
patients receiving transplants with human 
leukocyte antigen- identical sibling donors given 
polymerase chain reaction- based preemptive 
therapy against cytomegalovirus. 
Transplantation 2004;77(4):526- 31.[03RVNB]
[Ljungman, P. 2014] Ljungman P. The role of cytomegalovirus 
serostatus on outcome of hematopoietic stem cell 
transplantation. Curr Opin Hematol. 2014 
Nov;21(6):466 -9.[04HYZL]
[Ljungma n, P., et al 
1998]Ljungman P, Aschan J, Lewensohn -Fuchs I, 
Carlens S, Larsson K, Lönnqvist B, et al. Results 
of different strategies for reducing 
cytomegalovirus- associated mortality in 
allogeneic stem cell transplant recipi[INVESTIGATOR_840]. 
Transplantation 1998;66(1 0):1330- 4.[03RVNH]
[Ljungman, P., et al 
2002]Ljungman P, Griffiths P, Paya C. Definitions of 
cytomegalovirus infection and disease in 
transplant recipi[INVESTIGATOR_840]. Clin Infect Dis 
2002;34:1094- 7.[03RT9X]
08C0PW
PRODUCT: MK-8228 164
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890317] -2022
[Ljungman, P., et al 
2011]Ljungman P, Hakki M, Boeckh M. 
Cytomegalovirus in hematopoietic stem cell 
transplant recipi[INVESTIGATOR_840]. Hematol Oncol Clin North 
Am 2011;25:151 -69.[03RRN9]
[Ljungman, P., et al 
2016]Ljungman P, Boeckh M, Hirsch HH, Josephson 
F, Lundgren J, Nichols G, et al. Definitions of 
Cytomega lovirus Infection and Disease in 
Transplant Patients for Use in Clinical Trials. 
Clin Infect Dis. 2016 Sep 28. [Epub ahead of 
print].[04K6N0]
[Lopo, S., et al 2011] Lopo S, Vinagre E, Palminha P, Paixao MT, 
Nogueira P, Freitas MG. Seroprevalence to 
cytom egalovirus in the Portuguese population, 
2002- 2003. Euro Surveill 2011;16(25):1 -6.[03X60B]
[Lowance, D., et al 
1999]Lowance D, Neumayer H -H, Legendre CM, 
Squifflet J -P, Kovarik J, Brennan PJ, et al. 
Valacyclovir for the prevention of 
cytomegalovirus dis ease after renal 
transplantation. N Engl J Med 1999;340:1462-
70.[03RT6R]
[Ludwig, A. 2009] Ludwig A, Hengel H. Epi[INVESTIGATOR_660175]. Euro 
Surveill 2009;14(9):1- 7.[03X5YD]
[Martino, R., et al 
2001]Martino R, Rovira M, Carreras E, Solano C, 
Sierra J, De La Rubia J, et al. Severe infections 
after allogeneic peripheral blood stem cell 
transplantation: a matched -pair comparison of 
unmanipulated and CD34+ cell -selected 
transplantation. Ha ematologica 2001;86:1075 -
86.[03RVN7]
[Marty, F. M. and 
Boeckh, M. 2011]Marty FM, Boeckh M. Maribavir and human 
cytomegalovirus- what happened in the clinical 
trials and why might the drug have failed? Curr 
Opin Vir 2011;1:555 -62.[03RVNC]
08C0PW
PRODUCT: MK-8228 165
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890318] -2022
[Marty, F. M., et al 
2011]Marty FM, Ljungman P, Papanicolaou GA, 
Winston DJ, Chemaly RF, Strasfeld L, et al. 
Maribav ir prophylaxis for prevention of 
cytomegalovirus disease in recipi[INVESTIGATOR_660176]- cell transplants: A phase 3, 
double -blind, placebo- controlled, randomised 
trial. Lancet Infect Dis 2011;11:284 -92.[03RVMT]
[Miller, W., et al 
1986]Miller W, Flynn P, McCullough J, Balfour Jr. 
HH, Goldman A, Haake R, et al. 
Cytomegalovirus infection after bone marrow 
transplantation: An association with acute graft-
v-host disease. Blood 1986;67(4):1162- 7.[03RVN6]
[National Cancer 
Institute 2009]National Cancer Ins titute. Common terminology 
criteria for adverse events (CTCAE) version 4.0. 
U.S.Department of Health and Human Services; 
2009. 79p.[03RCHC]
[Neofytos, Dionissios, 
et al 2012]Neofytos D, Lombardi LR, Shields RK, 
Ostrander D, Warren L, Nguyen MH, et al. 
Administration of Voriconazole in Patients With 
Renal Dysfunction. Clin Infect Dis 
2012;54(7):913- 21.[03RVQF]
[Özdemir, E., et al 
2007]Ozdemir E, Saliba RM, Champlin RE, Couriel
DR, Giralt SA, de Lima M. Risk factors 
associated with late cytomegalovirus reactivation 
after allogeneic stem cell transplantation for 
hematological malignancies. Bone Marrow 
Transpl 2007;40:125 -36.[03RTB5]
[Prasad, B., et al 2016] Prasad B, Gaedigk A, Vrana M, Gaedigk R, 
Leeder JS, Salphati L, et al. Ontogeny of Hepatic 
Drug Transporters as Quantified by [CONTACT_29864] -MS/MS 
Proteomics. Clin Pharmacol Ther. [ADDRESS_890319];100(4):362 -70.[04SBQN]
[Prohn M, Dykstra K, 
Cho C, et al. 2017]Modeling and Simulation Report: L etermovir 
population PK Phase I modeling, 2017[04LVRJ]
[Razonable, R. R. 
2005]Razonable RR. Epi[INVESTIGATOR_660177]. 
Am J Health Syst Pharm. 2005 Apr 15;62([ADDRESS_890320] 1):S7- 13.[04HYZR]
08C0PW
PRODUCT: MK-8228 166
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890321] -2022
[Romkens, T. E., et al 
2016]Romkens TE, Bulte GJ, Nissen LH, Drenth JP. 
Cytomegalovirus in inflammatory bowel disease: 
A systematic review. World J Gastroenterol. 
2016 Jan 21;22(3):1321- 30.[04JBHN]
[Schwartz, G. J. 2009] Schwartz GJ, Work DF . Measurement and 
estimation of GFR in children and adolescents. 
Clin J Am Soc Nephrol. 2009 Nov;4(11):1832 -
43.[04HDS5]
[Snydman, D. R. 
2011]Snydman DR. Why did maribavir fail in stem -
cell transplants? Lancet Infect Dis 2011;11:255-
7.[03RT9Z]
[Söderberg, C., et al 
1993]Söderberg C, Larsson S, Bergstedt -Lindqvist S, 
Möller E. Definition of a subset of human 
peripheral blood mononuclear cells that are 
permissive to human cytomegalovirus infection. 
J Virol 1993;67(6):3166 -75.[03RVN8]
[Thompson, C., et al 
2015]Thompson C, Lombardi D, Sjostedt P, Squires 
L, et al. Best practice recommendations 
regarding the assessment of palatability and 
swallowability in the development o f oral dosage 
forms for pediatric patients. Therapeutic 
Innovation & Regulatory Science. 2015, 
49(5):647 -58.[04PJDV]
[Thomson, M. M., et 
al 2016]Thomson MM, Hines RN, Schuetz EG, 
Meibohm B. Expression Patterns of Organic 
Anion Transporting Polypeptides 1B1 and 1B3 
Protein in Human Pediatric Liver. Drug Metab 
Dispos. 2016 Jul;44(7):999 -1004.[04NV74]
[Tomblyn, M, et al 
2009]Tomblyn M, Chiller T, Einsele H, Gress R, 
Sepkowitz K, Storek J, et al. Guidelines for 
preventing infectious complications among 
hematopoietic cell transplantation recipi[INVESTIGATOR_840]: A 
global perspective. Biol Blood Marrow 
Transplant 2009;15(10):1143.[03R3X3]
08C0PW
PRODUCT: MK-8228 167
PROTOCOL/AMENDMENT NO .: 030-[ADDRESS_890322] -2022
[Tomonari, A., et al 
2007]Tomonari A, Takahashi S, Ooi J, Tsukada N, 
Konuma T, Kato S, et al. Impact of 
cytomegalovirus serostatus on outcome of 
unrelated cord blood transplantation for adults: a 
single -institute experience in Japan. Eur J 
Haematol. 2007;80:251- 7.[04VTVC]
[Viberg A, Prohn M, 
Dykstra K, et al. 2017]Modeling and Simulation Report: Population PK 
in Phase 3 Subjects, 2017[04KBBP]
[Wang, Y., et al 2012] Wang Y, Jadhav PR, Lala M, Gobburu JV. 
Clarification on precision criteria to derive 
sample size when designing pediatric 
pharmacokinetic studies. J Clin Pharmacol . [ADDRESS_890323];52(10):1601- 6.[042QFB]
[Winston, D. J., et al 
2008]Winston DJ, Young JH, Pullarkat V, 
Papanicolaou GA, Vij R, Vance E, et al. 
Maribavir prophylaxis for prevention of 
cytomegalovirus infection in allogeneic stem cell 
transplant recipi[INVESTIGATOR_840]: a m ulticenter, randomized, 
double -blind, placebo- controlled, dose -ranging 
study. Blood 2008;111(11):5403 -10.[03RVNG]
[Zhou, W., et al 2009] Zhou W, Longmate J, Lacey SF, Palmer JM, 
Gallez -Hawkins G, Thao L, et al. Impact of 
donor CMV status on viral infecti on and 
reconstitution of multifunction CMV -specific T 
cells in CMV -positive transplant recipi[INVESTIGATOR_840]. 
Blood. 2009 Jun 18;113(25):6465 -76.[04J8SK]
08C0PW